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Summary 
(6S)-6-Fluoroshikimic acid 1 was developed as a potential antimicrobial which was 
converted to 6-fluorochorismate 2 and hence targeted the post-chorismate pathway to p- 
aminobenzoic acid 2 and folic acid (fig. 1). Although successful against microbial 
challenge, resistance developed rapidly. This resistance was found to be due to 
mutation at the shiA locus which codes for a transporter required for the entry of 
shikimic acid into bacterial cells. 
02H 
(50 
02H 
,,., 
F F 
HO'''*OH CO2H 
OH OH NH2 
123 
Figure 1: Mechanism of action of (6S)-6-fluoroshikimic acid 
In the initial part of our research, we aimed to synthesise five peptide-based `smugglins' 
4-8 which would target the oligopeptide permease and hence provide a route for the 
entry of (6S)-6-fluoroshikimic acid into bacterial cells (fig. 2). 
JYH 
H2 
J=N 
N 
OH 
RH0 
OH 
R= Me 4, CH2CH(CH3)2 5, CH2Ph 6, CH2OH 7, (CH2)2CO2H 8 
Figure 2: Smugglins designed to target the oligopeptide permease 
Attempts to synthesise the required (6S)-6-fluoroshikimic acid 1 by biotransformation 
from erythrose -4-phosphate and fluoro-phosphoenolpyruvate were not successful. 
However, a published route from shikimic acid 9 eventually provided sufficient material 
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for the synthesis of the test compounds (flg. 3). The details of these syntheses are 
described in Chapter 2. 
002H 02M e 02M e O2H 
OH F 
HO" - OH q 
O'", OH HU"' O' OH 
OH /ý /r OH 
9\1 
Figure 3: Published route to (6S)-6-fluoroshikimic acid from shikimic acid 
The smugglins were synthesised using standard Fmoc-based solid-phase peptide 
synthesis using DIC/HOBt to catalyse peptide coupling and BOP/Et3N to catalyse the 
coupling of (6S)-6-fluoroshikimic acid to the peptide moiety. Testing of the 
phenylalanine and leucine-based smugglins 5 and 6 fig. 2) for antibacterial activity 
against wild-type Escherichia coli has so far been unsuccessful. Details of these 
syntheses and investigations are described in Chapter 3. 
As a secondary aim a route to pure 3-dehydroquinic acid (DHQ) 10, required for the 
kinetic analysis of 3-dehydroquinate dehydratase (DHQase), was investigated. Initial 
attempts using acetal protecting groups developed to be selective for diequatorial diols 
were unsuccessful. However, modification of a published route to halogenated 
derivatives of dehydroquinic acid gave DHQ in good yield on a gram scale (fig. 4). 
HO 02H HO HQ HO 02H 
-ý -ý 0 
HO, " OH HO" -00 OH ÖH ÖTBDMS OTBDMS OH 
10 
Figure 4: Route to DHQ from quinic acid 
This pure DHQ was then used for the kinetic investigation of the type 11 DHQase from 
Helicobacter pylori and a mutant type II DHQase: Bacillis subtilis F28Y. Details of 
these syntheses and investigations are described in Chapter 4. 
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1 The Shikimate Pathway 
1.1 Overview 
Shikimic acid 9 was first isolated in 1885 by J. F. Eykmann from the fruits of Illicium 
religiosum and Illicium anisatum (Eijkman, 1885; Eykmann, 1891). Its fundamental role in 
the pathway which takes its name was eventually recognised by Davis (Davis, 1955). 
The shikimate pathway (fig. 5) is a complex, branching metabolic pathway leading to the 
aromatic amino acids found in proteins (Phe, Trp, Tyr), p-aminobenzoic acid (PABA) 
which is the precursor of folic acid, the lipid-soluble isoprenoid quinones involved in 
electron transport, and the structural polymer lignin. The pathway is also a major source of 
secondary metabolites (those compounds which are produced by specific organisms for 
purposes other than the basic requirements of growth) such as phenols and alkaloids in 
plants and antibiotics in micro-organisms. For reviews on the biosynthesis of shikimate 
metabolites, see the series in Natural Product Reports, most recently authored by Andrew 
Knaggs (Knaggs, 2003). For an overview of the entire pathway, see Ronald Bentley's 
detailed study (Bentley, 1990) and Edwin Haslam's book (Haslam, 1993); along with two 
reviews which focus only on the `main trunk' of the pathway to chorismate (Mousdale & 
Coggins, 1993; Herrmann & Weaver, 1999). Additionally, a review focussing on the 
chemical aspects of the shikimate pathway was published in 1998 (Jiang & Singh, 1998) 
Depending on the organism studied, the central enzymes of the shikimate pathway (DHQ 
synthase to EPSP synthase) exist singly or in the form of multifunctional enzymes. In 
Necrrospora crassa, Aspergillus nidulans and Saccharomyces cerevisiae as well as other 
fungal species, the enzymes are found in the form of the arom multi-functional enzyme 
encoded by a single gene (Lumsden & Coggins, 1977; Coggins & Boocock, 1986; Duncan 
et a!., 1987). In contrast, the corresponding enzymes in Escherichia coli exist as five 
monofunctional enzymes encoded by genes dispersed throughout the genome (Coggins et 
al., 1985). Many suggestions have been put forward as to why multifunctional enzymes 
exist, but the most convincing advantages would seem to be co-ordinate regulation of 
enzyme activity and of gene transcription, with protection of unstable reaction 
intermediates, and spatial organisation of enzyme functions as a secondary advantage 
(Hardie & Coggins, 1986). 
As is the case with many other long biosynthetic pathways leading to amino acids, vitamins 
and nucleotides, the enzymes of the shikimate pathway have been lost by vertebrates. This 
is believed to be due to the high metabolic cost of maintaining the enzymes while the 
products can be obtained from the diet. As mammals are thus unable to synthesise aromatic 
compounds by this route, the enzymes of the shikimate pathway are attractive targets in the 
search for novel antimetabolites (Kishore & Shah, 1988; Payne et al., 2000) 
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Figure S: The Shikimate Pathway 
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The pathway has long been known to exist in plants, archaea, bacteria, and fungi (Bentley, 
1990). The recent discovery of shikimate pathway enzymes in apicomplexan parasites, 
including the clinically important Plasmodium (malaria), Cryptosporidium and Toxoplasma 
species, has given further impetus to the search for effective enzyme inhibitors and hence 
possible pharmaceuticals (Roberts et al., 1998; Keeling et al., 1999; McConkey, 1999; 
Roberts et al., 2002). It is believed that the apicomplexa are vulnerable to compounds 
which target bacterial enzymes due to the presence of a plastid, the apicoplast, which is 
thought to be the result of endosymbiosis of a cyanobacterial-like cell (McFadden & Roos, 
1999). 
Mutation or deletion of shikimate pathway genes in pathogenic species results in attenuated 
strains which are non-infective and non-viable in vivo (Poirer et al., 1988). These have 
been used in the development of live oral vaccine candidates against Salmonella 
typhimurium, Shigellaflexneri and the fish pathogen Aeromonas salmonicida (Hoiseth & 
Stocker, 1981; Dougan et al., 1988; Edwards & Stocker, 1988; Verma & Lindberg, 1991; 
Vaughan et at., 1993). Additionally, with the resurgence of tuberculosis world-wide, 
evidence that the shikimate pathway is essential for the viability of Mycobacterium 
tuberculosis has provided not only the possibility of new treatments, but also of new and 
more effective vaccines based on attenuated strains (Parish & Stoker, 2002). 
-4- 
1.2 The `main trunk' enzymes of the shikimate pathway 
1.2.1 3-Deoxy-D-arabino-heptulosonate 7-phosphate synthase 
DAHP HQ, 02H 2 OsP synthase 
++ POg3- 
HO2 OPO32' HO'ý" _ 
ýO M2+ 
2 03P 
_ OH 
11 OH ÖH 
12 13 
Figure 6: The reaction catalysed by DAHP synthase 
3-Deoxy-D-arabinio-heptulosonate 7-phosphate (DAHP) synthase catalyses the formation 
of 3-deoxy-D-arabino-heptulosonate 7-phosphate (DAHP) 13 from phosphoenolpyruvate 
(PEP) 11 and D-erythrose 4-phosphate (E4P) 12 and is properly referred to as phospho-2- 
hydro-3-deoxyheptonate aldolase, EC 4.1.2.15 (1ig. 6). DAHP synthase activity was 
unequivocally detected in 1959 in E. coli cells and has since been observed in many 
microbial and plant sources (Srinivasan et al., 1959). 
Various different DAHP synthase isozymes have been identified in bacteria and plants due 
to the wide variety of feedback mechanisms involved in controlling carbon flow through 
the shikimate pathway by means of DAHP synthase regulation. The catalytic activity and 
actual concentration of certain DAHP synthase isozymes are affected by availability or 
otherwise of end-products such as the aromatic amino acids and caffeic acid (a secondary 
metabolite); or intermediates such as chorismic acid (Bentley, 1990). 
In wild-type E. coli cells three DAHP synthase isozymes, each inhibited by a single 
aromatic amino acid, are encoded by the genes aroF (tyrosine sensitive), aroG 
-5- 
(phenylalanine-sensitive) and aroH (tryptophan-sensitive) (Jensen & Nasser, 1968). 
DAHPS(Phe), which is a homotetramer, is the major isoform and constitutes around 75 % 
of activity in wild-type cells (McCandliss et al., 1978). DAHPS(Trp), which contributes 
less than I% of activity, and DAHPS(Tyr), which contributes 25 %, are homodimers 
(Schoner & Herrmann, 1976; Akowski & Bauerle, 1997). 
It was originally believed that DAHP synthases could be divided into two groups: those 
found in plants, and those found in microbes (Herrmann, 1995; Weaver et al., 1993). It has 
since been shown that plant-like DAHP synthase enzymes (Mr - 54 000) exist in 
Streptomyces spp. as well as in Neurospora crassa (Walker et al., 1996). The E. coli-like 
DAHP synthases (Mr - 40 000) have therefore been renamed `type I', and the plant-like 
enzymes `type II'. 
The first DAHP synthase enzyme to be purified was the tryptophan-sensitive isozyme from 
N. crassa (Nimmo & Coggins, 1981). The first X-ray crystal structure obtained was of the 
phenylalanine-sensitive isozyme from E. coli (Shumilin et al., 1999). The structure was 
confirmed as a dimer of two tight dimers, with the interesting proposal that four amino acid 
substitutions seen in DAHPS(Tyr) and DAHPS(Trp) would eliminate the hydrophobic 
interactions forming the tetramer to give the observed dimeric structures for these enzymes. 
1.2.2 DHQ synthase 
More properly known as 7-phospho-3-deoxy-D-arabino-heptulosonate phosphate lyase (EC 
4.6.1.3), 3-dehydrogtiinate (DHQ) synthase catalyses the formation of DHQ 10 from 
DAHP 13 (lig. 7). 
-6- 
HO, 02H HO 02H 
DHQ synthase 
+ POg 2-O3P 
OH NAD+, Zn2+ 0 OH 
OH OH 
13 10 
Figure 7: The reaction catalysed by DHQ synthase 
DHQ synthase from E. coli has been purified by various groups with a particularly high- 
yielding overexpression system reported by Frost (Frost et al., 1984; Mehdi et al., 1987). 
The enzyme has an absolute requirement for both NAD4 and a divalent metal cation 
generally believed to be Zn2r (Lambert et al., 1985) 
The reaction catalysed by DHQ synthase was initially believed to be an extreme example of 
the capabilities of a single active site as it involves oxidation, (3-elimination, reduction, and 
an intramolecular aldol reaction (Bartlett at al., 1988). Later work demonstrated that the 
enzyme functions mainly as a dehydrogenase and structural template with elimination 
spontaneously following oxidation, and the aldol reaction occurring even in the absence of 
the enzyme (Widlanski et al., 1989; Bartlett at al., 1994). 
The structure of the DHQ synthase domain of the AROM protein from Aspergillus nidulans 
has been determined by X-ray crystallography (Carpenter et al., 1998). The enzyme is a 
homodimer with the active site located in the cleft between the two domains of each 
monomer. The authors propose that while many of the steps in DHQ synthesis may not be 
catalysed by the enzyme, reaction intermediates may be stabilised by interactions with the 
active site. This would explain the presence of reaction byproducts in the non-catalysed 
-7- 
formation of DHQ, and their absence in the enzyme-catalysed synthesis (Bartlett et al., 
1994). 
1.1.3 Dehydroquinase 
The enzyme which converts DHQ 10 to 3-dehydroshikimic acid (DHS) 14 is correctly 
referred to as 3-dehydroquinate dehydratase (EC 4.2.1.10) (fig. 8). 
HQ 02H A02H 
dehydroquinase 
+ H2O 
0 OH 0 OH 
OH OH 
10 14 
Figure 8: The reaction catalysed by dehydroquinase 
Dehydroquinase (DHQase) enzymes occur in two distinct forms with differing chemical 
and biochemical properties (Kleanthous et al., 1992). Type I enzymes occur in the 
shikimate pathway in fungi, plants and some bacteria. They are dimeric and catalyse a syn- 
elimination of water via an imine intermediate involving a conserved lysine residue (Butler 
et al., 1986; Chaudhuri et al., 1991; Smith et a!., 1970; Schneier et a!., 1991). Type II 
DHQases are found in the quinate pathway of fungi and the shikimate pathway of many 
bacteria. They are dodecameric and catalyse an anti-elimination of water via an enolate 
intermediate (Harris et al., 1993; Harris et al., 1996) 
The two types of DHQase are unrelated at the sequence level, and X-ray crystal analysis 
has shown them to be structurally unrelated (Gourley et al., 1999; Roszak et al., 2002). 
The dimeric type I enzyme possesses an a/ß barrel structure, while the type II enzyme has a 
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flavodoxin-like fold with subunits arranged as a tetramer of trimers. These differences are 
consistent with the differing stereochemical and mechanistic paths of the dehydration 
reactions catalysed by the two types of DHQase. 
1.1.4 Shikimate dehydrogenase 
Shikimate dehydrodgenase (EC 1.1.1.25) converts DHS 14 to shikimic acid (SHK) 9 using 
NADPH as the reducing agent (fig. 9). As a result, it has been termed shikimate: NADP" 
oxido-reductase, but is commonly abbreviated to SDHase. 
H 02H 
shikimate 
O2 
dehydrogenase 
O OH HO's OH 
OH NADPH NADP+ OH 
14 9 
Figure 9: The reaction catalysed by shikimate dehydrogenase 
In E. coli the enzyme is encoded by the aroE gene, and is monomeric with Mr - 32 000 
(Chaudhuri & Coggins, 1985). In plants bifunctional DHQase: shikimate dehydrogenase 
enzymes have been described as well as the monofuctional shikimate dehydrogenases 
(Lourenco & Neves, 1984; Blume & McClure, 1980). 
The enzyme has an absolute requirement for a C-4 hydroxyl in the substrate and shows a 
stereochemical bias towards compounds with the S configuration at both C-1 and C-4 
(Bugg, 1988). 
Shikimate dehydrogenase from E. coli has been crystallised (Michel et al., 2003). The 
enzyme consists of two a/(3 domains separated by a cleft in which NADP is bound in the 
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crystallised protein. The observation of protein molecules in `open' and `closed' forms in 
the crystal structure was taken as evidence of a conformational change on substrate binding 
in which the cleft between the domains closes. 
1.1.5 Shikimate kinase 
Shikimate kinase (EC 2.7.1.71) catalyses the transfer of phosphate from ATP to the C-3 - 
hydroxyl of shikimic acid 9 to form shikimate-3-phosphate (S3P) 15 (fig. 10). 
02H 
Ha - OH OH 
9 
shikimate 
kinase 
ATP ADP 
f02H 
2'03PO" OH 
OH 
15 
Figure 10: The reaction catalysed by shikimate kinase 
Shikimate kinase exists in isozymic forms in both E. coli and S. typhimurium (Haslam, 
1993; Pittard, 1996). In E. coli, shikimate kinase I is encoded by the aroK gene, and 
shikimate kinase II by the aroL gene (Millar et al., 1986; Lobnerolesen & Marinus, 1992). 
The proteins are similar in length, and have 30 % sequence homology (Whipp, 1995). The 
enzymes do, however, have widely differing affinities for shikimic acid. Shikimate kinase I 
has an affinity in excess of 20 mM, while that of shikimate kinase 11 is 200 p. M (DeFeyter 
& Pittard, 1986; Millar et at., 1986). This suggests that shikirnate kinase II normally 
functions in the biosynthetic shikimate pathway while shikimate kinase I is believed to 
have an alternative biological role (DeFeyter & Pittard, 1986; Vinella et al., 1996), 
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E. coli shikimate kinase II is monomeric with Mr - 19 000 and has an absolute requirement 
for a divalent metal cation, believed to be Mgt+(Krell et al., 1998). The type II enzyme 
from Erwinia chrysanthemi, which has 53 % amino acid sequence identity with the E. coli 
enzyme, has been crystallised in the presence of Mg-ADP (Krell et al., 1998). The enzyme 
is an a/ß protein which resembles adenylate kinase in that it has a central nucleotide- 
binding core with two flexible domains. Evidence for significant structural change on 
substrate and cofactor binding due to induced-fit movement was observed using circular 
dichroism (CD) spectra. 
1.1.6 EPSP synthase 
With such a lengthy formal name, it is unsurprising that phosphoenolpyruvate: 3- 
phosphoshikimate 5-0(1-carboxyvinyl)transferase (EC 2.5.1.19) should more commonly 
be referred to as EPSP synthase. Catalysing the reaction between shikimate 3-phosphate 15 
and PEP (fig. 11) this enzyme is the target of the post-emergence herbicide glyphosate 
(Steinrücken & Amrhein, 1980; Boocock & Coggins, 1983; Krell et al., 1988). As a result, 
the structure and mechanism have been intensively studied. 
002H 
EPSP 
02H 
+ P043- 
synthase 
1110 
2-O3PO"' OH 
+ 
HO2 OP032" 2'O3PG, " OJIýI CO2H 
OH 11 OH 
15 16 
Figure 11: The reaction catalysed by EPSP synthase 
In E. coli, monofunctional EPSP synthase is encoded by the aroA gene and has M, - 46 000 
(Lewendon & Coggins, 1983; Duncan et al., 1984). In S. typhimuriwn, the causative agent 
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of typhoid fever, EPSP synthase has only 11 % amino acid sequence divergence from the 
E. coli enzyme (Stalker et al., 1985). In both organisms, expression of aroA is linked to 
that of serC, which codes for 3-phosphoserine aminotransferase, in an unusual mixed- 
function operon (Duncan & Coggins, 1986; Hoiseth & Stocker, 1985). Overexpression of 
EPSP synthase in E. coli results in resistance to glyphosate (Duncan et al., 1984). 
In plants, EPSP synthase is found in the stromal fraction of chloroplasts (Mousdale & 
Goggins, 1984). Plant EPSP synthases show significant homology with bacterial enzymes, 
which can function in plants provided the chloroplast transit sequence has been added to the 
enzyme (delta-Cioppa et al., 1987). A great deal of research effort has been concentrated 
on the development of glyphosate-resistant lines. This has involved the overexpression of 
EPSP synthase, modification of the enzyme to reduce sensitivity to the inhibitor, or 
modification to increase the specific activity of the enzyme (Rogers et al., 1983; Amrhein 
et al., 1983; Shah et al., 1986; Comai et al, 1983; Comai et al., 1985; Stalker, 1985; 
Steinrücken, 1986). 
EPSP synthase has been crystallised in the presence and absence of glyphosate. (Abdel- 
Meguid et al., 1985; Stallings et al., 1991; Schönbrunn et al., 2001). The enzyme consists 
of two globular domains which are roughly equal in size. The ligand binding site is 
situated at the interface between the domains where the macrodipole effect of multiple a- 
helices is believed to result in the accumulation of positive charge (Stallings et al., 1991). 
Substrate binding induces a radical change in conformation as the cleft between the 
domains closes. 
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1.1.7 Chorismate synthase 
The enzyme catalysing the 1,4-elimination of phosphate from EPSP 16 to give chorismate 
17 is correctly named 05-(1-carboxyvinyl)-3-phosphoshikimate phosphate lyase (EC 
4.6.1.4) but more commonly referred to as chorismate synthase (fig. 12). 
02H 
chorismate 
02H 
synthase 
I + HP042' 
2"03PO O CO2H FADH2or FMNH2 
ý00 I-% ýC02H 
OH OH 
16 17 
Figure 12: The reaction catalysed by chorismate synthase 
The reaction is unusual in two respects. Firstly, elimination is anti with loss of the C-6HR 
proton, and secondly, there is an absolute requirement for a reduced flavin cofactor in 
catalysis even though there is no change in the overall oxidation state of the substrate (Hill 
& Newkome, 1969; Onderka & Floss, 1969; Welch et al., 1974). In addition, despite 
intensive study, the mechanism of the reaction has not yet been conclusively proven 
(Macheroux et al., 1999; Bornemann, 2002) 
Chorismate synthases can be divided into two groups based on the way in which the 
reduced flavin cofactor is obtained. Monofunctional chorismate synthases such as those 
found in B. coli and plants require the presence of reduced FMN in the environment. 
Bifunctional chorismate synthases, generally fungal, possess an intrinsic flavin reductase 
activity which uses NADPI-1 to reduce FMN (White et al., 1988). There is a third type, 
exemplified by the B. subtilis enzyme, which associates with a separate NADPH: FMN 
oxidoreductase (Hasan & Nester, 1978). Early data suggested that large chorismate 
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synthase enzymes (Mr - 50 000) were bifunctional, while smaller ones (Mr - 40 000) were 
monofunctional (White et al., 1988). However, the small bifunctional enzyme from 
Saccharomyces cerevisiae (Mr 40 800) runs counter to this classification (Henstrand et al., 
1995; Henstrand et al., 1996). 
The x-ray crystal structure of chorismate synthase has not been published. 
1.1.8 PABA synthase 
02H 
O C02H 
OH 
17 
ADC synthase, Mg 2+ 
L-glutamine L-glutamate 
02H 
O1CO2H 
NH2 
18 
ADC 
pyruvate Iyase 
PLP 
02H 
O 
+ MCO2H 
NH2 
3 
Figure 13: The formation of PABA via 4-amino-4-deoxychorismate (ADC) 
4-Aminobenzoic acid (p-aminobenzoic acid, PABA) 3 is an essential component of 
dihydrofolate which acts as a 1-C carrier in biosynthesis. The conversion of chorismate 17 
to PABA is a two-step process (rig. 13) (Nichols et al., 1989). The first step, catalysed by 
ADC synthase, is the reversible amination of chorismate to give ADC 18 (Anderson et al., 
1991). ADC synthase consists of two non-identical subunits: a glutamine amidotransferase 
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(GATase) encoded by the pabA gene, and the ADC synthase proper, encoded by the pabB 
gene (Kaplan & Nichols, 1983; Ye, et al., 1990). ADC synthase requires both glutamine 
and Mg2+ for activity. The GATase activity is conditional on complex formation, while 
ADC synthase activity is increased fourfold in the complex compared to the isolated 
subunit (Roux & Walsh, 1992; Viswanathan eta[., 1995) 
The second step is the cleavage of pyruvate from ADC to give PABA 3. This is carried out 
by ADC pyruvate lyase which is encoded by the pabC gene (Greene & Nichols, 1991; 
Green et al., 1992). Pyridoxal-5'-phosphate (PLP) acts as a cofactor in this reaction. ADC 
pyruvate lyase has been crystallised and the structure determined using X-ray 
crystallography (Nakai et at., 2000). The enzyme is a homodimer with M, 60 000. Each 
subunit consists of a small N-terminal domain and a larger C-terminal domain, with the 
active site of the enzyme (and the site of PLP binding) situated at the domain and subunit 
interface. 
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1.2 The Quinate Pathway 
Quinic acid esters are common storage compounds in plants and quinic acid may consist of 
up to 10 % by weight of decaying leaves (Hawkins et al., 1993). This abundant source of 
carbon is utilised by saprophytic organisms by means of a group of inducible catabolic 
enzymes. 
to (i-ketoadipate pathway 
HO, 02H 
QUINATE PATHWAY 02H 
Ha" OH (catabolic) 
OH 
19 HO 
OH 
quinate 20 
dehydrogenase dehydroshikimate 
dehydratase 
HO 02H O2H 
dehydroquinase 
O OH . 10 -O OH 
OH 
10 14 
HQ synthase 
/oH 
shikimate 02H 
HO 02H dehydrogenase 
2 03P 
OH SHIKIMATE PATHWAY 
HO'ýý _ OH 
OH 
(biosynthetic) OH 
9 
13 
Figure 14: The inducible catabolic quinate pathway 
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Quinic acid 19 is initially converted to protocatechuic acid 20 and hence, via the ß- 
ketoadipate pathway and oxidative cleavage of the aromatic ring, to acetyl CoA and 
succinic acid fig. 14) (Gross, 1958; Ornston & Stanier, 1966). 
The enzymes required for quinate utilisation are tightly regulated, being induced by the 
presence of quinic acid but inhibited by other, preferred, sources of carbon such as glucose 
(Giles et al., 1985; Grant et al., 1988). Of interest to our work is the fact that the DHQase 
isoenzyme found in the quinate pathway is entirely separate from that found in the 
shikimate pathway, having a different primary sequence, structure and mechanism of action 
(see Section 1.2 above) (Kleanthous et al., 1992). 
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1.3 Known antimetabolites targeting the shikimate pathway 
The best-known inhibitor of a shikimate pathway enzyme is the non-specific post- 
emergence herbicide N-(phosphonomethyl)-glycine (glyphosate) which has been 
commercialised under the trade name Roundup®. The herbicidal action is due to inhibition 
of the enzyme EPSP synthase. EPSP synthase catalyses the transfer of the enolpyruvyl 
group from PEP 11 to the 5-hydroxyl of shikimate-3-phosphate 15 to give EPSP 16 and 
inorganic phosphate (Steinrücken & Amrhein, 1980; Mousdale & Coggins, 1984; 
Mousdale & Coggins, 1985; Kishore & Shah, 1988). 
02- 
2- 03pa"OH 
OH 
15 
+ 
02AOP032 
11 
02 
2- 
032- 
03PO R02 
OH 
tetrahedral intermediate 
21 
02- 
2-03Po CO2- 
OH 
16 
Figure 15: EPSP synthase reaction 
The reaction proceeds via a tetrahedral intermediate 21 (fig. 15), and it is this intermediate 
which is believed to be mimicked by the formation of a ternary complex 23 between 
shikimate-3-phosphate 15 and glyphosate 22 on the enzyme (fig. /6) (Boocock & Coggins, 
1983; Anderson & Johnson, 1990; Schönbrunn et at., 2001). 
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Figure 16: Proposed mechanism for inhibition of EPSP synthase by glyphosate 
Various structural analogues of shikimate pathway substrates have been synthesised as 
potential inhibitors (fig. 17). The homophosphonate analogue of DAHP 24 inhibits DHQ 
synthase with K; = 2.5 yM (Reimer et al., 1986). The carbocyclic analogue 25 is more 
potent still with K; = 1.7 jM and the phosphonate equivalent 26 is the best known inhibitor 
of the enzyme with Ki - 0.8 nM (Widlanski et al., 1989). The carbocyclic malonate 27 
analogue (K; = 0.7 pM) is inhibitory in the sub-micromolar range (Tian et al., 1996) while 
the cyclohexenyl equivalent 28, which was designed to mimic an E1cB-like transition state 
on the enzyme, is also inhibitory at nanomolar concentrations (K; = 8.6 nM) (Montchamp 
and Frost, 1997). 
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Figure 17: Potent inhibitors of DHQ synthase 
The structural and mechanistic differences between type I and type II DHQases have been 
exploited in the design of specific inhibitors. The substrate analoues (2R)-2- C, 
bromodehydroquinate 29 and (2R)-2-fluorodehydroquinate 30 were designed as inhibitors 
of type I DHQase as they lacked the C-2-pro-R hydrogen while still being substrates for 
type II DHQases which require a C-2-pro-S hydrogen (fig. 18) (Gonzalez-Bello et al., 
2000). 
HO OOH 
Br"., 
O OH 
OH 
29 
HO OOH 
F,, 
O OH 
OH 
30 
Figure 18: Irreversible selective inhibitors of type I DHQase 
Compounds designed to selectively inhibit type II DHQases have been designed based on 
the structure of the M. tuberculosis DHQase (Gourley et al., 1999) and the type 11 enzyme 
from Streptomyces coelicolor (Roszak et al., 2002). Based on the fact that the elimination 
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catalysed by type II DHQases proceeds via an EIcB mechanism and is thought to involve 
an enolate intermediate four compounds modified at C-3 were tested against DHQases from 
a variety of organisms (Coggins et al., 2003). The carbonyl at C-3 is required for imine 
formation with type I enzymes, so it was expected that both 2,3-anhydroquinic acid 31 and 
the reduced equivalent 32 (Frederickson et al., 1999) would be selective for type II 
enzymes (fig. 19). The oxime 33 (Frederickson et al., 1999) and fluorinated analogue 34 
(Frederickson et al., 2002) were designed to mimic the enolate intermediate. All were 
significantly better competitive inhibitors of the type II enzymes than of the type I enzyme 
tested (Coggins et a!., 2003). 
HO OOH HO OOH HO OOH HO OOH 
_ OH - 
OH HO-N - OH 
OH 
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Figure 19: Selective inhibitors of Type II DHQase 
Halogenated derivatives of shikimic acid have also been investigated as possible inhibitors 
of shikimate pathway enzymes from shikimatc kinase onwards (fig. 20). Modification at C- 
2 to give 2-bromo- 35 and 2-fluoroshikimic acids 36 was carried out using a combination of 
synthesis and biotransformation (Gonzalez-Bello et a!., 1998). Modification at C-3 gave 
the (3R)- 37 and (3S)-fluoro 38 analogues of shikimic acid as well as the (3S)-chloro 
analogue 39 in syntheses starting from shikimic acid (Brettle et al., 1996a; Brettle et a!., 
1996b). The difluoro-substituted shikimic acid 40 was synthesised from quinic acid (Jiang 
et a!., 1999). None of these compounds was tested against shikimate pathway enzymes. 
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Figure 20: Halogenated derivatives of shikimic acid 
By contrast, the 6-fluoroshikimic acids 41 and 1 were designed based on, amongst other 
considerations, the fact that the C-6 pro-R hydrogen is lost during the transformation of 
EPSP to chorismate (Davies et al., 1994). 
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1.4 (6S)-6-fluoroshikimic acid 
1.4.1 Design of a drug candidate 
In considering an enzyme inhibitor as a potential antimetabolite, a crucial issue is whether 
the targeted organism is able to obtain the end-products of the inhibited pathway from 
external sources or alternative biosynthetic routes. Mutations of enzymes in the shikimate 
pathway have been shown to result in severely attenuated strains of pathogenic organisms 
which have potential use as live vaccines (1-loiseth & Stocker, 1981; Poirer et al., 1988; 
Verma & Lindberg, 1991; Vaughan et al., 1993). These `aro"' strains are unable to 
synthesise PABA, which is not imported into the cells, and hence have no source of the 
folate coenzymes involved in C-I transfer in biosynthesis. In targeting the shikimate 
pathway, the ideal compound would therefore either be, or be converted into, a derivative 
of chorismate which could not be converted into PABA. 
1.4.2 Modifications chosen/reasons 
Shikimic acid was selected as a suitable candidate for modification as it is small, stable, and 
is known to be transported into bacterial cells (Pittard & Wallace, 1966; Pittard & Wallace, 
1966b). Modification at C-6 was chosen as the conversion of EPSP to chorismate was 
known to proceed with the loss of the C-6 pro-R hydrogen. In substituting fluorine for 
hydrogen, the overall size and shape of the derivatives would be largely unchanged from 
the parent compound due to the similar atomic radii of the two atoms. As a result the 
modified compounds would be expected to bind to enzymes in a similar way to the natural 
substrate (Davies et al., 1994). The substitution would, however, have a significant effect 
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on the ability of enzymes to catalyse the normal sequence of reactions. The fluorine-carbon 
bond (552kJ/mol) is almost twice as strong as the hydrogen-carbon bond (338 kJ/mol) 
making any elimination far less likely to occur, and the electronegativity difference 
between F and H suggested that enzyme-substrate interactions at this position would be 
disrupted. 
Both (6R)- 41 and (6S)-6-fluoroshikimic acids 1 were synthesised. The authors stated that 
they expected the (6R)-6-fluoro- compound to be converted to (6R)-6-fluoro-shikimate-3- 
phosphate 42 and hence to (6R)-6-fluoro-EPSP 43. This was expected to inhibit chorismate 
synthase as the normal elimination reaction would not be catalysed (flig. 21) (Davies et al., 
1994). 
02H 
shikimate 
02H EPSP 
02H 
F kinase synthase Fý 
OH H2O3P0 OH H2O3PO" O CO2H 
ÖH OH OH 
41 42 43 
chorismate 
synthase 
02H 
O CO2H 
OH 
17 
Figure 21: Expected transformation of (6R)-6-fluoroshikimic acid 
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The authors also hoped that the (6S)-6-fluoro- derivative 1 would be converted to 2- 
fluorochorismate 2 via (6S)-6-fluoro-shikimate-3-phosphate 44 and (6S)-6-fluoro-EPSP 45. 
2-Fluorochorismate 2 was expected to inhibit PABA synthase (fig. 22). 
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Figure 22: Expected transformation of (6S)-6-fluoroshikimic acid 
1.4.3 Antibacterial action 
In vitro testing showed that (6R)-6-fluoroshikimic acid 41 was weakly antibacterial against 
wild-type E. coli grown on minimal medium with a minimum inhibitory concentration 
(MIC) of 64 Frg. mL1. (6S)-6-Fluoroshikimic acid 1 was more potent, displaying MICs of 
between 0.25 and 0.1 hg. mL-' depending on the strain of E. coif tested. The inhibition of 
growth caused by (6S)-6-fluoroshikimic acid was reversed by the addition of p- 
aminobenzoic acid 3 to the growth medium, but not by the addition of any or all of the 
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aromatic amino acids phenylalanine, tyrosine or tryptophan. The slow formation of 2- 
fluorochorismate 2 in the growth medium, along with the reversal of inhibition detailed 
above were consistent with the theory that inhibition of PABA synthesis was crucial for the 
antibacterial activity of (6S)-6-fluoroshikimic acid. 
Earlier studies had already shown that both (6R)- and (6S)-6-fluoro-EPSP 43 and 44 are 
inhibitors of chorismate synthase (Balasubramanian, 1991) but their conversion to 2- 
fluorochorismate was not observed. More detailed studies, however, showed that (6S)-6- 
fluoro-EPSP is converted to 6-fluorochorismate by the enzyme chorismate synthase 
(Bornemann, 1995). 
As (6S)-6-fluoroshikimic acid 1 was more effective as an antimicrobial in vitro it was tested 
against bacterial challenge in mice. Immunocompromised mice (cyclophosphamide- 
treated) were infected with ten times the lethal dose of the bacterial strains used, and then 
injected peritoneally with the antibacterial compound being tested. The PDT (mg. kg-1) of 
(6S)-6-fluoroshikimic acid against the wild-type E. coli B was below 3.1, while against 
Pseudomonas aeruginosa and Staphylococcus aureus it was 28. Cefotaxime was protective 
at an almost identical dosage against S. aureus challenge, and while (6S)-6-fluoroshikimic 
acid could not compare with vancomycin in the treatment of MRSA infection it was 
effective at a four-fold lower dose than methicillin. 
Under exactly the same test conditions, mice infected with a spontaneously resistant strain 
of E. coil B (designated E. coli B 12) were not protected by treatment with (6S)-6- 
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fluoroshikimic acid, confirming that the test compound was acting directly against the 
bacteria. 
1.4.4 Microbial resistance to (6S)-6-fluoroshikimic acid 
As resistance to (6S)-6-fluoroshikimic acid arose spontaneously after overnight incubation 
of a surface innoculum in the presence of the compound, further studies were undertaken in 
an attempt to determine the frequency and mechanism of resistance to (6S)-6- 
fluoroshikimic acid (Ewart, 1995). Four species of enterobacteria were investigated, and 
found to spontaneously develop resistance at frequencies between 10-6 and 10.2 with most 
being around 10-5. Resistant variants of E. coli K-12 were used for the biochemical and 
genetic study of resistance to (6S)-6-fluoroshikimic acid. 
Uptake of [14Clshikimate by the resistant strains was negligable, and all strains resistant to 
(6S)-6-fluoroshikimic acid were also resistant to (6R)-6-fluoroshikimic acid. This 
suggested that resistance was due to a change in the transport of shikimate into the bacterial 
cells. More detailed genetic analysis suggested that mutation at the AM locus had occurred 
(Ewart, 1995). ShiA is one of the two known loci controlling shikimate uptake (Pittard & 
Wallace, 1966b; Brown & Doy, 1976; Whipp, 1998) and these results confirmed that 
resistance was most likely caused by a lack of uptake of shikimate in resistant strains. 
Further work using various shikimate analogues in exchange-diffusion experiments with 
I'4CIshikimate showed that (6S)-6-fluoroshikimic acid is a substrate for the shikimate 
transport system (Jude, 1996). The authors also speculated that their experiments with 
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respiration inhibitors and uncouplers suggested that the shikimate transport system was in 
some way kinetically gated, and could be used to transport a variety of toxic shikimate 
analogues into cells. They cautioned, however, that the high frequency at which the 
transport system appeared to be lost under selective pressure meant that alternative 
transport mechanisms would have to be used along with the shikimate transport system in 
order to introduce these drugs into the bacterial cytoplasm. 
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1.5 A possible solution to transport resistance: peptide based prodrugs 
1.5.1 Prodrugs: an introduction 
In the development of a new drug, chemical modification of the basic structure is used to 
achieve a compound with the desired pharmacological activity. If this optimised compound 
shows undesirable physicochemical characteristics, reversible derivatives can be used to 
optimise the clinical application of the drug. These derivatives are known as prodrugs and 
are chemical derivatives of drugs which are pharmacologically inactive but can be 
converted into the active drug molecule in vivo. 
Prodrugs can be designed to target specific enzymes or carriers. Both enzymes and 
membrane-based carrier proteins are targeted to improve oral bioavailability of a drug or to 
allow site-specific delivery of the active compound (Kearney, 1996; Sherwood, 1996). 
Activation may then be by means of an enzyme found only in the tissue of interest, or more 
generally by such ubiquitous enzymes as peptidases and esterases. 
Peptide transporters are an attractive target in prodrug design as they have both broad 
substrate specificity and generally high capacity. They have also been extensively studied, 
providing useful leads as to the types of modifications which will be tolerated by each 
carrier system (Payne, 1994). 
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1.5.2 Transport in bacterial cells 
1.5.2.1 The need for transport systems 
Bacterial cells, like all other cells, are surrounded by a semi-permeable cell membrane 
which limits the entry and/or exit of substances from the cell. The membrane thus provides 
a separate compartment in which the conditions are kept optimal for biological reactions, as 
well as controlling the exchange of material and information between the cell and its 
environment. 
The phospholipid bilayer of the cell membrane is an extremely effective barrier to the 
diffusion of most polar solutes. As a result, bacteria have developed methods for the 
uptake and export of biologically important compounds. Most of these methods involve 
coupling energy expenditure to the transport of a specific compound required for growth or 
defence. 
The situation is further complicated in Gram negative bacteria by the presence of an outer 
cell membrane beyond the cell wall. While this membrane is relatively permeable to small 
solutes, it is a barrier to larger molecules (Lugtenberg & Van Alpen, 1983; Nikaido & 
Vaara, 1985; Nakae, 1986). Channel-forming proteins, the porins, in this membrane allow 
the diffusion of solutes with molecular weights up to approximately 600 Da (the limiting 
factor is the hydrodynamic or "Stokes radius") into the periplasm (Benz, 1988; Nikaido, 
1992). Thus the outer membrane acts as a molecular sieve, limiting the size of molecule 
which can reach the cell membrane and the transport systems associated with it (Payne & 
Gilvarg, 1968; Nakae & Nikaido, 1975; Decad & Nikaido, 1976). Some porins do show 
limited substrate specificity, and thus certain solutes will only be taken up by bacterial cells 
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with functioning porins of the correct specificity e. g. OmpF and OmpC in E. coli are 
required for the movement of peptides across the outer membrane (Andrews & Short, 1985; 
Alves, 1985). 
1.5.2.2 Why peptides are transported 
Amino-acid synthesis is extremely energetically demanding. Atkinson used an ATP- 
currency to estimate the relative metabolic costs of various metabolites including cc-amino 
acids (Atkinson, 1977). These range from 12 ATP-equivalents for glycine to 78 ATP- 
equivalents for tryptophan. Mammals no longer have the ability to synthesise the more 
costly of these amino acids, obtaining them instead from the diet. Only the few enzymes 
required to synthesise those amino acids which can be made in a few steps from 
intermediates in the citrate cycle or glycolysis have been retained. 
Bacteria have the ability to import and hydrolyse short-chain peptides in order to obtain 
amino acids for protein synthesis. The metabolic cost of de novo amino acid synthesis far 
outweighs the energy expended in active transport. For a review of these non-specific 
bacterial peptide permeases as well as other microbial peptide transport mechanisms, see 
Payne & Smith, 1994. 
1.5.3 Peptide transport in E. coli and S. typhimurium 
The peptide uptake systems of E. coli and S. typhiinuriuin have been studied in some detail. 
There are three main routes by which small peptides of between two and five amino-acid 
residues in length are imported into the bacterial cells. The dipeptide permease (Dpp) 
transports dipeptides, and to a limited extent tripeptides; the tripeptide permease (Tpp) 
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transports tripeptides, and to a limited extent dipeptides; and the oligopeptide permease 
(Opp) transports di- and oligopeptides with up to five amino-acid residues. The Opp is by 
far the best characterised of these systems and, as a binding protein-dependent transport 
system, it has been studied as a model of this type of transporter. 
1.5.3.1 Binding-protein-dependent transport systems 
Binding-protein-dependent transport systems are part of the ATP-binding cassette (ABC) 
superfamily of proteins (Holland & Blight, 1999). Typically, ABC transporters consist of a 
highly conserved ABC-ATPase and at least one membrane domain which provides the 
transport pathway, although the basic unit is generally accepted to be a dimer containing 
two of each. In this way, the energy of ATP hydrolysis is coupled to the transport of 
solutes across cellular membranes. 
ABC transporters are involved in a wide variety of transport processes in both eukaryotes 
and prokaryotes such as solute uptake and antibiotic resistance in bacteria, multidrug 
resistance systems in eukaryotes, and the excretion of various compounds. Their 
importance is illustrated by the fact that the genome sequence of E. coli K-12 contained at 
least 80 identifiable ABC proteins, which equates to I-2% of total proteins (Blattner et 
al., 1997). For reviews on ABC transporters, see Ames et al., 1990; Higgins, 1992; Linton 
& Higgins, 1998; Holland, 1999; Jones, 1999 and Schmitt, 2002. 
Periplasmic binding-protein dependent systems are a type of ABC transporter found in 
Gram-negative bacteria. They generally consist of four different protein components which 
can be either subunits or domains of a single multifunctional peptide associated with the 
cell membrane. The defining feature, however, is the presence of a soluble substrate- 
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binding protein in the periplasm. These systems transport a wide range of substrates and 
include the transporters for maltose, histidine and oligopeptides. Binding-protein 
dependent systems have also been called `shock-sensitive transport systems' as osmotic 
shock leads to the loss of the soluble periplasmic binding protein and hence the loss of 
transport activity (Ames, 1986). 
It was initially believed that these transport systems were unique to Gram-negative bacteria, 
as Gram-positive bacteria lack an outer membrane and periplasm. However, analogous 
systems have been found in Gram-positive bacteria and archaea where the binding protein 
is a secreted glycolipid which is anchored to the outer surface of the cell membrane, e. g. the 
trehalose/maltose transport system of the hyperthermophilic archaeon Thermococcus 
litoralis (Horlacher et al., 1998). Obviously, these anchored binding proteins will not be 
lost if the cell is subjected to osmotic shock. 
1.5.3.2 The oligopeptide permease 
The oligopeptide permease (Opp) is a periplasmic binding protein-dependent system which 
transports peptides ranging in length from two to five amino acid residues (Matthews & 
Payne, 1980; Payne, 1978; Payne, 1980). The upper size limit for transport by the Opp is 
controlled by the outer membrane porins. These have a channel diameter of -I nm which 
equates to a molecular weight of about 600 Da for the peptides being transported. 
Transport assays of the oligopeptide permease showed that it possesses greatest affinity for 
tripeptides, but will transport any cc-amino peptide up to a pentapeptide (Alves et al., 1985; 
Payne, 1980.; Payne, 1986). 
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The opp locus consists of four genes, oppA, oppB, oppC, and oppD which are organised as 
a single operon and cotranscribed. OppA is a 60 kDa protein which makes up - 8% of the 
total protein in osmotic shock fluid from E. coli (Guyer, 1985). It preferentially binds tri- 
and tetrapeptides, with limited binding to pentapeptides and none to isolated amino acids or 
dipeptides (Guyer, 1986). Binding to oppA does not appear to be greatly influenced by the 
amino acyl side chains of peptides. In contrast, modification of the amino or carboxy 
termini of a peptide greatly reduced binding to oppA (Tame, 1994). 
OppA has been crystallised with a variety of natural and unnatural peptide substrates 
(Tame, 1994; Tame, 1995; Davies, 1999; Sleigh, 1999). Unlike most other periplasmic 
binding proteins, which consist of two hinged domains which enclose substrates like a 
Venus' fly-trap closing, OppA is organised into three domains, but the relative organisation 
of the outer two domains resembles that of the two lobes found in the common binding 
proteins (Tame, 1995). 
Peptides bound to OppA do so in an extended conformation, with tight interactions 
between the peptide backbone of the substrate and ß-sheets in the binding protein (Tame, 
1995). The amino terminus of the substrate is bound to an aspartate residue, and the 
carboxy terminus to one of several charged side chains depending on the length of the 
peptide bound, thus explaining the loss of binding affinity to N-acylated or C-esterified 
peptide substrates (Tame, 1994). Amino-acid side chains are accommodated in large 
hydrated pockets within OppA, with highly-ordered water molecules within these pockets 
satisfying hydrogen-bond requirements without imposing binding specificity (Tame el al., 
1996; Sleigh, 1999; Rostom, 2000). 
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1.5.4 Examples of peptide-based prodrugs 
In the design of prodrugs, oral administration is generally a desirable outcome. As a result, 
peptide-based prodrugs have not been widely used. Those peptide prodrugs which do exist 
have often been targeting specific mammalian transporters such as the proton-coupled 
transporters PEPT 1 and PEPT2 which are found in the human gut (Nielsen & Brodin, 
2003). 
Prodrugs utilising bacterial transporters to target antimicrobial compounds have been 
referred to as `smugglins' (Payne, 1976). Toxic amino acids have been incorporated in 
peptides, e. g. alafosphalin (Allen, 1978) while impermeant non-peptide molecules have 
been attached to amino-acyl side chains e. g. 5-fluorouracil (Kingsbury et al., 1984). 
Importantly, extensive in vivo studies have shown that the development of transport 
resistance to compounds targeting peptide permeases is unlikely (Ringrose, 1985). 
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2 (6S)-6-fluoroshikimic acid 
2.1 Published syntheses of 6-fluoroshikimic acids 
2.1.1 From quinic acid 
A chiral synthesis of both (6R)- and (6S)-6-fluoroshikimic acid from quinic acid was 
published by the Davies group (fig. 23) (Sutherland et al., 1989). The known lactone 46 
was prepared in 85 % yield from quinic acid (Elliott et al., 1983). The tertiary hydroxyl of 
46 was then protected using benzyl chloroformate to give 47 and the lactone cleaved to 
give the ester 48. Sequential treatment with trifluoromethanesulfonic anhydride (Tf20) and 
1,8-diazabicyclo[5.4.0] undec-7-ane (DBU) gave the alkene 49. Hydrolysis followed by 
acetylation gave the acid 50 which yielded the ß-lactone 51 on bromolactonisation. The 
lactone was cleaved with simultaneous removal of the acetate protecting group to give 
bromohydrin 52. Epoxidation of the alkene gave 53 which was then dehydrated to give 54. 
This dehydration was problematic and was only successful when the sulfurane 
lPhC(CF3)20I2SPh2 (Martin's Reagent) was used. Epoxide ring opening with HF-pyridine 
was unfortunately non-specific and gave the epimeric fluorohydrins 55 and 56 along with 
the regioisomer 57. These were partially separated using silica-gel column 
chromatography, and purified using a C18 HPLC column. Hydrolysis of the ester and 
cleavage of the cyclohexylidene group gave the desired shikimate derivatives 1 and 41 
along with the regioisomer 58. The synthesis requires six steps from quinic acid, with an 
approximate overall yield of 3% of (6S)-6-fluoroshikimic acid 1. 
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Figure 23: Route to 6-fluoroshikimic acids from quinic acid 
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The lack of specificity of the epoxide ring opening on reaction of 54 is the major problem 
with this synthetic approach. Normally, attack by fluoride at an epoxide would be expected 
to occur in an SN2-like manner, giving 55. However, in this case, a significant proportion 
of an SN1-like reaction appears to have occurred. The positive charge formed on opening 
of the epoxide ring may be stabilised by delocalisation, allowing attack by fluoride from the 
opposite face to the bulky cyclohexylidene group at both C-2, giving 56; and C-6, giving 
57. 
An improvement to this synthesis was outlined a few years later in a communication 
published by the same group (fig. 24) (Sutherland et al., 1993). 
The known diene 49 was made in five steps from quinic acid (fig. 23) (Sutherland et al., 
1989). Osmium catalysed dihydroxylation using N-methylmorpholine N-oxide (NMO) as 
the stoichiometric oxidant gave 59 which was selectively protected as the C-5 triflate to 
give 60. Treatment with NaH in dichloromethane resulted in a trans-transesterification to 
give the regioisomer 61. Dehydration using Martin's reagent and hydrogenolysis gave the 
hydroxyshikimic acid derivative 62. Reaction with N, N-diethylaminosulfur trifluoride 
(DAST) then gave the desired (6S)-6-fluoro derivative 63 in approximately 16 % yield over 
11 steps from quinic acid. If similar deprotection methods to those used in the 1989 
synthesis were used to generate (6S)-6-fluoroshikimic acid 1 (fig 23), the overall yield for 
this route from quinic acid would be in the 6- 10 % range. 
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2.1.2 By biotransformation from 3-fluoro-phosphoenolpyruvate 
Multistep enzymatic synthesis had been used successfully to generate isotopically labelled 
intermediates in vitamin B12 biosynthesis (Scott, 1994). As a result, the Abell group 
decided to look for an enzymatic route to both (6R)- and (6S)-6-fluoroshikimic acids 
(Duggan et al., 1995). 
The conversion of 3-fluoroPEP to 3-fluoroDAHP was known (Pilch & Somerville, 1976). 
3-fluoroDAHP had also been used as a substrate for DHQ synthase in the presence of 
DHQase (Le Marechal et al, 1986). Additionally, (6S)-6-fluoroshikimic acid was known to 
be converted to (6S)-6-fluoroEPSP and 2-fluorochorismate by the relevant enzymes 
(Bornemann et al., 1995). It therefore seemed a reasonable assumption that purified 
enzymes along with the relevant cofactors could be used to convert both isomers of 3- 
fluoroPEP 64 and 65 to the 6-fluoroshikimic acids 1 and 41 (fig. 25). 
A test reaction using a mixture of the four enzymes required together with their cofactors 
was followed spectrophotometrically by monitoring the consumption of NADPH at 340 
nm. The results suggested that a shikimate derivative was being formed. On a preparative 
scale, the reaction was carried out in 50 mM MOPS buffer at pH 7 with sequential addition 
of the enzymes and cofactors as each step was completed. An initial decrease in 
absorbance at 234 nm was indicative of the consumption of 3-fluoroPEP 64 and 65. An 
increase in absorbance at the same wavelength showed the formation of the 6- 
fluorodehydroshikimates 70 and 71 on the addition of DHQ synthase, DHQase, Co" and 
NAD'. The reaction was considered complete when the addition of further aliquots of 
SDHase had no effect on the levels of NADPI-1 in the reaction mixture. 
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Figure 25: Proposed biotransformation route to the 6-fluoroshikimic acids 
A combination of anion exchange and ion-exclusion HPLC was used to purify the 6- 
fluoroshikimates 1 and 41 giving isolated yields of approximately 17 % of each epimer. 
Unexpectedly, despite the ratios of the 3-fluoroPEP substrate 64 and 65 being 88: 12 the 6- 
fluoroshiki mates were isolated in equimolar amounts. 19F-NMR analysis was used to show 
that this was at least partly due to the very slow conversion of (3S)-3-fluoroDAHP 67 to 
(6S)-6-fluoroDHQ 69 compared to the reaction of (3R)-3-fluoroDAHP 66. A suggestion 
put forward was that the rate of the spontaneous reaction of (3S)-3-fluoroDAHP 67 was 
comparable to that of the enzyme-catalysed reaction, and that this led to the loss of 
stereospecificity in the conversion (C. Abell, Fluorine Research Conference, 2002). An 
alternative product was formed from 67 during the course of the 19F-NMR reaction. This 
further reduced the yield of the desired shikimate derivatives but was not characterised by 
the authors (Duggan et al., 1995). 
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Compared with the synthetic routes (fig. 23 and fig. 24), this biotransformation route has 
two significant advantages. The yield is at least double that of the best total synthesis, and 
the total time required for the reaction is 26 h followed by HPLC purification as compared 
to the weeks or months required for some challenging synthetic chemistry. Disadvantages 
are that the method requires experience in enzyme purification and in the use of enzymes in 
transformations. Also, the substrate erythrose-4-phosphate is both unstable and very 
expensive. 
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2.1.3 From shikimic acid 
In late 2001, the Singh group published a shorter synthesis of (6S)-6-fluoroshikimic acid 1 
from shikimic acid 9 (fig. 26) (Song et a!., 2001). By extracting the starting material from 
Chinese star anise (Illicium verum) on a large scale in the laboratory, the authors avoided 
the major disadvantage of this route which is the high cost of commercially available 
shikimic acid (Aldrich, 1g= £38.80). 
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Figure 26: Synthesis of (6S)-6-fluoroshikimic acid from shikimic acid 
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Shikimic acid 9 was esterified by heating in methanol under acid catalysis. The resulting 
ester was further protected using 2,2-dimethoxypropane and camphorsulfonic acid (CSA) 
to give the acetonide 72. Reaction with Tf2O formed the triflate 73 which was then treated 
with cesium acetate in DMF to yield the diene 74. Osmium-catalysed dihydroxylation of 
the diene using NMO as secondary oxidant gave the diols 75 and 76 in approximately equal 
amounts. After separation, the C-5 hydroxyl of diol 76 was selectively protected as the 
`butyldimethylsilyl (TBDMS) ether, forming the protected hydroxyshikimic acid derivative 
77. Treatment with an excess of DAST then gave the fluorinated derivative 78. Hydrolysis 
of the ester using lithium hydroxide was followed by treatment with aqueous trifluoroacetic 
acid (TFA) to remove the silyl and isopropylidene protecting groups. The desired (6S)-6- 
fluoroshikimic acid 1 was thus synthesised in nine steps and 15 % overall yield from 
shikimic acid. 
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2.2 Results: attempted syntheses of (6S)-6-fluoroshikimic acid 
2.2.1 Biotransformation from 3-fluoroPEP 
The published biotransformation from 3-fluoroPEP to both epimers of 6-fluoroshikimic 
acid fig. 25) (Duggan et al., 1995) is both higher-yielding and less time-consuming than 
the chiral syntheses from quinic acid (flig. 23 & 24) (Sutherland et al., 1989; Sutherland et 
al., 1993). Initial attempts to synthesise (6S)-6-fluoroshikimic acid 1 were therefore made 
using the biotransformation method. 
E-4-P 12 is very expensive and is also known to be unstable in solution where it dimerises 
to give compounds which are not substrates for DAHP synthase (Duke & MacLeod, 1981). 
It was therefore decided to attempt to generate E-4-P in situ from D-fructose-6-phosphate 
(F-6-P) 79 using transketolase from bakers' yeast (fig. 27) (Reimer et al., 1986). This 
method has been used to convert 3-fluoro-PEP to the corresponding DAHP derivatives 66 
and 67 (Parker, 1996) and had been validated in our laboratories (C-A. Deans, Senior 
Honours project, 1999, University of Glasgow). The generation of E-4-P was carried out in 
the presence of DAHP synthase, its cofactors and an excess of 3-fluoro-PEP, thus avoiding 
the high concentrations of E-4-P which result in the formation of unreactive dimers. 
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Figure 27: Proposed biotransformation to 3-fluoro-DAHP using in situ generated E-4-P 
This route had not been extended beyond 3-fluoro-DAHP to the shikimate derivatives 
desired. As significant modifications to the published route were proposed, it was decided 
to attempt the initial biotransformation reaction using the natural substrates. 
2.2.1.1 Enzyme preparation 
An overproducing strain of E. coli (E. coli W3110/pJB14) was used to obtain fresh stocks 
of dehydroquinate synthase, which converts DAHP to DHQ. As the enzyme had been 
extensively studied in the group, a protocol was available both for the purification of the 
enzyme and for assaying its activity (Mousdale & Coggins, 1993). All other enzymes 
required for the biotransformation were available in sufficient quantity in the group. For 
enzyme preparation methods and assay conditions, see Chaudhuri et al., 1987a, b; Coggins 
et al., 1987; Mehdi et a!., 1987; Gourley et al., 1999; Maclean et a!., 2000 and Michel et 
al., 2003 
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2.2.1.2 Model studies using PEP 
The proposed biotransformation involved the conversion of PEP to shikimic acid 9 in a 
single pot with in situ generation of E-4-P 12 fig. 28). It was therefore necessary to find a 
buffer system which allowed a reasonable rate of reaction for all the enzymes involved, as 
well as ensuring that the conditions required for the formation of E-4-P were compatible 
with the remainder of the proposed route. 
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Figure 28: Proposed biotransformation from PEP to shikimic acid 
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The published biotransformation route to both 6-fluoroshikimic acids was carried out in 50 
mM MOPS at pH 7 (Duggan et al., 1995). By contrast, the synthesis of DAHP 13 using in 
situ generation of E-4-P was carried out in unbuffered aqueous solution under anaerobic 
conditions with the pH adjusted to pH 7 prior to reaction initiation (Parker, 1996). 
Transketolase, either from bakers' yeast (commercial) or Leishinania inexicana (gift, N. 
Veitch) and its cofactor cocarboxylase were added to a mixture of F-6-P 79 and an excess 
of PEP in either water or 4-morpholinepropanesulfonic acid (MOPS) buffer at pH 7. The 
formation of DAHP 13 was followed using the thiobarbituric acid assay of sialic acids 
developed by Warren (Warren, 1959). In this assay, a pink chromagen absorbing at 549 nm 
is formed by the reaction of oxidised DAHP with thiobarbituric acid (4,6-dihydroxy-2- 
mercaptopyrimidine). 
In MOPS buffer, DAHP formation was markedly decreased compared to reaction in 
unbuffered aqueous solution (fig. 29). Strict anaerobic conditions were not maintained 
during these reactions, as the cofactors required for the later stages of the biotransformation 
reacted adversely with the dithiothreitol and sodium azide which would normally have been 
used. Dissolved oxygen was, however, removed from the reaction mix by displacement 
with nitrogen. 
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(AU) 
A539 H2O pH7 
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T=O 0.14 0.09 
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Figure 29: Formation of DAHP in 50 mM MOPS vs. H2O both at pH 7 
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The conditions of the E. coli DHQ synthase assay were then used to investigate the 
formation of DHS 14 from PEP (Coggins et al., 1987). The reaction was monitored 
spectrophotometrically, with an increase in absorbance at 234 nm corresponding to the 
formation of DHS. When the mixture of DHQ synthase, Co", NAD+ and DHQase were 
added to purified DAHP 13 in water with the pH adjusted to pH 7, the initial reaction rate 
was 1.4 x 10"2 AU. s". However, when the enzymes and cofactors were added to the 
biotransformation mix containing DAHP, no measurable change in absorbance at 234 nm 
was observed over several hours. This lack of reaction was also observed if cocarboxylase 
was added to purified DAHP 13 along with DHQ synthase, DHQase and their cofactors. 
This result is consistent with the mechanism of action of transketolase, as the initial step is 
the addition of a ketone to thiamine pyrophosphate (cocarboxylase) (Stryer, 1988). The 
presence of a reactive carbonyl on both DHQ 10 and DHS 14 which could be attacked by 
the activated nitrogen of cocarboxylase was thought to be the reason for the failure of this 
approach. 
A two-pot approach was thus decided on. DAHP 13 was synthesised from PEP using 
transketolase to generate E-4-P 12 in situ and purified on a DEAE Sephacel column eluted 
with an ammonium hydrogen carbonate gradient. After lyophilisation, the purified DAHP 
was converted to shikimic acid 9 according to the literature protocol (Duggan et al., 1995). 
At this stage, the shikimic acid was not purified, but changes in the UV spectrum were 
consistent with those reported in the literature. 
The first two steps in the biotransformation were monitored at 234 nm, where an increase in 
absorbance corresponded to the formation of 3-dehydroshikimate 14. The final conversion 
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to shikimic acid 9 was monitored indirectly, as the consumption of NADPH gave a 
decrease in absorbance at 340 nm. 
2.2.1.3 Biotransformation from 3-fluoroDAHP 
As 3-fluoroDAHP which had been prepared previously in the group was available, it was 
decided to attempt the biotransformation to the 6-fluoroshikimic acids 1 and 41 using this 
material as substrate (fig. 30). Again, the conditions described in the literature were used 
for this biotransformation (Duggan et at., 1995). 
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Figure 30: Proposed route to the 6-fluoroshikimic acids from 3-fluoroDAHP 
Analysis of the biotransformation mix using a BioRad Organic Acids HPLC column as 
specified by the authors provided no evidence for the formation of the desired fluorinated 
products. '9F-NMR analysis of the starting material then showed that errors in 
characterisation had been made in the original synthesis, and that the compound provided 
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was in fact 3-fluoroPEP. Attention was therefore turned to attempts to form 3-fluoroDAHP 
by biotransformation from 3-fluoroPEP with in situ generation of E-4-P. 
2.2.1.4 Biotransformation from 3-fluoroPEP 
The conditions used to synthesise DAHP 13 from PEP with in situ generation of E-4-P (fig. 
28) were used in this attempt to synthesise 3-fluoroDAHP 66 and 67 from 3-fluoroPEP (fig. 
31). Unfortunately, the sialic acid assay used to follow the formation of DAHP is not 
suitable for assaying the fluorinated equivalents, and we had previously found changes in 
absorbance at 234 nm to be less reliable as an indicator of reaction progress. 
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Figure 31: Attempted biotransformation to 3-fluoroDAHP 
The decrease at 234 nm which would correspond to the consumption of 3-fluoroPEP and 
hence the formation of 3-fluoroDAHP 66 and 67 was not observed over a series of 
reactions. As a result, it was decided to attempt to follow the reaction indirectly. 
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A larger-scale biotransformation was carried out using the same conditions. The reaction 
mix was purified as before on a DEAE Sephacel column eluted with an ammonium 
hydrogen carbonate gradient. The column fractions were assayed for the presence of 
inorganic phosphate after treatment with alkaline phosphatase (Lanzetta et al., 1979). 
Again, the formation of 3-fluoroDAHP was not detected. There was also no reaction when 
the column fractions were assayed using dehydroquinate synthase and dehydroquinase 
along with the relevant cofactors. 
In case a contaminant of the 3-fluoro-PEP used was inhibiting the enzymes, it was decided 
to follow the reaction using19F-NMR to look for anomalous product formation. A greatly 
increased concentration of 3-fluoroPEP 64 and 65 was required compared to that used in 
the earlier biotransformation reactions in order to obtain meaningful 19F-NMR spectra. The 
literature conditions were modified in that the MOPS buffer was omitted, and the E-4-P 
was provided by in situ generation from F-6-P, but otherwise were as published (Duggan et 
al., 1995). Unfortunately, over 12 h, the only fluorinated compounds observed were the 
original isomers of 3-fluoroPEP and the trace fluorinated impurities present in the starting 
material. Changes in the relative height of the peaks in the spectrum were not observed 
over the course of the reaction, indicating that the failure of the biotransformation was not 
due to breakdown of the starting materials under the reaction conditions. 
The published 19F-NMR experiment was then replicated precisely, using freshly 
regenerated, commercially available, E-4-P in 50 mM MOPS buffer at pH 7. Again, no 
sign of the desired 3-fluoroDAHP derivatives 66 and 67 were observed over 42 h. All the 
enzymes had been assayed immediately prior to use in the experiment, and all reagents 
were as specified in the original paper (Duggan et al., 1995). The 3-fluoroPEP used, 
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however, had been a specially commissioned synthesis by D. Picken (Link Technology, 
MIA 31317) and although the major compounds present were the desired isomers of 3- 
fluoroPEP, trace fluorinated impurities were visible in the19F-NMR signal. It is possible 
that an impurity was inhibiting DAHP synthase activity which was not present in the 
original synthesis. This route to (6S)-6-fluoroshikimic acid was therefore abandoned. 
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2.2.2 Synthesis from shikimic acid 
As the paper detailing this synthesis was a communication and therefore gave minimal 
experimental detail, the methods I used (fig. 32) may differ slightly from those which 
yielded the published results. 
McOH, 99 % 
HO OH ii. pTsOH, Me2C(OMe)2 94% 
OH 
9 
02Me O2Me 
Tf2O, DMAP, py 
OH DCM ."c- OTf 
94% 
0 
5ý 
0 
72 73 
1.5 eq. CsOAc 
DMF 
94% 
02Me H GO2Me O2Me 
OH H cat. OsO4, NMO 
OH tBuOH: H2O = 10: 1 
0 
ý0 
46%76 p 
76 75 74 
1.05 eq. TBDMSOTf, 
Et3N, DCM 
70% 
02H I. Amberlite IR120 H+ 
McOH, 99 % 
n ii. pTsOH, Me2C(OMe) 
77 
"F 5 eq. DAST EIIIIIIILOTBDMS 
MS DCM 
89% 
3ýO 
78 
i. LiOH 
dioxane: H20 = 1: 1 
ii. TFA: H20 = 9: 1 
90 
HO " OH 
ÖH 
1 
Figure 32: Synthesis of (6S)-6-fluoroshikimic acid from shikimic acid 
F 
a, 
-OTBDMS 
e 
-54- 
Initial attempts focussed on replicating the published conditions (fig. 26; Song et al., 2001) 
but it was immediately apparent that the synthesis of methyl shikimate could not be carried 
out using CSA as catalyst if it was to be purified prior to acetal formation. The desired 
methyl ester was formed, and could be converted into the protected shikimate derivative 72 
without purification, but the yields obtained were not as high as those quoted. The original 
reference (Chahoua et at., 1992) used amberlite ion-exchange resin to catalyse the 
formation of the methyl ester, and this alternative method was used to form methyl 
shikimate in excellent yield. 
Freshly distilled 2,2-dimethoxypropane was used to form the acetal 72 using pTsOH as the 
acid catalyst. The distillate was less pure than 2,2-dimethoxypropane as purchased, 
however, and higher yields were obtained using the commercially available material. 
After extensive experimentation it was found that the triflate 73 was unstable and had a 
tendency to eliminate partially during workup. If the entire workup was kept cold (Ross et 
al., 2001) including removal of the solvent under reduced pressure, and the material was 
used immediately after purification, both high yields and purity were achieved. 
Initial attempts to form the diene 74 by elimination of 73 were unsuccessful as CsOAc is 
hygroscopic and the reaction appears to be unpredictable if conditions are not strictly 
anhydrous. This was achieved by drying the CsOAc under high vacuum for 30 min before 
adding a solution of the triflate 73 in DMF. Further difficulties were experienced due to the 
instability of the diene. Even at -20°C the material decomposed completely within 10 h, 
and at 25°C evidence of decomposition was observed within a few hours. Excellent yields 
were eventually achieved by using an excess of dry CsOAc, carrying out the workup using 
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solvents and aqueous materials cooled to 4°C, and by using the diene 74 immediately after 
purification. 
Formation of the diol 76 by osmium catalysed dihydroxylation using NMO as the 
stoichiometric oxidant was carried out using a combination of the conditions given in the 
communication (Song et al., 2001) and the proportion of reagents used for the 
dihydroxylation of a similar quinic acid-derived compound (Barco et al., 1998). Separation 
of 75 and 76 was achieved using a gradient elution on a silica-gel column and the desired 
compound was eventually isolated in moderate yield. The use of Os04 which had not been 
in solution for longer than six weeks was found to be crucial as dihydroxylation of both 
double bonds of diene 74 was found to occur more readily when the Os04 catalyst had been 
stored for an extended period in aqueous solution. 
Treatment of the diol 76 with 1.1 equivalents of TBDMSOTf gave selective protection of 
the C-S hydroxyl as a silyl ether in good yield. Using a greater excess of TBDMSOTf 
reduced the yield of the desired compound as formation of the bis-silylated product was 
found to predominate. The difficulties associated with purification were also increased 
under these conditions. The crystalline product 77 was then treated with DAST 
(Middleton, 1974) in DCM. The protected 6-fluoroshikimic acid derivative 78 was 
obtained in excellent yield after purification. 
Deprotection was carried out in two steps. The methyl ester was cleaved by treatment with 
LiOH in a water/dioxane solvent mix. The crude material from this reaction was then 
treated with a TFA/water mix to simultaneously cleave the silyl ether and acetal protecting 
groups. By'H-NMR three fluorine-containing compounds were formed, with the major 
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product being the desired (6S)-6-fluoroshikimic acid 1. Only a small amount of material 
was deprotected in order to confirm that the correct diastereomer had been formed as the 
protected derivative 78 was required for further syntheses. 
Purification of (6S)-6-fluoroshikimic acid 1 was attempted on an Organic Acids HPLC 
column eluting with 50 mM formic acid at 0.6 mL. min-'. The major peak, believed to be 
(6S)-6-fluoroshikimic acid by 'H-NMR analysis, eluted at 10.2 min as compared with the 
literature value of 10.8 min during a series of analytical runs on a small sample of the crude 
material (Duggan, 1995). However, when the remainder of the product was dissolved in 
water and a preparative run was attempted, the compound was found to have decomposed. 
No further purification was possible. 
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2.3 Conclusions and future work 
The decision to synthesise (6S)-6-fluoroshikimic acid by biotransformation from E-4-P and 
F-PEP was based on a number of factors. Firstly, the chemistry involved in the syntheses 
from quinic acid (flig. 23 & 24) was not only likely to be time-consuming, but also required 
a degree of experience in the reactions carried out which was not available in our 
laboratory. Secondly, the biotransformation route (fig. 25) was both higher yielding and 
apparently less time-consuming. Members of our laboratory had experience of working 
with the enzymes of the shikimate pathway and the purification methods required for the 
enzyme substrates. 
As detailed in this chapter, attempts to synthesise (6S)-6-fluoroshikimic acid by 
biotransformation were unsuccessful. We believe that this was due to an inorganic 
contaminant of the F-PEP substrate which was not apparent during 
'H-NMR or '9F-NMR 
analysis and which was inhibiting DAHP synthase. It is possible that purification of the 
substrate on an ion-exchange column would have eliminated this contaminant. 
The synthesis from shikimic acid (fig. 26 & 32) is a significant improvement over those 
from quinic acid as it is both shorter and higher-yielding. It is unfortunate that the (6S)-6- 
fluoroshikimic acid decomposed unexpectedly before full purification could be carried out, 
as this resulted in the lack of a positive control for the biological testing of the smugglins. 
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3 Peptide-shikimate conjugates as prodrugs 
3.1 Prodrugs 
As detailed in Chapter 1 (section 1.6), prodrugs are pharmacologically inactive derivatives 
of drug molecules which are converted into the active form in vivo. Changes to the 
structure of the molecule may be made in order to increase bioavailability by modifying 
e. g. solubility, but prodrugs can also be designed to target specific enzymes or carriers e. g. 
peptide transporters. 
3.2 The oligopeptide permease as a prodrug target 
As detailed in Chapter 1, the oligopeptide permease (Opp) is a periplasmic binding protein- 
dependent system which preferentially transports tri-and tetrapeptides into bacterial cells 
(Matthews & Payne, 1980; Payne, 1978; Payne, 1980). Amino-acid side chains are 
accommodated in large hydrated pockets within OppA, with highly-ordered water 
molecules within these pockets satisfying hydrogen-bond requirements without imposing 
binding specificity (Tame et al., 1996; Sleigh, 1999; Rostom, 2000). 
This ability to accommodate a wide variety of natural and unnatural amino-acyl side chains 
suggested the possibility of constructing a `smugglin' which would target the Opp as a 
means of transporting (6S)-6-fluoroshikimic acid into bacterial cells. 
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3.3 Peptides conjugated to (6S)-6-fiuoroshikimic acid 
3.3.1 Design 
As (6S)-6-fluoroshikimic acid has been shown to be an effective antimicrobial both in vitro 
and in vivo, the prodrug approach to increasing bioavailability is unnecessary. (Davies et 
al., 1993) However, the rapid development of resistance to the compound due to mutation 
of the specific bacterial transporter involved suggested that a `smugglin' approach might be 
viable (Ewart et al., 1995). 
As all three peptide permeases in E. coli and S. typhimuricun transport tripeptides to some 
extent, it was decided to attempt an initial synthesis of tripeptide conjugates of (6S)-6- 
fluoroshikimic acid. The tripeptides were chosen based on the known specificity of the 
oligopeptide permease, the crystallographic data available on binding to OppA, and the 
need for a cleavable linkage from the peptide to (6S)-6-fluoroshikimic acid. 
Modification of the N- or C-terminal ends of a tripeptide eliminates, or at least greatly 
reduces, binding to OppA and transport by the oligopeptide permease. As a result, it was 
decided to attach (6S)-6-fluoroshikimic acid to an arnino-acyl side chain using a linkage 
which would be readily cleaved within bacterial cells. Both an ester linkage to the 
hydroxyl of serine and an amide linkage to the c-amino group of lysine were considered. 
The amide linkage was chosen as it is more stable, but likely to be readily cleaved by 
intracellular peptidases to release the active compound. 
Various binding studies of OppA have suggested that positively charged side chains in a 
peptide reduce binding to OppA, while hydrophobic residues are preferred. (Guyer et al., 
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1986) The detail of crystal structures also showed that the C-terminal amino acyl side 
chain was often disordered, and suggested that modifications at this position might be 
better tolerated than at either of the first two. (Davies et al., 1999) The results obtained 
from co-crystallising a series of unnatural amino acids in tripeptides of the form Lys-X-Lys 
with OppA (Davies et al., 1999) also suggested that relatively large moieties could be 
accommodated in the side-chain binding pockets. 
In order to maximise the potential information on the transport of peptide-shikimate 
conjugates, it was decided to synthesise tripeptides of the form XXLys where X could be 
aliphatic, aromatic, polar, or charged. The amino acids chosen were alanine, leucine, 
phenylalanine, serine and glutamic acid. (65)-6-Fluoroshikimic acid would then be linked 
to the side-chain of the C-terminal lysine in each tripeptide to give compounds 4 through 8 
(fig. 33). 
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Figure 33: Structure of the smugglins designed to target the Oligopeptide permease 
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3.3.2 Proof of concept: N-s-shikimoyl-L-lysyl-L-phenylalanine 
As an initial proof-of-concept, it was decided to attempt the synthesis of an easily-purified 
dipeptide-shikimate conjugate. Using shikimic acid instead of (6S)-6-fluoroshikimic acid 
would allow method development while the synthesis of the fluorinated derivative was 
ongoing, while also reducing the cost of the model synthesis. Synthesising a dipeptide 
conjugate rather than the tripeptide conjugates would facilitate purification, as solution- 
phase peptide synthesis could be used rather than the solid-phase methods preferred for 
longer-chain peptides. 
The dipeptide conjugate chosen was N-c-shikimoyl-L-lysyl-L-phenylalanine 83. The 
phenylalanyl moiety was chosen to facilitate purification by increasing the hydrophobicity 
of the dipeptide and peptide conjugate, as well as to give a clearly distinguishable UV- 
active TLC. A further advantage of the phenylalanyl moiety was that 'H-NMR signals 
from the dipeptide would be unlikely to overlap with those from the shikimate moiety. 
Results and discussion: 
The hydroxyl groups of shikimic acid were protected as acetates by reaction with acetic 
anhydride in pyridine. The reaction was carried out on both a gram and milligram scale to 
give the tri-acetate 80 in excellent yield. 
02H 
HO - OH 
OH 
9 
Ac20, pyridine 
OOC -. rt 
98% 
02H 
AcO" OAc 
OAc 
80 
Figure 34: Protection of shikimic acid as the tri-O-acetate 
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The protected dipeptide Boc-Lys(Z)-Phe-OMe 81 (Boc is butoxycarbonyl; Z is 
benzyloxycarbonyl) was synthesised using standard solution-phase methodology and was 
obtained in excellent yield. The coupling reagent 1-(3-dirnethylarninopropyl)-N- 
ethylcarbodiimide hydrochloride (EDC) was used with the addition of 1- 
hydroxybenzotriazole (HOBt) to minimise racemisation. After deprotection of the s-amino 
group of the lysine moiety by hydrogenolysis, a standard peptide coupling reaction with 
protected shikimic acid 80 gave the fully protected peptide conjugate 82 in good yield. 
Deprotection was carried out by sequential treatment with NaOH and TFA to give the 
desired dipeptide-shikimate conjugate 83 as the major product by'I-l-NMR analysis. 
Analysis of the crude isolate by I-IPLC using a combined UV and conductivity detection 
system showed a single major peak. 
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3.3.3 Model syntheses: tripeptide shikimate conjugates on solid phase: 
As previously discussed, five tripeptide conjugates of the form XXLys (where X is one of 
alanine, leucine, phenylalanine, serine or glutamic acid) were chosen for the initial 
investigation of the oligopeptide permease as a means of targeting (6S)-6-fluoroshikimic 
acid to bacterial cells. It was decided to develop the solid-phase methodology using 
shikimic acid to reduce the cost of the model syntheses and to allow method development 
to be carried out in tandem with attempts to synthesise (6S)-6-fluoroshikimic acid. 
The substitution of a fluorine atom for a hydrogen atom at C-6, while having a significant 
effect on the biological activity of shikimic acid, was not thought likely to have any major 
effect on either the reactivity or solubility of the compound. As a result, it was believed 
that the methods developed in the syntheses of the five model conjugates would be directly 
applicable to the final target syntheses. 
N-a-Fmoc-amino acid residues (Fmoc is 9-fluorenylmethoxycarbonyl) were used to build 
up the tripeptides on Wang resin in all syntheses. The resin was purchased pre-derivatised 
with an orthogonally protected lysine residue 84. 
H 
Fmoc"N O-Wang Resin 
84 
Figure 36: Wang resin coupled to an orthogonally protected lysine residue. 
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As shikimic acid was to be coupled to the c-amino group of the C-terminal lysine the 
protecting group for this amino group needed to be stable to standard Fmoc solid phase 
chemistry. It also needed to be readily cleavable under conditions which would not cause 
cleavage of the peptide from the resin, or cleavage of the t-butyl protecting groups on the 
side chains of the glutamic acid and serine residues. The 4-methyltrityl (Mtt) protecting 
group, which is base stable, but readily cleaved using 1% TFA, 5% tri-isopropyl silane 
(TIPS) in DCM, was a logical choice (Aletras et a!., 1995). 
Results and Discussion: 
The basic method of synthesis was invariant, and is summarised in figure 37. Later 
syntheses involved the coupling of shikimic acetate 80 to preformed tripeptide chains as in 
the synthesis of the (6S)-6-fluoroshikimate conjugates 4-8 (fig. 42). 
The 4-methyltrityl protecting group on the resin-bound lysine residue 84 was removed by 
treatment with 1% TFA in dry DCM with the addition of 5% tri-isopropylsilane (TIPS) to 
trap the trityl cations and reduce the likelihood of side-reactions. The resin was then dried 
under a steady air stream at reduced pressure as the presence of residual methanol used to 
wash the resin during deprotection completely inhibited coupling to shikimic acetate. The 
dried resin was then coupled to shikimic acetate 80 using a large excess of DIC and HOBt 
in dry DCM and extended reaction times to ensure coupling occurred. If the standard 3 eq. 
of DIC was used in this step, coupling was either extremely limited or non-existent, 
depending on the tripeptide involved. 
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Figure 37: Solid-phase synthesis of shikimate tripeptide conjugates 
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The Fmoc protecting group on the now-derivatised resin-bound lysine residue 85 was 
cleaved by treatment with 20 % piperidine in dry DMF. Bromophenol blue was initially 
used to test for the presence of free amino groups on the resin, but the inaccuracy of the 
results meant that this approach was abandoned. All cleavage reactions were then carried 
out a set number of time, over a fixed minimum reaction time. The deprotected residue was 
then coupled to the relevant Fmoc protected amino acid derivative using a large excess of 
di-isopropyl carbodiimide (DIC) and HOBt in dry DMF to give the protected, resin- 
attached dipeptide-shikimate conjugate 86. Again, the use of bromophenol blue to test for 
complete reaction gave unsatisfactory results and all coupling reactions were allowed a 
minimum reaction time of two hours. The deprotection and coupling steps were repeated to 
give the desired resin-attached tripeptide-shikimate conjugate 87. 
Cleavage from the resin using 25 % TFA in DCM gave the desired tripeptides conjugated 
to shikimic acid protected as the triacetate. At this stage, 'H-NMR was used to confirm that 
coupling had occurred. The characteristic doublet of doublets at -2.5 ppm due to the CH2 
protons on C-6 of shikimic acid was generally not obscured by peptidic protons, and 
provided a marker for successful coupling reactions. 
'H-NMR analysis was followed by deprotection of the shikimate moiety by treatment with 
NaOH in MeOH: H20 (1: 4). As the product tripeptide conjugates 88 were only soluble in 
methanol or acid, it was found impossible to separate them from the NaOAc released in this 
deprotection step without recourse to HPLC. HPLC-Mass spec analysis was used to 
confirm the presence of the desired compounds in the crude material, with ms/ms 
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confirming the identity of selected peaks, before the method was applied to the synthesis of 
the target tripeptide-(6S)-6-fluoroshikimic acid conjugates. 
The conjugates were not purified at this stage, as it was felt that the limited time remaining 
for experimentation would be better used in attempting the synthesis of the final target 
compounds. Crude yields are noted in the experimental section (Chapter 5) 
3.3.4 Tripeptide (6S)-6-fluoroshikimic acid conjugates on solid phase: 
As `H-NMR analysis had shown the successful formation of all five model peptide- 
shikimate conjugates, an attempt was made to transfer the methodology to the synthesis of 
the same five tripeptides conjugated to (6S)-6-fluoroshikimic acid. 
Problems were immediately encountered, as attempts to protect the hydroxyl of (6S)-6- 
fluoroshikimic acid 1 by reaction with acetic acid in pyridine led to total decomposition and 
the formation of 3,5-diacetoxybenzoic acid 89 (rig. 38). The substitution of a fluorine for a 
hydrogen on C-6 gave only a 0.1 ppm change in the 'H-NMR signal for the protons on both 
C-3 and C-5, characteristic of a slight increase in acidity at these positions. Surprisingly, 
therefore, base-catalysed elimination of the components of acetic acid, followed by those of 
hydrofluoric acid, was observed. Fluoride is normally an extremely poor leaving group, but 
the driving force of aromatisation was apparently sufficiently strong as to overcome this. 
It would be possible to overcome this difficulty by using a base such as 2,6-lutidine which 
is more sterically hindered than pyridine, and hence less nucleophilic. However, as the 
tripeptide conjugates are all protected at the N-terminus with an Fmoc group, and this is 
removed using 20 % piperidine in DMF (which is likely to have the same effect as 
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pyridine), an alternative protection strategy for the hydroxyl groups of (6S)-6- 
fluoroshikimic acid was required. 
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Figure 38: Base-catalysed aromatisation of (6S)-6-fluoroshikimic acid 
The obvious solution was to use the product of the penultimate step in the synthesis of (6S)- 
6-fluoroshikimic acid detailed in Chapter 2 (jig. 32), where the C-5 hydroxyl is protected as 
a silyl ether, and the C-3 and C-4 hydroxyls as a ketal (90). As this compound has already 
been shown to be stable to LiOH hydrolysis during the saponification of a methyl ester, 
deprotection of Fmoc groups should not be problematic. Additionally, as these groups are 
removed by treatment with 90 % TFA in DCM, purification of the peptide conjugates after 
cleavage from the resin should be simplified relative to the model compounds. 
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As the phenylalanine-containing tripeptide-shikimate conjugate had shown the most 
complete coupling by 'H-NMR analysis (conjugate: tripeptide = 1: 3 by visual inspection), 
it 
was decided to attempt the synthesis of this tripeptide conjugated to (6S)-6-fluoroshikimic 
acid in the first instance 91 (fig. 39). 
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Figure 39: Proposed coupling of fully protected (6S)-6-fluoroshikimic acid to resin-bound 
Fmoc-Phe-Phe-Lys 
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Again, direct transfer of the methods developed in the model synthesis was not possible. 
After cleavage of the products from the resin, 'H-NMR analysis showed no coupling 
between the E-amino group of lysine and the carboxylic acid of the (6S)-6-fluoroshikimic 
acid derivative 90. Addition of triethylamine to the coupling mix, in an attempt to increase 
the proportion of deprotonated carboxylic acid, was also unsuccessful. 
We now believe that the increased electronegativity at C-6 due to the presence of the 
fluorine in (6S)-6-fluoroshikimic acid reduces the reactivity of the carboxylic acid moiety 
towards electrophiles. As a result, addition of the carboxylic acid to DIC in the initial step 
of peptide bond formation is less likely to occur, and hence the lack of coupling observed. 
The formation of `difficult' peptide bonds, such as those involved in synthesising cyclic 
dipeptides, is often facilitated by benzotriazol-l-yloxy-tris(dimethylamino)phosphonium 
hexafluorophosphate (BOP) 92, also known as Castro's Reagent (El Mahdi et al., 2000). 
The initial step in BOP-coupled peptide bond formation is attack by the carboxyl moiety 
onto a charged phosphorus atom with the strong thermodynamic driving force of P-O bond 
formation favouring reaction. In contrast, carbodiimide coupling reagents involve attack by 
the carboxyl moiety on a neutral carbon atom. As a result, the deactivated carboxyl of the 
acid derivative 90 should react to give the activated HOBt ester 93 and hence peptide bond 
formation. 
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Figure 40: Suggested initial step of BOP-facilitated peptide bond formation 
Test reactions on the derivatised resin 84 showed that the desired amino-acid conjugate 94 
was formed, although a tertiary amine was also required to be present in excess. The 
coupling did not proceed to completion, reaching -45 % after 24 h reaction by 'H-NMR 
analysis of the crude material cleaved from the resin. 
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5% TIPS, H0 
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,. F,, 
F 
OTBS Cr%%' OTBS 
Figure 41: Test coupling of (6S)-6-fluoroshikirnic acid to resin-bound lysine 
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Synthesis of the five tripeptide-(6S)-6-fluoroshikimic acid conjugates 4 to 8 (Chapter 3, fig. 
33) was then undertaken. It was believed that steric hindrance at the resin would favour 
carrying out the challenging coupling to lysine before building the peptide chain. However, 
as complete coupling could not be achieved even over 24 h reaction and with a 6-fold 
excess of BOP (fig. 41), it was decided to avoid the formation of a wide variety of branched 
peptides by coupling the (6S)-6-fluoroshikimic acid derivative to the completed tripeptide 
chains (fig. 42). 
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Figure 42: Solid-phase synthesis of tripeptide-(6S)-6-fluoroshikimic acid conjugates 
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The conditions developed for the synthesis of the model compounds were used in order to 
synthesise the tripeptide chains, i. e. standard Fmoc-based solid phase synthesis using 
DIC/HOBt coupling. After cleavage of the Mtt group, BOP with the addition of an excess 
of Et3N was used to couple the (6S)-6-fluoroshikimic acid derivative to the c-amino group 
of lysine of the tripeptide 95 to give the protected resin-bound conjugates 96. The 
conjugates were then cleaved from the resin and partially deprotected by treatment with 3: 1 
TFA: DCM. Protection was completed by treatment of the crude material with 9: 1 
TFA: H20. Crude yields are given in figure 43. 
Compound 
synthesised 
4 
(Ala) 
5 
(Leu) 
6 
(Phe) 
7 
(Ser) 
8 
(Glu) 
resin-bound lysine: 72 72 72 72 72 
starting material 
( lmol) 
crude material 43 62 86 67 81 
isolated (mg) 
Figure 43. Crude yields of tripeptide-(6S)-6-fluoroshikimate conjugates 
HPLC/Ms-ms analysis was used to confirm the presence of the desired compounds 4 to 8 in 
the crude material cleaved from the resin. All five compounds were present and could be 
separated from the crude mixture using an RP Max HPLC column eluting with a3 to 50 % 
gradient of 50 mM formic acid in MeCN. 
It was decided to attempt the purification of the leucine 5 and phenylalanine 6 containing 
conjugates as these gave the most clearly separated peaks. A preparative RP Max HPLC 
column was used for the separation. The fractions containing the desired compounds were 
selected by analysing a small sample of the eluent by Ms-ms. These fractions were 
combined, lyophilised, and stored at -20°C. 
-77- 
3.1.5 Biological testing of (6S)-6-fluoroshikimic acid conjugates 
Initial biological testing was carried out by Dr R. Aitken at the University of Glasgow. A 
lawn of E. coli K12 (the strain used for the original testing of (6S)-6-fluoroshikimic acid) 
was grown on solid medium based on a minimal glucose medium with thiamine 
supplementation (buffer 56) first described in 1951 (Monod et al., 1951; Davies et al., 
1994; Ewart et al., 1995). 
A control experiment, spotting a solution of ampicillin into the centre of the lawn, gave 
inhibition in the 50 - 100 yg range. This suggested that the chosen test method was fairly 
insensitive. However, as (6S)-6-fluoroshikimic acid displayed MICs below 0.5 yg. mL"' 
against this strain of E. coli (Davies et al., 1994) it was decided to test the leucine- 5 and 
phenylalanine-containing 6 conjugates in the same way. 
The conjugates were dissolved in 50 mM formic acid, which had previously been shown to 
have no effect on bacterial growth, and spotted onto the centre of a lawn of E. coli K12 on a 
solid buffer 56 plate. No evidence of antibacterial activity was observed after overnight 
incubation at 37°C. 
A second method of testing was then attempted. E. coli K-12 (wild type) bacteria were 
brown at 37°C in a 96-well plate in buffer 56 liquid medium (Monod et al., 1951). 
Ampicillin (20 mg/mL), formic acid (50 mM) and phosphate buffered saline were used as 
controls against six- and two-fold serial dilutions of the test compounds in 50 mM formic 
acid. Growth was monitored by measuring the absorbance at 620 nm. 
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The leucine containing tripeptide conjugate appeared to have a very slight inhibitory effect 
on the growth of E. coli K-12 as compared to the negative controls, and this effect appeared 
to decrease with increasing dilution of the compound (fig. 44). However, the effect was not 
comparable with that of ampicillin (fig. 45), and the variation in absorbance values obtained 
suggested that growth inhibition by the conjugate was marginal. 
The concentrations given below are based on an assumed maximum yield of 2 mg of active 
compound after HPLC purification. This is due to the fact that although compound was 
clearly present after lyophilisation, a negative mass was obtained by difference using a four 
decimal-place balance. 
formic acid 
(negative control) 
6 (Phe) 5 (Leu) 
mm A620 
T=2h 
A620 
T=4.5 h 
`iM A620 
T=2 h 
A620 
T=4.5 h 
JIM A620 
T=2 h 
A620 
T=4.5 h 
12.5 0.432 0.460 407 0.362 0.470 457 0.257 0.269 
12.5 0.440 0.555 68 0.415 0.494 76 0.257 0.343 
12.5 0.471 0.578 11 0.532 0.593 13 0.405 0.516 
1.9 0.500 0.582 2.1 0.365 0.569 
0.3 0.378 0.479 0.4 0.306 0.458 
0.05 0.390 0.563 0.06 0.342 0.538 
Figure 44: Growth of E. coli K-12 (A620): six-fold serial dilution of active compounds 
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ampicillin 
(positive control) 
PheFshik 6 LeuFshik 5 
mm A620 
T=2 h 
A620 
T=5.5h 
YM A620 
T=2 h 
A620 
T=5.5h 
YM A620 
T=2 h 
A620 
T=5.5h 
23 0.088 0.069 650 0.163 0.186 732 0.148 0.176 
11 0.087 0.072 325 0.166 0.197 366 0.143 0.168 
5.7 0.089 0.071 163 0.175 0.212 183 0.156 0.198 
2.9 0.097 0.066 81 0.178 0.219 91 0.150 0.189 
1.4 0.097 0.073 41 0.189 0.288 46 0.164 0.199 
0.7 0.102 0.073 20 0.194 0.222 23 0.181 0.217 
0.4 0.104 0.073 10 0.205 0.228 11 0.239 0.221 
0.2 0.117 0.078 5.1 0.233 0.228 5.7 0.243 0.240 
Figure 45: Growth of E. coli K-12 (A620): two-fold serial dilution of active compounds 
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3.4 Conclusions/Future Work 
Although five `smugglins' consisting of (6S)-6-fluoroshikimic acid conjugated to 
tripeptides were synthesised, only two have been tested for biological activity. These were 
chosen for their ease of purification and as such are the least hydrophilic of the five 
compounds synthesised. 
This hydrophobicity may be a reason for the lack of biological activity observed when the 
conjugates were tested against E. coli K12. However, an alternative explanation is that 
while the oligopeptide permease will tolerate a wide variety of peptide side-chains, the 
addition of the (6S)-6-fluoroshikimic acid moiety to the side chain of lysine exceeds the 
space available in the binding pocket. 
The crystal structures of tripeptides containing one of a variety of unnatural amino acids 
bound to OppA were published in 1999 (Davies et al., 1999) and suggest that while a side- 
chain as bulky as naphthalene can be accommodated, it is tending towards the limit of what 
is possible. 
A modification of the smugglin design to take this into account could be easily made, with 
the substitution of 2,3-diaminopropionic acid for the C-terminal lysine. This could make 
the coupling of the protected (6S)-6-fluoroshikimic acid to the resin-bound tripeptide more 
challenging due to steric interactions between BOP and the resin. It would, however, 
greatly reduce the bulk of the `side chain' at position three of the tripeptide conjugates, and 
might therefore increase the likelihood of the smugglins being transported by OppA. 
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4 Dehydroquinase and 3-dehydroquinic acid 
4.1 Brief Introduction 
Dehydroquinase (3-dehydroquinate dehydratase EC 4.2.1.10; DHQase) catalyses the 
conversion of DHQ 10 to DHS 14 (fig. 46). This reaction is not only part of the shikimate 
pathway, as described in Chapter 1 (jig. 5), but is also part of a catabolic pathway found 
mainly in fungi: the quinate pathway (Chapter 1, fig. 14). In this catabolic pathway, 
quinate is converted to p-hydroxybenzoate which can be used as a carbon-source via the (3- 
ketoadipate pathway (Gross, 1958; Ornston & Stanier, 1966). 
HQ O2H AHA 
dehydroquinase 
O OH O H 
ÖH OH 
10 14 
Figure 46: The reaction catalysed by DHQase 
Two types of enzyme exhibiting DHQase activity have been described. Type I enzymes, 
which involve a syn elimination, generally catalyse the biosynthetic reaction. Type 11 
enzymes can catalyse either the biosynthetic or catabolic reaction, and involve an anti 
elimination. The two enzyme types differ in terms of their amino-acid sequence, their 3- 
dimensional structure, and their catalytic mechanism (Gourlay et al., 1999; Roszak et al., 
2002). Type I enzymes are dimers of 27 kDa subunits which contain an (a/13)8 fold while 
type II enzymes are dodecameric, with the 16 kDa subunits arranged as tetramers of 
trimers. Each type 11 subunit adopts a flavodoxin-like fold consisting of a 5-stranded 
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parallel ß-sheet core flanked by 4 a-helices. The reaction catalysed by the type I DHQases 
is known to proceed via an imine intermediate (Butler et a!., 1974; Chaudhuri et al., 1991), 
while that catalysed by type II enzymes is believed to involve an enol intermediate (Roszak 
et al., 2002). 
HQ O2H 
a, 
b 
O OH 
OH 
AO 
b 
Type 
DHQase O OH 
ÖH 
14 
10 Type II 
DHQase 
02H 
a 
O OH 
OH 
Figure 47: The differing outcomes of catalysis by type I and type II DHQases 
Kinetic characterisation of the type II DHQases appears to divide them into two groups. 
The first group, consisting of the enzymes from organisms such as Streptomyces coelicolor 
and Aspergillus nidulans, has relatively high values of kcal at between 100 and 1000 s"' at 
pH 7.0 and 25°C. The second group, which includes the enzymes from Helicobacter 
pylori, Mycobacterium tuberculosis and Neurospora crassa, has much lower values of kc,, 
in the range 10 s"' or lower. Unusually, there appears to be no obvious correlation between 
the values of kcand Km for these enzymes (Evans et al., 2002). 
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4.2 Rationale for a new synthesis of 3-dehydroquinic acid 
DHQ is required in quantity for the kinetic investigation of type II DHQases in our 
laboratory. In particular, stopped-flow kinetic analysis requires equimolar concentrations 
of enzyme and substrate in order to study the first few milliseconds of a reaction. At these 
concentrations, any minor impurity in the substrate can greatly affect both the interaction of 
enzyme and substrate and the UV absorbance of the reaction mixture. 
In addition, several versions of type II DHQases with very low rates of reaction have been 
obtained either by isolation or by genetic modification in the laboratory. Even steady-state 
kinetic investigation of these mutants involves very high concentrations of the substrate 
DHQ. As a result, the elimination of background absorbance from the substrate used was 
crucial for the observation of activity. 
A source of uncontaminated DHQ is therefore essential for unambiguous experimental 
results. 
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4.3 Published syntheses of 3-dehydroquinic acid 
4.3.1 Nitric acid 
The synthetic method of choice in our laboratory has been the classical synthesis in which 
quinic acid 19 was oxidised by concentrated nitric acid over 45 h to give DHQ 10 (fig. 
48)(Grewe & Jeschke, 1966). 
HQ 02H 
HO', ' OH 
OH 
19 
HNO3,0°C 
45-50% 
HO 02H 
0 OH 
OH 
10 
Figure 48: Synthesis of DHQ by nitric acid oxidation of quinic acid 
The reaction products were separated by lengthy ion-exchange chromatography using the 
acetate form of basic Amberlite CG-400/1 and the DHQ further purified by a difficult 
crystallisation as the ammonium salt (55 - 60 %). The free acid was obtained by ion- 
exchange chromatography using Amberlite IR-120 and crystallised from isopropanol/pet. 
ether (45 - 50 %) 
In our hands, complete separation of the 3- and 5-dehydroquinic acids formed was not 
achieved, and the product was further contaminated by a highly UV-absorbing aromatic 
compound. These contaminants severely limited the utility of the product as 5- 
dehydroquinic acid is thought to be an inhibitor of DHQase, and at the concentrations 
required for kinetic analysis, the spectrophotometer was overloaded by the UV absorbance 
of the aromatic impurity. 
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4.3.2 Pt catalysed oxidation 
An alternative preparation was reported in 1961 (Heyns & Gottschalk, 1961). Their 
method was based on the observation that under catalytic conditions, an axial hydroxyl will 
be oxidised to the corresponding ketone while any equatorial hydroxyls are unaffected. 
The six-membered ring of quinic acid 19 exists in a chair conformation, with the Cl- 
carboxyl group equatorial. As a result, both the C-4 and C-5 hydroxyl groups are 
equatorial, while the C-1 and C-3 hydroxyl groups are axial. Platinum thus catalyses the 
exclusive oxidation of the C-3 hydroxyl to the ketone (fig. 49). 
HO 02H 
H H20, Pt/02 
HO2 1 OH 
1 31 
OH OH 500C O OH 
OH 
19 10 
Figure 49: The Pt-catalysed oxidation of quinic acid to DHQ 
The published reaction was carried out in water on a5g scale using a platinum catalyst in 
an oxygen atmosphere. The product was isolated as the brucine salt in 45 % yield after 
repeated recrystallisation. 
4.3.3 Formal synthesis to methyl ester 
In their investigation of inhibitors of DHQ synthase, the Frost group utilised the butane 2,3- 
bisacetal (BBA) protecting group to selectively protect the trans diequatorial diol of quinic 
acid (Tian et al., 1996). BBA was developed to avoid problems associated with the earlier 
trans-diol selective protecting groups 3,3', 4,4'-tetrahydro-6,6'-spirobi-2H-pyran (bisDHP) 
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and 1,1,2,2-tetramethoxycyclohexane (TMC) (Montchamp et at., 1996). It is easily 
prepared, does not require chromatographic purification, unlike bisDHP it can be used in 
methanol, and unlike TMC it does not give a complex NMR signal (Ziegler, 1994). 
HQ 02H 
Ha', ' - OH OH 
19 
1. MeOH, Dowex 50 H+ 
2. TMB, HC(OMe)3, CSA 
81 %, 2 steps 
97 
Me 
KlO4, K2C03, RUCI3 
H2O/CHC13 
77% 
HO O2Me 
O 
, OMe 
MeO 
98 
Figure 50: Formal synthesis of DHQ 
Quinic acid 19 was protected as the methyl ester by refluxing in acidified methanol. The 
ester was then reacted with TMB in the presence of trimethyl orthoformate and catalytic 
(±)-10-camphorsulfonic acid (CSA) to give the protected compound 97 in 87 % yield. 
Ruthenium-catalysed oxidation of the unprotected C-3 hydroxyl then gave the protected 3- 
DHQ derivative 98 in 77 % yield (fig. 50). 
In their route to (-)-methyl shikimate and various derivatives modified at C-3, the Payne 
group used a modification of this synthesis (Alves et al., 1999). Starting from methyl 
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quinate 99, the BBA protection step was catalysed by p-toluenesulfonic acid (p-TSA). The 
reaction time for this protection was also shortened from 22 h to 1 h, increasing the yield 
from 81 % to 85 %. Swern oxidation of the quinate derivative 97 then afforded the fully 
protected 3-DHQ derivative 98 in 74 % yield with the corresponding protected shikimate 
derivative 100 as a significant byproduct fig. 51). 
HQ O2Me HQ O2Me TMB, HC(OMeh, 
p-TSA 
HO'" - OH 
85 % HO', 
OH .. 'OMe 
99 MeO 
97 
(COCI)2, DMSO, DIEA 
DCM 
95% 
HO O2Me O2Me 
OO 
,,, OMe 
- .,, OMe 
Me0 Me0 
98 100 
Figure 51: Formal synthesis of DHQ and DHS 
The DHQ derivative 98 was not deprotected in either of these synthetic routes. 
4.3.4 Benzylidene acetal/lactone protection 
A key intermediate in the synthesis of (2R)-2-bromodehydroquinic acid and (2R)-2- 
fluorodehydroquinic acid published by the Abell group was a protected form of 3- 
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dehydroquinic acid (Manthey et al., 1997). Reaction of quinic acid 19 with benzaldehyde 
under acid catalysis with azeotropic removal of water gave the benzylidene acetal 101, 
which was then hydrogenated to give quinic acid lactone 102 in excellent yield. Reaction 
of the lactone with tbutyldimethylsilyl chloride (TBDMSCI) in DMF gave a 1: 2 mixture of 
the C-5 protected compound 103 and the desired C-4 protected lactone 104. The authors 
noted that the undesired compound 103 could be converted to a mixture of 103 and 104 on 
re-exposure to the reaction conditions. The C-3 secondary hydroxyl was then oxidised 
using pyridinium dichromate (PDC) to give the acid-sensitive DHQ derivative 105 in 
excellent yield (fig. 52). 
HO 02H HQ HQ 
PhCHO, pTsOH H2, [10 %] Pd/C 
O 
HO'' OH PhMe, reflux AcOH, rt HO' 
OH 74%o H-O 94% OH 
Ph 
19 101 102 
TBDMSCI, DMAP, 
Et3N, Bu4N I 
DMF, 90 °C 
54 % of 4.11 
HQ HQ HQ 
PDC, 4A sieves + 
p DCM, rt HO'"' TBDMSO"' _ 
OTBDMS 87% OTBDMS OH 
105 104 103 
Figure 52: Formal synthesis of DHQ via the quinide. 
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The alternative method of direct lactonisation published by in 1954 (Panizzi, 1954) was 
mentioned in this paper, but the authors found it to be experimentally inferior to the two- 
step procedure. The one-step procedure involved refluxing quinic acid 19 in a large 
volume of dry dioxane with 0.3 eq. dry HCl for 6-7 hours, and neutralising with dry 
K2CO3 (fig. 53). 
HO 02H HO 
cJ 
1. dioxane-HCI 
0 
HO''' OH 2. K2CO3 HO', 
OH 42% OH 
19 102 
Figure 53. Direct lactonisation of quinic acid to give the quinide 
The quoted yield was 3.8 g of the lactone 102 from 10 g of quinic acid, or 42 % as 
compared to 70 % quoted for the two-step procedure. 
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4.4 Results and Discussion 
4.4.1 BBA 
The route to BBA-protected methyl-DHQ (Tian et al., 1996) (ftg 50) provided the logical 
starting point for an attempted synthesis of DHQ. The only novel steps involved would be 
removal of the acid-sensitive BBA moiety, and saponification of the ester. 
Attempts to replicate the literature protocol 
TMB 108 was prepared according to the literature protocol (Montchamp et al., 1996). 2,3- 
Butanedione 106 and trimethyl orthoformate 107 were treated with concentrated H2S04 in 
MeOH to give TMB 108 in a 45 % yield after distillation under high vacuum. 
+ 
/\ 
fJMe 
H-Cý-OMe 
OMe 
C. H2SO4 
pol 
MeOH, reflux 
M 
MeO We 
106 107 45% 
108 
Figure 54: Synthesis of TMB 
Methyl quinate was synthesised by the acid catalysed esterification of quinic acid 19 in dry 
MeOH in a yield of 90 % on a5g scale. The diequatorial diol was then protected as the 
butane bis-acetal by reaction with TMB in refluxing dry MeOH. p-TSA was used instead 
of CSA as the catalyst, giving the desired protected quinate derivative 97 in 64 % yield (fig. 
55). 
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HQ 02H 
HO'' - OH 
OH 
19 
1. MeOH, Dowex 50 H+ 
2. TMB, HC(OMe)3, p-TSA 
58 %, 2 steps 
97 
We 
Figure 55: Protection of quinic acid as the methyl ester and butane bis-acetal 
The authors state that it is unnecessary to distil TMB before use, although they routinely 
did so (Montchamp et al., 1996). Our attempts to use the crude products of the reaction of 
2,3-butanedione and trimethyl orthoformate to protect the diequatorial diol of methyl 
quinate were not successful. A second modification to the procedure, suggested by the Ley 
group (Hense et al., 1997), involves the in situ generation of TMB from 2,3-butanedione 
and trimethyl orthoformate under acid catalysis in MeOH at reflux. This was slightly more 
successful, but still only gave 24 % of the desired compound 97 after repeated silica-gel 
column chromatography purification and crystallisation attempts. 
We did, however, find that the first two steps could be carried out in a single pot without 
intermediate purification. The reaction of quinic acid 19 with TMB under acid catalysis in 
McOH at reflux gave the BBA-protected methyl quinate derivative 97 in an improved yield 
compared to the two-step procedure in our hands (fig. 57). We were also able to shorten 
the reaction time relative to the one-pot, two-step procedure (Montchamp et al., 1996). 
Ruthenium-catalysed oxidation of the C-3 hydroxyl group of 97 using potassium periodate 
as the secondary oxidant in a chloroform/water two-phase system was then attempted. 
While the authors of the paper quote a 77 % yield, the reaction time required to reach 
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complete oxidation was not given. We found that after 3 days of exposure to the oxidation 
conditions the reaction had only reached 95 % completion, and the desired 3-DHQ 
derivative 98 was obtained in less than 50 % yield (fig. 56). 
97 
KIO4, K2C03, RuCI3 HQ 02Me 
H2O/CHC13 
<50% O 
)Me - We 
MeO 
98 
Figure 56: Attempted Ru-catalysed oxidation to give DHQ 
The authors stated that they carried out small-scale oxidations using tetrapropylammonium 
perruthenate (TPAP) and 4-methylmorpholine N-oxide (NMO) rather than RuCI3/KI04 
which they used for large-scale (30 g) reactions. The difficulties we encountered may thus 
have been due to the absence of a phase-transfer catalyst (Morris & Kiely, 1987). 
Under aqueous alkaline conditions, the non-selective oxidant RuO4 is converted to the less 
reactive Ru042" (ruthenate). Classically, a solution of Ru04 in CCI4 was extracted into 
aqueous 1M NaOH to give a dark orange solution which was then used stoichiometrically 
to oxidise alcohols in the presence of alkenes and alkynes (Coates et al., 1982). Later, 
persulfate (K2S20$) was used as a secondary oxidant, again in aqueous solution, to carry out 
the same oxidations using catalytic ruthenium (Green et al., 1984). When reagent solubility 
necessitated a two-phase solvent system of water/CCI4 a phase-transfer catalyst was 
introduced along with either persulfate or periodate (KIO4) as secondary oxidant. Both 
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benzyltriethylammonium chloride and tetrabutylammonium chloride are mentioned in this 
regard (Morris & Kiely, 1984). 
At the time, we believed that our problems were due to a loss of catalyst activity as an 
insoluble black particulate material rapidly accumulated in the reaction vessel with a loss of 
the characteristic yellow-orange colour. An extensive literature search eventually led to the 
original Sharpless paper (Carlsen et at., 1981) on "Ruthenium tetraoxide catalysed 
oxidations". In this paper, the authors speculated that the presence of carboxylic acids in 
the reaction mixture was leading to the formation of low-valent ruthenium carboxylate 
complexes, and hence to the loss of catalyst activity. Using the then-standard mixed 
solvent system of CCI4: H20 (1: 1), ruthenium carboxylate complexes were inactive as 
oxidation catalysts, but the addition of MeCN to the reaction mixture rapidly restored the 
catalytic activity. The authors speculated that this was due to the ability of MeCN to 
coordinate low-valent transition metal ions, and hence break up the insoluble ruthenium 
carboxylate complexes. 
Using the Sharpless conditions of a CCI4: MeCN: H2O (2: 2: 3) mixed solvent system, but 
with the addition of K2CO3 as specified in the Montchamp paper to generate the more 
selective ruthenate species (Lee et al., 1984), the oxidation proceeded to completion within 
20 h (jig. 57). The desired protected DHQ derivative 98 was isolated in 79 % yield, which 
was an improvement over the literature yield (rig. 50). The explanation proposed by 
Sharpless, where carboxylic acids lead to catalyst inactivation cannot hold true for this 
reaction, as the C-1 carboxyl of quinic acid had been protected as the methyl ester. 
However, as Ru042 is water-soluble, and the protected quinic acid derivative is not, 
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perhaps the addition of MeCN to the solvent mixture allowed sufficient mixing of the 
aqueous and organic phases to allow oxidation to occur in the absence of a phase-transfer 
catalyst. 
HQ 02H 
HO'', = OH 
OH 
19 
TMB, pTsOH, HC(OMe)3 
)NO 
MeOH, reflux 
70% 
HO O2Me 
Ha" 
«O Me 
MeO 
97 
RuCI3, K2CO3, KIO4 
CCI4: MeCN: H2O 
(2: 2: 3) 
rt 
79% 
HO O2Me 
O 
.. OMe 
Me 
98 
Figure 57: Synthesis of DHQ protected as the methyl ester and butane bis-acetal using the 
Sharpless conditions for Ru-catalysed oxidation 
Substituting CHCI3 for CCI4 i. e. a CHCl3: MeCN: H20 (2: 2: 3) solvent system, gave a 78 % 
isolated yield of the desired compound 98. Interestingly, the reaction required 3 days of 
stirring at room temperature to reach 95 % completion as determined by'I-I-NMR peak 
heights as opposed to the 20 h sufficient for complete reaction using CCI,. 
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Extension of the literature protocol: cleavage of the BBA and methyl ester groups 
The acid-sensitive BBA protecting group of 98 was readily cleaved by treatment with 
trifluoroacetic acid (TFA) in a dichloromethane/water mix at -5°C (Riley, 1999) to give 
methyl dehydroquinate 109. Removal of the methyl ester, however, was to prove more 
challenging. 
HQ O2Me O2Me HQ O2H 
TFA: DCM: H20 various 
---------ý 
O 24: 25: 1 OHQ- OH O- OH 
OMe pH ÖH 
MeO 109 10 
98 
Figure 58: Attempted saponification of the methyl ester of methyl-DHQ 
Initial attempts to cleave the methyl ester using IM NaOH in a THE-water mix gave no 
recognisable products by 'H-NMR or mass spectrometry. Exposure of 109 to a- 
chymotrypsin in an ammonium bicarbonate buffer for 44 h gave only returned starting 
material, but at least showed that the compound was not decomposing at room temperature 
in this mildly acidic buffer. 
DHQ 10 is known to be base-sensitive, slowly forming 3,4-dihydroxybenzoic acid on 
exposure to even slightly elevated pH. It was therefore decided to attempt the cleavage of 
the methyl ester before removal of the BBA protecting group, hopefully reducing the 
likelihood of aromatisation (fig. 59). 
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Figure 59: Proposed alternative route for deprotection to give DHQ 
Standard base-catalysed hydrolysis of the DHQ derivative 98 11M NaOH (aq. ): MeOH = 
10: 1 at room temperature, followed by an acidic workupI gave a brown material which 
could not be purified. 'H-NMR analysis showed the presence of the starting material 98, 
BBA-protected methyl dehydroshikimic acid 100 and 3,4-dihydroxybenzoic acid 111 in an 
approximate ratio of 1: 2: 5 (jig. 60). This suggested that the methyl ester was only cleaved 
after elimination of the C-1 hydroxyl had formed the dehydroshiki mate derivative. 
Substituting THE or DCM for the MeOH, in an attempt to reduce the likelihood of the ester 
reforming, gave traces of 3,4-dihydroxybenzoic acid, and no other recognisable organic 
compounds by 'H-NMR analysis. The milder base LiOH in a THE-water mix at 0°C also 
gave an inseparable mixture of aromatic products. 
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Figure 60: Attempted saponification of the methyl ester of protected DHQ 
Cleavage using KO`Bu was then attempted as the relatively unsolvated hydroxide generated 
by the addition of 1 eq. of water to 2 eq. of KO'Bu is known to cleave hindered esters and 
amides at or below ambient temperature (Gassman & Schenk, 1977). It was hoped that 
addition of this `anhydrous hydroxide' to the ester would occur preferentially over 
elimination. There was also the possibility that the bulky'BuO- anion would not be able to 
approach closely enough to the C-2 proton to cause elimination. 
Reaction of the DHQ derivative 98 with a slurry of KO`Bu in a THE-H20 mix at 0°C did 
indeed lead to the formation of the desired compound 110 along with BBA-protected 
dehydroshikimate 112 and 3,4-dihydroxybenzoic acid 111 (fig. 61). The majority of the 
3,4-dihydroxybenzoic acid (the major product) could be separated by the simple expedient 
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of transferring the THF-H20 slurry to a second flask after 40 min reaction, leaving the 
yellow 3,4-dihydroxybenzoic acid 111 in the original flask as an oil. Attempts to separate 
the compounds obtained when the transferred THF-H20 was removed under reduced 
pressure (111: 110: 112 = 1: 2: 2 by 'H-NMR analysis of the crude material) by silica-gel 
column chromatography were not successful, and only 3,4-dihydroxybenzoic acid 111 was 
isolated. 
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Figure 61: Attempted saponification of the methyl ester of protected DHQ 
Lil in dry pyridine is considered to be a mild form of the standard `basic' ester cleavage 
method. The fully protected methyl DHQ derivative 98 was stirred in dry pyridine at reflux 
with 4 eq. of LiI (Magnus, 1984). After 30 min, 2h and 3 h, a portion was acidified and 
extracted into CHCI3. 'H-NMR showed the gradual conversion of the BBA-protected 
methyl DHQ 98 into the corresponding dehydroshikimate derivative 100 such that after 3h 
60 % conversion had occurred (fig. 62). The same elimination reaction was seen when the 
DHQ derivative 98 was stirred in pyridine at rt without the addition of LiI. 
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Figure 62: Attempted saponification of the methyl ester of protected DHQ 
The potassium salt of trimethylsilanol (TMSOK) has been used to convert esters to 
carboxylic acid salts under mild conditions. The authors noted that TMSOK appeared to 
act as a nucleophile rather than a base under the conditions given, as a-protons did not 
affect the desired reaction. (Laganis, 1984) Subsequently, TMSOK in THE was used to 
cleave the methyl ester of a base-sensitive shikimate derivative. (Jiang, 1999) 
In a similar manner, the protected dehydroquinate derivative 98 was stirred in a slurry of 
TMSOK in toluene for 4h (fig. 63). After removing the toluene, the residue was treated 
with 5% aq. NaHCO3 and extracted into Et20 in an attempt to separate any acid-containing 
products from the ester-containing starting materials without causing elimination. The 
aqueous fraction was then acidified and the solvent removed to give a yellow oil along with 
solid NaCl. The aqueous fraction was found to contain the BBA-protected 
dehydroshiki mate derivative 112 along with a trace of 3,4-dihydroxybenzoic acid 111, 
while the etherial layer consisted of a 2: 1 mixture of BBA protected methyl 
dehydroshikimate 100 and the starting material 98. Again, this suggested that the methyl 
ester was only removed after elimination of the C-1 hydroxyl. 
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Figure 63: Attempted saponification of the methyl ester of protected DHQ 
By this stage it had become apparent that derivatives of DHQ are extremely sensitive to 
base, eliminating water to give DHS derivatives in the first instance, and aromatising under 
more forcing conditions. As a result, a neutral to acidic method of ester hydrolysis was 
sought. Enzymatic hydrolysis using chymotrypsin in a5% ammonium bicarbonate buffer 
was attempted, but after 72 h no reaction had occurred. Chymotrypsin, a protease, had 
been recommended by an enzymologist for this transformation. It was decided that 
investigation of all the esterases and lipases available would be unrealistic, and the 
enzymatic approach was abandoned. 
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Bis(tributyltin) oxide I(Bu3Sn)201 has been used for the cleavage of simple esters (Mata & 
Mascaretti, 1988). The authors speculated that the mechanism involved an organotin ester 
intermediate which was converted into the free acid during workup. As the method is both 
mild and non-basic, it was hoped that the methyl ester would be cleaved without 
concomitant conversion to the dehydroshikimate derivative 112. 
After reaction with (Bu3Sn)20 in Et20 at rt, silica-gel column chromatography gave 
approximately 50 % returned starting material 98 despite TLC analysis of the reaction 
mixture suggesting that the reaction had proceeded to completion (fig. 64). Removal of Sn 
residues was not successful and as heavy metals are known to inhibit many enzymes this 
approach was abandoned. 
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Figure 64: Attempted cleavage of the methyl ester of protected DHQ 
BC13 and BBr3 are also `neutral' ester cleavage reagents (Barton et al., 1971; Felix, 1974), 
but they were thought to be far too reactive to provide a viable solution to this problem. 
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4.1.2 Dispoke 
The dispiroketal (Dispoke) protecting group was developed by the Ley group for the 
selective protection of trans diequatorial vicinal diols in carbohydrate systems (Ley et al., 
1992). The standard conditions for protection are treatment of the carbohydrate with bis- 
DHP in dry chloroform at reflux with catalytic CSA. Unlike BBA, therefore, it seemed 
likely that the dispoke protecting group could be used to protect the C-4 and C-5 hydroxyl 
groups of quinic acid without forming the methyl ester, solving the major problem with the 
previous synthetic route (fig. 65). 
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Figure 65: Proposed protection of quinic acid using Dispoke 
Bis-DHP 113 was synthesised via a palladium catalysed oxidative dimerisation reaction 
according to the method provided for large-scale reactions (Ley et al., 1992) (fig 66). The 
organolithium compound 116 was generated by adding `BuLi to dry distilled 3,4-dihydro- 
2H-pyran 115, and dimerisation was initiated by adding the solution of 116 to a slurry of 
the palladium catalyst in THE After quenching with an ammonium chloride/ammonia 
solution and extracting into ether, the product was purified by silica-gel column 
chromatography and crystallised from pet. ether. Due to difficulties experienced in 
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purification and consequent losses of material, the yields for these syntheses were poor, but 
sufficient pure bis-DHP 113 was obtained to test the protection method. 
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Figure 66: Synthesis of bis DHP 
Treatment of quinic acid 19 with 2 eq. bis-DHP 113 in refluxing CHCI3 with catalytic 
pTsOH gave a black mixture after 1 h. Removal of the solvent after 5h gave mostly 
unreacted bis-DHP in the chloroform-soluble fraction, where any of the desired protected 
quinate derivative 114 (fig. 65) would have been expected to be found. 
As quinic acid is completely insoluble in CHCl3, but soluble in warm DMF, the same 
reaction was attempted using triphenylphosphine hydrobromide (PPh3. HBr) as catalyst in 
DMF. 
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Figure 67: Attempted protection of quinic acid using bisDHP under modified protection 
conditions 
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This method was used by the Ley group to protect a glucopyranoside which gave 
unsatisfactory yields using the standard protection conditions (Hughes et al., 1994). The 
authors commented that the low solubility of the sugar derivative in CHCl3, and the 
instability of bis-DHP were probably both to blame for the low yields. 
After four days reaction the CHCl3-soluble fraction of the crude reaction mix showed `H- 
NMR peaks consistent with the decomposition of bis-DHP. The authors (Hughes et al., 
1994) did mention that the use of DMF as solvent generally gave breakdown of bis-DHP 
rather than the desired ketal formation under most circumstances, and this appears to be in 
accordance with our observations. 
This approach was abandoned as the insolubility of quinic acid in aprotic solvents meant 
that it was unlikely that any further modifications of the protection protocol would be 
successful. 
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4.1.3 Benzylidene acetal 
As mentioned previously, a key intermediate in the synthesis of fluorinated derivatives of 
DHQ (Manthey et al., 1997) is a protected form of DHQ 105. This route was initially 
disregarded as the third step in the reaction scheme involves distinguishing between the two 
secondary hydroxyls of the lactone 102 by means of TBDMS protection with a quoted 
yield of 54 %. However, the DHQ derivative formed by this route is protected solely using 
acid-sensitive groups and thus offers the possibility of a global deprotection step which 
should not lead to elimination of water and hence the aromatisation which dogged previous 
synthetic attempts. 
Attempts to replicate the literature protocol 
Using the method of Manthey et al., 1997 attempts were made to protect quinic acid as the 
benzylidene acetal. The use of toluene at reflux, however, led to extensive charring of the 
reagents after 2h reaction. The literature is fairly evenly divided between those who use 
toluene for this reaction and those who use benzene, so the reaction was repeated using 
benzene at reflux. The lower reaction temperature of around 90 °C gave a much cleaner 
reaction and the desired acetal 101 was isolated in a 35 % yield (rig. 68). 
Hydrogenolysis under acidic conditions gave the lactone 102 in 54 % yield after 
crystallisation from acetic acid. In contrast to the published procedure, we found this step 
required an average of three days to reach completion, while the crystallisation step was 
difficult and low-yielding even when the pure compound could be isolated. 
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Figure 68: Attempted replication of the literature protocol towards the synthesis of DHQ 
Selective protection of the C-4 hydroxyl of 102 as a TBDMS ether was carried out under 
thermodynamic conditions to give 104 in 31 % yield after silica-gel column 
chromatography and repeated recrystallisations. The reaction time of this step appears to 
be critical, as any shortening of the reaction time gives an increase of the C-3 protected 
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compound 103 while an increase in the reaction time gives the bis-silylated compound as 
the major product. Successful separation of the products by silica-gel column 
chromatography is essential, as the C-3 103 and C-4 104 protected compounds are co- 
crystalline when they are present in roughly equimolar quantities. 
Oxidation of the free C-3 hydroxyl using PDC in DCM with freshly activated, powdered, 
3A molecular sieves gave the protected DHQ derivative 105 in 48 % yield after 
crystallisation. Powdered molecular sieves were used as the oxidation occurred extremely 
slowly with pelleted 4A molecular sieves, and did not reach completion despite the use of a 
large excess of PDC. Using a two-fold excess (by mass) of freshly activated powdered 
sieves, complete oxidation was achieved with only 2 eq. PDC after 5h reaction. 
Pure DHQ 10 was obtained by stirring the protected derivative 105 in an AcOH-H20 mix at 
50°C for two days followed by repeated lyophilisation. 
The main problem with this approach was the low-yield obtained for formation of the 
lactone 102. It was therefore decided to attempt direct lactonisation rather than the two- 
step approach recommended by the authors (Manthey et al., 1997). 
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4.1.4 Direct lactonisation and deprotection 
The lactone 102 has been formed by heating under acid catalysis with simultaneous 
removal of water in 42 % yield (Panizzi et al., 1954), and also by direct heating (Wolinsky 
et al., 1964; Elliott et al., 1981) in up to 55 % yield. The step following the formation of 
the lactone requires the presence of an acid catalyst, and the lactone is formed in refluxing 
benzene during formation of the benzylidene acetal 101. It was therefore decided to 
attempt direct lactonisation in refluxing benzene with catalytic pTsOH in a Dean-Stark 
apparatus to facilitate removal of the water formed on lactonisation (fig. 69). 
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Figure 69: Modification of the literature protocol towards the synthesis of DHQ 
The desired lactone 102 was formed by stirring a suspension of quinic acid and catalytic 
pTsOH in refluxing benzene (fig. 69). The lactone is extremely moisture sensitive, and the 
yield given was determined by first dissolving a fixed mass of the crude material in dry 
MeOH, removing any insoluble material by filtration, and removing the solvent to give the 
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proportion of soluble compounds. The same procedure was carried out using CD3OD and 
'H-NMR analysis used to determine the proportion of the desired lactone 102 to pTsOH 
and any other impurities. The crude material from the lactonisation was then treated with 
TBDMSCI under thermodynamic conditions as before to give the C-4 silylated derivative 
104 in only slightly reduced yield compared to the literature method in our hands (fig. 68). 
Unfortunately, we were not able to even approach the literature yield for this step. 
The remaining steps in the synthesis were carried out as before on a gram scale to give 1.04 
g of 3-dehydroquinic acid 10 which has been used for detailed kinetic analysis of both 
naturally occurring and mutant type II dehydroquinase enzymes. 
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4.2 Kinetic studies using the 3-dehydroquinic acid synthesised 
4.2.1 Background 
Stopped-flow kinetic analysis is used to study the first few microseconds of a reaction, 
where any lag in the observed reaction course may be evidence of subtle mechanistic 
differences between enzymes. In order to give an accurate picture of the early stages of an 
enzyme-catalysed reaction, enzyme and substrate are used in equimolar amounts. The 
result is that the observed reaction is equivalent to the reaction of a single molecule of 
substrate on a single enzyme molecule. 
Steady-state kinetic analysis, where the enzyme is present at less than 1% of the 
concentration of the substrate, is used to give information on the specificity of an enzyme 
for a particular substrate and the general type of reaction mechanism involved. 
As discussed in Chapter 4, section 4.1, kinetic characterisation of the type II DHQases 
appears to divide them into two groups based on k, , with no obvious correlation 
between 
kcal and Km (Evans et at., 2002). The first group, which includes the enzymes from 
organisms such as Streptonryces coelicolor and Aspergillus nidulans, has relatively high 
values of k,  at between 100 and 1000 s"' at pH 7.0 and 25°C. The second group, which 
includes the enzymes from Helicobacter pylori, Mycobacterium tuberculosis and 
Neurospora crassa, has values of kc in the range 10 s"' or lower. 
As part of the research effort within the group, I carried out steady-state and stopped-flow 
kinetic analysis on the type II dehydroquinase enzyme from Helicobacterpylori which is a 
`low kcat' enzyme. I also investigated a putative type II dehydroyuinase enzyme from 
Bacillus subtilis. 
The YqhS protein of B. subtilis, which shows 47% identity to S. coelicolor DHQase, is 
completely inactive towards DHQ. However, when the substitution of F28Y was 
introduced by site-specific mutagenesis activity was restored albeit to a very limited extent. 
Tyr28 is believed to be the residue involved in deprotonation at C-2 of DHQ and as such is 
thought to be essential for the catalytic activity of the enzyme. This mutant F28Y enzyme 
is an ideal candidate for the investigation of the mechanism of type II DHQase enzymes. 
The `slow' enzyme allows for more detailed investigation of the early part of the reaction, 
where mechanistic differences might be apparent. 
As has been mentioned previously, the source of DHQ for the kinetic analysis of DHQase 
enzymes in our group had been the classical synthesis involving nitric acid oxidation of 
quinic acid (fig. 48). We had reason to believe that this material was contaminated with 5- 
dehydroquinic acid, and there had been some concern that this compound was a potential 
inhibitor of DHQase. In addition, the presence of highly UV-absorbing contaminants in the 
substrate meant that the investigation of enzymes with low activity or binding affinity was 
not possible, as the small changes in absorbance were swamped by the background. 
The availability of an improved synthesis of DHQ (fig. 69, Chapter 4) which was known to 
be free from contamination made it possible to compare the historic values for k,  and K,,, 
with those obtained using `clean' substrate. 
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4.2.2 The reaction catalysed by type II dehydroquinases 
Type II dehydroquinases catalyse the anti elimination of water with the loss of the more 
acidic axial pro-S hydrogen of DHQ (Roszak et al. 2002). The reaction is thought to 
involve an enolate intermediate but recent work has suggested the possibility of an enol 
(Harris et al., 1996; Roszak et al. 2002). The structure of the S. coelicolor type II DHQase 
has been published both in the apo form and complexed with a variety of ligands (Roszak et 
al. 2002). This structural information was used to devise a detailed explanation of the 
possible reaction mechanism (fig 70). 
The axial C-2 pro-S hydrogen is abstracted by the side chain of Tyr 28 which is 
deprotonated due to the close proximity of Arg 113. The enolate intermediate thus formed 
is stabilised by a proton from a conserved water molecule held in the active site by Asn 19, 
Pro 15 and Ala 81. Elimination of the C-I hydroxyl follows, with His 106 acting as the 
proton donor. The intermediate formed undergoes a structural change and becomes planar 
as the product dehydroshikimate is formed, and this is proposed to drive the release of 
product from the active site. 
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Figure 70: Proposed reaction mechanism of type II DHQases 
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4.2.3 Stopped-flow kinetic analysis: Results 
Stopped-flow analysis of both enzymes showed no sign of a lag phase suggesting that 
analogous mechanisms were operating in both cases. This was confirmed by work carried 
out on a number of type II DHQases from other organisms in our laboratory by L. Evans. 
However, work investigating the binding of polyanions to the type II DHQases of S. 
coelicolor and M. tuberculosis can be correlated with the existence of a single binding site 
in the S. coelicolor enzyme and multiple sites in the M. tuberculosis enzyme (Evans et al., 
2002). These differences in binding may provide a structural explanation for the observed 
differences in k.  
4.2.4 Steady state kinetic analysis: Results 
Steady-state kinetic analysis of the two enzymes was carried out at 20°C in Tris-acetate 
buffer at pH 7 in a total volume of I mL. The assays were carried out at the lower 
temperature rather than the 25°C which had become routine in our laboratory to enable 
comparison with historical data (White et al., 1990). The formation of DHS was monitored 
spectrophotometrically at 234 nm. The values of Km and Vmýý were obtained by fitting the 
raw data to the Michaelis-Menten equation by non-linear regression using Microcal Origin 
software (fig. 71 & fig. 72). The values of k., were calculated based on M, = 20 000 for H. 
pylori DHQase and M, = 18 000 for B. subtilis F28Y. 
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Analysis of B. subtilis F28Y at 20°C in Tris. acetate buffer pH 7.0 gave Km = 622 lpM and 
kcat = 0.22 s"'. 
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Figure 71: Data obtained by steady-state kinetic analysis of B. subtili. s F28Y 
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Analysis of H. pylori DI-lQase at 20°C in Tris. acetate buffer pH 7.0 gave Km = 251 pM and 
kqt = 19.4 s-'. This is similar to the values of Km = 205 <<M and k,  = 0.9 s"' obtained by L. 
Evans at 25°C (Evans et al., 2002). 
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Figure 72: Data obtained by steady-state kinetic analysis of H. pylori type II DHQase 
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4.3 Conclusions and future work 
The synthesis of DHQ from quinic acid via the lactone (fig. 69), despite its length and 
relatively low overall yield, is still an improvement on the classical nitric acid oxidation 
synthesis (fig. 48). The product is pure by 'H-NMR analysis and has a negligable 
absorbance at 234 nm, facilitating the kinetic investigation of DHQase enzymes with 
extremely low values of kca,. 
The attempted synthesis of DHQ from quinic acid using the diol-selective protecting group 
BBA was unsuccessful. However, if methyl dehydroquinic acid could be maintained at a 
steady pH sufficiently high to saponify the ester without leading to dehydration, this 
method would be a great improvement over the synthesis used to generate DHQ. The 
synthesis of methyl quinate by this method was high-yielding, and the chemistry was less 
challenging than the route eventually followed. 
The comparison of historic values of kc and K,,,, determined using substrate which may 
have been contaminated with enzyme inhibitors and those determined using the clean 
substrate, is still ongoing in the group. However, the availability of large amounts of pure 
DHQ has already facilitated the use of stopped-flow kinetic analysis to probe the early 
reaction mechanism of type II DHQase enzymes. The pure substrate has also been used in 
the investigation of polyanion binding to type II DHQase enzymes (Evans et al, 2002) 
providing further insight into the structural basis for the observed differences in kam,,. 
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Experimental 
5.1 Starting materials and solvents: 
AcOH was distilled from quinoline under reduced pressure and stored over 4A molecular 
sieves at 4°C. 
PhH was stirred over CaH for a minimum of 2 h, distilled under reduced pressure and 
stored over 4A molecular sieves 
Butan-2-ol was dried by standing over activated 4A molecular sieves for at least 24 h. 
CHC13 was distilled from, and stored over, molecular sieves. 
DCM was distilled from calcium hydride. 
DMF was stirred for 18h over CaH2, then distilled under reduced pressure and stored over 
4A molecular sieves. 
DMAP was crystallised from toluene and dried under high vacuum for at least 12h. 
Et3N was distilled from calcium hydride, and stored over potassium hydroxide. 
MeOH was distilled from magnesium methoxide and used immediately (storage over 
activated 3A molecular sieves was unsatisfactory). 
Molecular sieves were routinely dried and activated by heating for at least 12 h in an oven 
at 140°C. 
Petrol was distilled from 4A molecular sieves. 
Piperidine was distilled from, and stored over, potassium hydroxide. 
Pyridine was distilled from, and stored over, potassium hydroxide. 
THE was distilled from sodium benzophenone. 
All enzyme buffers were prepared using distilled water and sterile glassware. 
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Water used for HPLC was purified using a Millipore UV purification system, filtered and 
degassed for 20 minutes per litre. All HPLC buffers were stored for a maximum of 48 
hours prior to use. 
Unless stated otherwise, all starting materials were used as purchased. 
Unless stated otherwise, all compounds are known. 
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5.2 Apparatus: 
Glassware was dried for at least 30 minutes in an oven at approximately 140°C. Analytical 
thin layer chromatography was performed on precoated silica gel plates with visualisation 
under UV2.4 light and by dipping in phosphomolybdic acid solution (phosphomolybdic acid 
(12g) in EtOH (200 mL). `H NMR and '3C NMR were measured on a Bruker DPX 400 
(400 and 100 MHz respectively). All chemical shifts are given in ppm relative to residual 
CHC13 (S = 7.27 and S= 77.0) in CDCl3 solutions, residual HOD in D2O solutions (S = 
4.60), or residual CHD2OD in CD3OD (S = 3.35). 19F NMR was carried out on a Bruker 
360 with chemical shifts given in ppm relative to external CF2Cl2. Coupling constants are 
given in Hz and are uncorrected. Mass spectra were determined on a JMS 700 
spectrometer. Infra red spectral analysis was carried out on a Perkin Elmer 410 
spectrometer. Melting points were carried out using a Stuart Scientific capillary apparatus 
SMP2 and are uncorrected. HPLC analysis carried out in the laboratory was on a Dionex 
system using UV and ampomeric detection. Enzyme assays were carried out using an 
HP8453 diode array spectrophotometer. 
-121- 
5.3 Enzyme sources and specific activity 
Transketolase 
The N-terminal His tagged recombinant transketolase used was a gift of Ms Nicola Veitch. 
The protein was expressed in E. coli BL21(DE3) cells using pET16b. The enzyme was 
provided fresh as required. Details of the activity of each preparation were provided by Ms 
Veitch with a typical value being 0.2 units. mg '. 
DAHP synthase 
The DAHPS(phe) used was a gift of Mr John Greene. The protein was expressed in E. colt 
CB198 using pttGl(phe). The activity of a typical enzyme preparation as provided by Mr 
Greene was 59 units. mg-'. 
Dehydroquinate synthase 
The DHQ synthase used was a gift of Mr John Greene. The protein was expressed in E. 
coii W31 10 using pJB 14. The activity of a typical enzyme preparation as provided by Mr 
Greene was 36 units. mg''. 
Dehydroquinate dehydratase 
The type II DHQase used in the biosynthesis was a gift of Mr John Greene. The protein 
was expressed in E. coli AB2848 using pKD203. The activity of a typical enzyme 
preparation as provided by Mr Greene was 747 units. mg1. 
The B. subtilis wild type and F28Y DHQase enzymes, as well as the S. coelicolor and H. 
pylori enzymes used in the kinetic analysis experiments were a gift of Mr Lewis Evans. 
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Shikimate dehydrogenase 
The shikimate dehydrogenase used was a gift of Mr John Greene. The protein was 
expressed in E. coli BL21 using pTB361. The activity of a typical enzyme preparation as 
provided by Mr Greene was 854 units. mg''. 
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5.4 General procedures: 
5.4.1 Enzyme assays 
DAHP synthase (Schoner & Hermann, 1976) 
The assay was carried out at 25°C, pH 7.0 in a1 mL, 1 cm path length cuvette. 
The assay mixture, total volume I mL, consisted of 10 mM 1,3-bis[tris-(hydroxy- 
methyl)methylaminoIpropane (BTP) buffer pH 7.0,100 {cM PEP and 300 INM E4P. 
Reaction was initiated by the addition of DAHP synthase. 
The rate of change of absorbance at 234 nm is related to the enzyme activity in units per 
mL as follows: 
Activity = DA232. min"'. mL'' 
6 
Dehydroquinate synthase (Lambert et al., 1985) 
c= 2.8 x 103M-'. cm"' 
The assay was carried out at 25°C, pH 7.0 in a1 mL, 1 cm path length ctivette. 
The assay mixture, total volume 1 mL, consisted of 50 mM potassium phosphate buffer pH 
7,40 µM NAD', 0.2 yM CoCI2,2 units E. coli dehydroquinase and 4 units E. coli 
dehydroquinate synthase. Reaction was initiated by the addition of 200 µM DAHP. 
The rate of change of absorbance at 234 nm is related to the enzyme activity in units per 
mL as follows: 
Activity = DA234. min"'. mL"' 
e 
F- = 12 x 103 M-'. cm-' 
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Dehydroquinate dehydratase (dehydroquinase) (White et al., 1990) 
Assays were carried out at 20°C in a1 mL, 1 cm path length cuvette. The limiting change 
in Ate, on the addition of S. coelicolor type II dehydroquinase (1 jig) to a solution of DHQ 
in the reaction buffer was used to calculate the concentration of substrate. Calculations 
took into account the fact that the equilibrium constant for the reaction is 15 (Kleanthous et 
al., 1991). 
The assay mixture, total volume 1 mL, consisted of 50 mM Tris. acetate buffer pH 7.0 and 1 
mM DHQ (variable for kinetic determination). Reaction was initiated by the addition of 
DHQase. 
The activity of the enzyme in units per mL was calculated as follows: 
Activity = DA23,. min"'. mL"' s= 12 x 103 M"'. cm"' 
E 
Shikimate dehydrogenase (Chaudhuri & Coggins, 1985) 
The assay was carried out at 25°C, pH 10.6 in a1 inL, I cm path length cuvette. The 
enzyme was assayed in the reverse direction, monitoring the reduction of NADP` at 340 
nm. The assay mixture, total volume l mL, consisted of 100 mM Na. 2CO3 buffer pH 10.6,4 
mM shikimic acid and 2 mM NADP+. Reaction was initiated by the addition of SDHase. 
Activity = AA340. min"'. mL"' e=6.2 x 103 M''. cm-' 
E 
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5.4.2 Chemical assays 
Sialic acid (thiobarbituric acid) assay for DAHP (Warren, 1959) 
The test solution (10 µL) was added to 0.2M Na104 in 9M H3PO4 (25 µL) and left at room 
temperature for 20 min. 0.75 M NaAsO2 in 0.5 M Na2SO4: 50 mM H2SO4 (100 µL) was 
added and the solution mixed. 40 mM Thiobarbituric acid (750 µL) was added and the 
solution incubated at 100°C for 15 min. A pink chromagen absorbing at 549 nm was 
formed and the absorbance related to the concentration of DAHP by comparison with 
standard solutions. 
Phosphate assay (Lanzetta et al., 1979) 
Solutions required: 
0.045% malachite green hydrochloride 
4.2% ammonium molybdate in 4M HCI 
34% sodium citrate. 2I-120 (w/v) 
10 mM KH2PO4 for use as standard 
A 3: 1 mixture of the malachite green and ammonium molybdate solutions was stirred for 
20 min and filtered to form the `colour reagent'. 
To 100 ;L of the assay sample was added 800 pL of the colour reagent. After I min, 100 
1tL of the citrate solution was added, and the colour left to develop for 30 min at rt. 
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5.4.3 Fmoc-based solid-phase peptide synthesis 
Fmoc-Lys(Mtt)-wang resin was used as the basis for these syntheses. The DCM used was 
freshly distilled, while the DMF and piperidine had been distilled and stored over activated 
4A molecular sieves. The MeOH used was reagent grade but otherwise unpurified. 
Fmoc deprotection: 
The resin was swelled in DMF (2 mL) for 5 min and drained. The swelled resin was 
treated with 20 % piperidine in DMF (2 mL, 4x 15 min), washing with DMF (5 x1 mL) 
after each iteration. The deprotected resin was then washed with DCM (5 xI mL) and 
McOH (5 x1 mL) and dried under reduced pressure in an air stream for 1 hour. 
Coupling of amino acid residues: 
The resin was swelled in DMF (2 ml-) for 5 min and drained. The desired Fmoc-protected 
amino acid derivative (3 eq. ) was added to the swelled resin along with HOBt (3 eq. ) and 
DIC (10 eq. ). DMF (2 mL) was added and the mixture was agitated at room temperature for 
3 h. The reaction mix was drained from the resin, and the resin washed with DMF (5 xI 
mL). 
Mtt deprotection: 
The resin was swelled in DCM (2 mL) for 5 min and drained. The swelled resin was 
treated with 1% TFA, 5% TIPS in DCM (2 mL, 5x 10 min), washing with DCM (5 xI 
mL) after each iteration. This treatment was continued until no further yellow coloration 
was observed on the addition of the deprotection mix. The deprotected resin was then 
washed with MeOH (5 x1 mL) and dried under reduced pressure and an air stream for 1 
hour. 
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Coupling of shikimic acetate derivative: 
The resin was swelled in DCM (2 mL) for 5 min and drained. The swelled resin was 
treated with shikimic acetate 80 (3 eq. ), HOBt (3 eq. ) and DIC (10 eq. ). DCM (2 mL) was 
added and the mixture was agitated at room temperature for between 12 and 18 hours. The 
reaction mix was drained and the resin was washed with DCM (5 xI mL) and MeOH (5 x 
I mL) and dried in a steady air stream under reduced pressure for 30 min. 
Coupling of (6S)-6-fluoroshikimic acid derivative: 
The resin was swelled in DCM (2 ml-) for 5 min and drained. The swelled resin was 
treated with the (6S)-6-fluoroshikimic acid derivative 90 (3 eq. ), BOP (6 eq. ) and Et3N (3 
eq. ). DCM (2 mL) was added and the mixture was agitated at room temperature for 24 
hours. The reaction mix was drained into sat. NaHCO3 (aq. ) to neutralise the HMPA 
formed. The resin was then washed with DCM (5 x1 mL) and MeOH (5 x1 mL) and 
dried in a steady air stream under reduced pressure for 30 min. 
Cleavage of peptides from resin: 
The resin was swelled in DCM (2 ml-) for 5 min and drained. The swelled resin was 
treated with TFA (1.5 mL) and DCM (0.5 mL) and the mixture was agitated at room 
temperature for 45 min. The solvent was drained into a suitable flask. The resin was 
washed with DCM (5 x1 mL) and these washings were added to the flask. The solvent 
was removed under reduced pressure. 
Final deprotection: 
a. tBu ether and ester cleavage 
Serine and glutamic acid-containing conjugates (protected as the tBu ether and ester 
respectively) were cooled to 0°C. TFA (2 mL) was added and the mixture stirred for 45 
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min at 0°C and a further 45 min at rt. The TFA was then removed under reduced pressure 
to give the crude product. 
b. acetate cleavage 
Conjugates containing shikimic acetate were treated with THE (2 mL) and 1M NaOH (aq. ) 
(0.5 mL). The mixture was stirred at rt for 90 min and the solvent removed under reduced 
pressure. The crude material obtained was analysed by `H-NMR and HPLC-mass- 
spectrometry. 
c. TBDMS ether cleavage 
Conjugates containing the protected (6S)-6-fluoroshikimic acid derivative 90 were treated 
with 100 % TFA (2 ml-) for 90 min [occasionally, 90 % TFA in DCM was used]. The TFA 
was removed under reduced pressure to give the crude product which was analysed by 'H- 
NMR and HPLC-mass-spectrometry. 
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5.5 Experimental for Chapter 2 
Formation of DAHP 13 by biotransformation from D-fructose-6-phosphate 79: 
Reactions were carried out using conditions based on those given in Duggan et al., 1995. 
Reactions were carried out on a 2.5 mL scale, in a variety of buffers: 
The standard reaction mix contained: fructose-6-phosphate (6.5 mg, 21 µmol), D-ribose-5- 
phosphate (14.2 mg, 52 µmol), phosphoenol pyruvate (7.6 mg, 28 p. mol), MgCI2 (5.5 mg, 
27 µmol), and cocarboxylase (trace). 
Dissolved oxygen was removed by bubbling N2 through the solution for 2 min. The 
reaction was initiated by adding transketolase (0.2 units) and DAHP synthase (1 unit). 10 
µL aliquots were taken at 30 min intervals and assayed for DAHP formation using the 
thiobarbituric acid assay (5.4.2). 
Formation of 3-dehydroshikimic acid 14 by biotransformation from PEP 11: 
Reactions were carried out in aI mL, 1 cm path length cuvette for continuous monitoring. 
To I mL of the DAHP biotransformation reaction mix was added: CoSO4 to a final 
concentration of 50 µM and NAD+ to a final concentration of 0.2 ECM. The reaction was 
initiated by the addition of E. coli dehydroquinase (2 units) and E. coli dehydroquinate 
synthase (4 units), and monitored for the formation of DHS at 234 nm. 
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Formation of 3-dehydroshikimic acid 14 by biotransformation from DAHP 13: 
Reactions were carried out in a1 mL, 1 cm path length cuvette for continuous monitoring. 
The conditions used for the assay of E. coli DHQ synthase were utilised with the rate of 
reaction monitored spectrophotometrically at 234 nm in various buffers. The effect of the 
constituents of the DAHP biotransformation from F-6-P was investigated by the addition of 
these components to the reaction mix. 
Formation of shikimic acid 9 by biotransformation from DAHP 13: 
Reactions were carried out in a1 mL, 1 cm path length cuvette for continuous monitoring. 
The conditions used for the assay of E. coli DHQ synthase were utilised in order to obtain a 
reaction mix containing dehydroshikimic acid. This was treated with NADPH and E. coli 
shikimate dehydrogenase at varying concentrations and the rate of reaction monitored by 
the consumption of NADPH at 340 nm and the consumption of dehydroshikimic acid at 
234 nm. 
Reactions used for HPLC method development involved higher concentrations of reagents: 
To 6 mL of 50 mM MOPS pH 7,50 pM CoSO4 was added DAHP (10 mb, 30 j1mol), 
NAD' (0.15 ymol by dilution), dehydroquinase (4 units) and dehydroquinate synthase (16 
units). The reaction was incubated at 25°C overnight. To aI mL aliquot of this 
biotransformation mix was added NADPH (30 mb, 36 Eimol) and shikimate dehydrogenase 
(8 units) and the mixture was incubated at 25°C. 2 jiL Aliquots of the biotransformation 
mix were taken at regular intervals. The formation of shikimic acid was monitored using a 
Dionex Carbopac HPLC column and ampomeric detection, eluting with a5 mM - 100 mM 
NaOH gradient. 
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Biotransformation to form (6S)-6-fluoroshikimic acid 1 and (6R)-6-fluoroshikimic 
acid 41 
3-fluoro-PEP. C6HNH3 (126 mg, 0.4 mmol), fructose-6-phosphate (140 mg, 0.45 mmol), 
D-ribose-5-phosphate (180 mg, 0.65 mmol), cocarboxylase (1 mg) and MnSO4 (0.4 mg, 
50, uM) were added to 15 mL H2O. The pH was adjusted to pH 6.8 using 10% NaOH and 
the total volume made up to 50 mL with H20. The reaction was initiated by the addition of 
transketolase (10 u) and DAHP synthase (32 u). After 10 hours reaction, a further aliquot 
of DAHP synthase (16 u) was added and the biotransformation continued for 16 hours. 
The biotransformation was purified using an ammonium bicarbonate gradient (5 to 500 mM 
over 400 mL) on a DEAE sephacel column pre-equilibrated with 5 mM NH4. HCO3 (600 
mL) taking 5 mL fractions. These fractions were assayed for inorganic phosphate using the 
Lanzetta phosphate assay after overnight equilibration of 200 EiL aliquots with alkaline 
phosphatase. 
Investigation of the transformation of F-PEP to F-DAHP by 19F-NMR: 
3-fluoro-PEP. C6HNH3 (30 mg, 0.064 mmol) was dissolved in 1 mL D2 O. Fructose-6- 
phosphate (30 mg, 0.064 mmol), D-ribose-5-phosphate (20 mg, 0.064 rnmol), a trace 
amount of cocarboxylase, and MgCI2 (2.0 mg , 0.01 mmol) was added. 
The solution was 
degassed by bubbling a stream of N2 through for 2 min. The pH was adjusted to pH 7.1 
using 0.1 M NaOH solution. Transketolase (1 unit) and DAHP synthase (3 units) were 
added. The '9F-NMR spectrum was taken at regular intervals. There was no change from 
the observed spectrum of the substrate 3-fluoro-PEP. 8. (188.3 MHz; D20): -140.8 (IF, dm, 
Z-F), -150.0 (IF, dm, E-F). 
Literature values (Duggan et al., 1995): 6F(235 MHz; D20): -141.4 (Z-F), -152.7 (E-F) 
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Methyl shikimate (Chahoua et a[., 1992) 
02M e 
HO" OH 
OH 
Shikimic acid 9 (1.00 g, 5.74 mol) was heated to reflux in dry MeOH (40 mL) in the 
presence of Amberlite IR120 H+ ion-exchange resin (1.0 g). After 18 h the resin was 
removed by filtration and the solvent evaporated to give the desired ester (1.07 g, 5.69 
mmol, 99 %) as a white solid. 
8H(400 MHz; CDCl3) 6.84 - 6.82 (1 H, m, H-2), 4.41 (1 H, br in, H-3), 4.03 (1 H, td, J 5.2 
and 1.8, H-4), 3.78 (3H, s, OMe), 3.73 (1 H, dd, J 7.3 and 4.2, H-4), 2.75 (1 H, ddt, J 18.2, 
4.9 and 1.8, H-6) 2.24 (1 H, ddt, J 18.2,5.4 and 1.6, H-6); ßc(100 MHz; CDCI3) 169.1 
(COZCH3), 139.5 (C=CH), 130.6 (CH=C), 73.0 (C-OH), 68.8 (C-OH), 67.7 (C-OH), 52.8 
(CO2CH3), 32.0 (CH2)* 
lit. (Chahoua et al., 1992) 8,, (250 MHz; CD3OD) 6.79,4.37,4.00,3.74,3.69,2.70,2.20 
(abbreviated data quoted). 
Methyl 3,4-O-isopropylidene-shikimate 72 (Chahoua et al., 1992) 
02Me 
"'( 
- OH ýO 
Methyl shikimate (1.04 g, 5.53 mmol) was dissolved in 2,2-dimethoxypropane (20 mL). 
pTsOH (105 mg, 0.55 mmol, 10 %) was added and the solution stirred at rt. After 50 min 
the reaction was quenched with sat. NaHCO3 (aq. ) (10 nil-) and extracted into Et20 (3 x 40 
mL). The etherial extracts were dried (Na2SO4), filtered and evaporated under reduced 
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pressure to give the crude product (1.18 g) as a pale yellow oil. Silica-gel column 
chromatography (EtOAc: Petrol = 1: 1) gave the desired acetal 72 (1.16 g, 5.08 mmol, 92 %) 
as a colourless oil. 
SH(400 MHz; CDCl3) 6.92 (1 H, m, H-2), 4.75 (1 H, m, H-3), 4.09 (1 H, t, J 7.2, H-4), 3.93 - 
3.87 (1 H, m, H-5), 3.77 (3H, s, OMe), 2.73 (1 H, dd, J 17.4 and 4.6, H-6), 2.37 (1 H, d, J 
2.7, OH), 2.18 (1H, ddt, J 17.4,8.3 and 1.9, H-6), 1.45 (3H, s, CMe), 1.40 (3H, s, CMe); 
Sc(100 MHz; CDCl3) 166.5,133.9,130.6,109.7,77.9,72.2,68.8,52.1,29.3,27.9,25.7; 
nt/z (Cl') 229.18 ([M+H+J, 10%), 213.16 (100%), 197.17 (20%), 171.15 (20%), 153.14 
(40%), 139.13 (30%). 
lit. (Chahoua et al., 1992) 8(200 MHz; CDCI3) 6.90,4.73,4.08,3.88,3.75,2.79,2.22, 
1.44,1.39. 
(abbreviated data quoted). 
Methyl 3,4-O-isopropylidene-5-O-trifluoromethanesulfonate-shikimate 73 
02M e 
OTf ý0 
The protected shikimate compound 72 (2.92 g, 12.80 mmol) was dissolved in dry DCM (50 
mL) and the solution cooled to -20°C. DMAP (156 mg, 1.28 mmol, 10%) was added to the 
stirred solution. Pyridine (4.14 mL, 51.2 mmol, 4 eq. ) was added dropwise with stirring. 
Tf2O (4.33 mL, 25.6 mmol, 2 eq. ) was added dropwise with stirring over a period of 50 
min, during which the temperature was kept below -10°C. The reaction was quenched by 
pouring the reaction mixture into ice-cold sat. NaHCO3 (aq. ) (70 ml-) and the aqueous and 
organic layers were separated. The organic layer was washed with 0.2 M citric acid (3 x 70 
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mL), sat. NaHCO3 (aq. ) (70 mL) and brine (70 mL). The organic layer was then dried 
(MgSO4), filtered and evaporated under reduced pressure to give the desired triflate (4.35 g, 
12.08 mmol, 94 %) as a pale yellow oil. 
SH(400 MHz; CDCl3) 7.00 (1 H, m), 5.01 (1 H, dt, J 8.1 and 4.9), 4.84 (1 H, br dd, J 5.0 and 
4.8), 4.32 (1 H, t, J 6.9), 3.81 (3 H, s), 3.05 (1 H, dd, J 17.5 and 4.8), 2.62 (1 H, br ddt, J 17.5 
and 8.5), 1.47 (3H, s), 1.43 (3H, s); in/z (Cl') 361.1 ([M+H+], 100%), 345.1 (20%), 153.1 
(90%), m/z HRMS found: [M+H+] 361.0568, C12H1607F3S requires 361.0569 
Methyl (3R, 4S)-O-isopropylidenedioxycyclohexa-1,5-diene carboxylate 74 
02M e 
The protected triflate 73 (4.12 g, 11.45 mmol, ) was dissolved in dry DMF (15 mL). CsOAc 
(3.47 g, 18.08 mmol, 1.58 eq. ) was dried under high vacuum with vigorous stirring for 30 
min. Dry DMF (5 mL) was added to the dry CsOAc and the mixture stirred at rt for 10 
min. The solution of 73 in DMF was added to the CsOAc/DMF mixture and the resulting 
pink solution stirred for 2.5 h. The CsOAc did not fully dissolve during this time. The 
reaction mix was partitioned between iced water (100 mL) and petrol (100 mL). The 
aqueous layer was extracted into petrol (3 x 100 mL). The organic extracts were combined, 
dried (MgSO4) and the solvent removed under reduced pressure to give the desired 
protected diene 74 (2.26 g, 10.76 mmol, 94 %) as a pale yellow oil. The temperature of the 
workup was maintained below 10°C at all times. 
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SH(400 MHz; CDC13) 6.87 (1 H, d, J 3.7, C=CH), 6.55 (1 H, d, J 6.9, C=CH), 6.05 (1 H, dd, J 
9.9 and 4.0, C=CH), 4.82 (1 H, dd, J, 8.8 and 3.7), 4.66 (1 H, dd, J 8.8 and 4.0), 3.81 (3H, s, 
OMe), 1.42 (3H, s, CMe), 1.40 (3H, s, CMe) 
Methyl 3,4-O-isopropylidene-(6R)-hydroxy-shikimate 76 (Song et al., 2001) 
T 02M e 
OH 
OH 3ýO 
The fully protected diene 74 (2.15 g, 10.20 mmol) was dissolved in tßuOH. NMO (1.25 g, 
10.71 mmol, 1.05 eq. ) was added to the solution. OsO4 (51.9 mg, 0.20 mmol, 2 %) in H2O 
(5.2 mL) was added and the solution was stirred at rt in the dark. After 14 h sat. Na2SZO3 
(aq. ) (50 mL) was added to quench the reaction and the mixture stirred for a further 5 h. 
The aqueous and organic layers were separated and the organic layer was stored overnight 
at -20°C. The product was adsorbed onto silica and placed on top of a plug of the same 
material. A flash column (EtOAc) yielded a pale yellow oil (2.33 g). Silica-gel column 
chromatography (Hexane, 60 % EtOAc: 1 column volume; then Hexane: 80 % EtOAc) gave 
partial separation of the dihydroxylated compounds 75 and 76. The fractions containing the 
compound 76 were pooled and the solvent removed under reduced pressure. Silica-gel 
column chromatography (DCM, 10 % acetone: 1 column volume; then DCM, 20 % acetone) 
gave the desired compound 76 (841 mb, 3.44 mmol, 34 %) as a clear colourless oil. 
SH(400 MHz; CDC13) 6.93 (1 H, d, J 3.4), 4.80 (11-1, dd, J 5.0 and 3.4), 4.67 (1 H, d, J 3.0), 
4.46 (1 H, t, J 6.0), 4.13 - 4.11 (1 H, br s), 3.83 (3H, s), 3.78 (1 H, br s), 2.80 (11-1, br s), 1.40 
(61-1, s); Sc(100 MHz; CDC13) 166 (COZCH3), 137.1 (CH=C), 130.3 (C1-1=C), 110.0 (CMe2), 
71.7 (CHOR), 70.0 (CHOR), 65.1 (CHOR), 52.4 (CHOR), 27.8 (CCH3), 25.8 (CCH3). 
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lit. (Song et al., 2001) 8H(270 MHz; CDCl3) 6.95,4.83,4.68,4.45,4.14 - 4.10,3.98 - 3.93, 
3.81,3.55 - 3.62,1.43,1.40 
(abbreviated data quoted) 
Methyl 3,4-O-isopropylidene-5-O-rbutyldimethylsilyl-(6R)-hydroxy-shikimate 77 
The diol 76 (841 mg, 3.44 mmol) was dissolved in dry DCM (40 mL) and cooled to 
between -20°C and -30°C. Et3N (2.40 mL, 17.22 mmol, 5 eq. ) was added dropwise with 
stirring. TBDMSOTf (0.83 mL, 3.62 mmol, 1.05 eq. ) was added dropwise with vigorous 
stirring while the reaction mix was maintained at -20°C. Vigorous stirring at -20°C was 
continued for a further 30 min and the reaction was then quenched by the addition of ice- 
cold sat. NaHCO3 (aq. ) (40 mL). The aqueous and organic layers were separated and the 
organic layer was extracted into DCM (4 x 40 mL). The combined organic extracts were 
dried (Na2SO4), filtered and evaporated under reduced pressure to give the crude product 
(1.54 g). Silica-gel column chromatography (hexane: Et2O = 2: 1) yielded the desired 
protected diol 77 (868 mg, 2.42 mmol, 70 %) as a colourless oil. Crystallisation from 
hexane at -20°C gave flat square colourless crystals, but these returned to an oil at rt. 
8H(400 MHz; CDCI3) 6.90 (1 H, d, J 3.1), 4.87 (1 H, dd, J 6.8 and 3.1), 4.55 (1 H, d, J 3.2), 
4.39 (1 H, t, J 7.2), 3.80 (3H, s), 3.69 (1 H, dt, J 7.4 and 3.2), 2.21 (11-1, d, J 7.1), 1.47 (3H, 
s), 1.41 (3H, s), 0.87 (9H, s), 0.19 (3H, s), 0.05 (31-1, s). 
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Methyl 3,4-O-isopropylidene-5-O-`butyldimethylsilyl-(6S)-fluoro-shikimate 78 (Song et 
al., 2001) 
02M e 
OTBDMS 5ýO 
The protected diol 77 was dissolved in dry DCM (20 mL) and cooled to -78°C. DAST 
(1.02 mL, 7.75 mmol, 5 eq. ) was added to the cooled solution with vigorous stirring. The 
solution was allowed to warm gradually to rt and stirred for a further 4h before being 
cooled to -78°C. The reaction was quenched by the addition of IM NaHCO3 (40 mL) and 
the stirred mixture allowed to warm to rt. Stirring was continued until no further gas was 
evolved. The aqueous layer was extracted into DCM (3 x 40 ml-) and the combined 
organic extracts were washed with 0.2M citric acid (120 mL) and brine (120 rnL). The 
organic layer was then dried (Na2SO4), filtered and the solvent removed under reduced 
pressure to give an orange oil. Silica-gel column chromatography (hexane: Et2O = 3: 1) 
yielded the desired protected (6S)-6-fluoroshikimic acid derivative 78 (461 mg, 1.28 mmol, 
83 %) as a pale yellow oil. 
S, i(400 MHz; CDCl3) 7.00 (1 H, t, J 3.3), 5.02 (1 H, dd, 146.2 and 3.2), 4.73 - 4.70 (1 H, m), 
4.41 (1 H, dt, J 11.3 and 3.4), 4.25 (1 H, t, J 4.5), 3.84 (3 H, s), 1.41 (6H, s), 0.87 (9H, s), 
0.14(3I-1, s), 0.13 (3H, s); Sc(100 MHz; CDCI3) 165.6 (COZMe), 139.4 (CH=C, d, J 6.5), 
127.3 (CH=C, d, J 17.5), 111.1 (CMe2), 84.5 (CF, d, J 173.3), 74.7 (CHOR, d, J 1.6), 71.2 
(CHOR, d, J 2.6), 69.1 (CHOR, d, J 25.4), 52.2 (COZCH3), 27.9 (CCH3), 26.4 (CCH3), 25.6 
(CMe3), 17.9 (SiCMe3), -5.04 (SiMe2). 
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lit. (Song et al., 2001) Sfi(270 MHz; CDCl3) 7.02 - 6.95,5.15,4.74 - 4.68,4.45 - 4.37,4.24, 
3.84,1.40,0.86,0.13. 
(abbreviated data quoted) 
(6S)-6-fluoroshikimic acid 1 
6I, 
11F 
F 
HO " OH 
OH 
Fully protected (6S)-6-fluoroshikimic acid 78 (461 mg, 1.28 mmol) was dissolved in 
dioxane (10 mL). LiOH (aq. ) (1.1 eq., 1.41 mmol, 1.4 mL of a1M solution) and H2O (8.6 
mL) were added and the solution was stirred at rt for 2 h. The pH was adjusted to pH 4 
with IM HCl and the product extracted into EtOAc (3 x 30 mL). The EtOAc was dried 
(Na2SO4), filtered and concentrated under reduced pressure to give it pale yellow oil (399 
mg) which was used without further purification. 
Selected NMR peaks: SH(400 MHz; CDCl3) 7.02 (1 H, t, J 2.9), 5.02 (1 H, dd, J 46.2 and 
3.0), 4.65 - 4.62 (1 H, in), 4.34 (1 H, dt, J 10.5 and 3.8), 4.16 (1 H, t, J 4.8), 1.27 (6H, s), 0.77 
(9H, s), 0.04 (6H, s). 
A small amount of this free acid 90 (73 mg, impure) was dissolved in TFA (1.8 mL) and 
H2O (0.2 mL) and the mixture was stirred at rt for 2.5 h. The solvent was removed under 
reduced pressure to give an orange oil which was partitioned between f 120 (10 nil-) and 
Et20 (10 mL). The aqueous layer was washed with Et20 (2 x 10 mL) and lyophilised to 
give a yellow/brown foaming oil (42 mg). 
Selected NMR peaks: SH(400 MHz; CD3OD) 6.95 (1 H, d, J 4.3), 5.12 (1 H, dd, J 47.7 and 
5.1), 4.41 - 4.39 (1 H, m), 4.17 - 4.09 (11-1, rn), 3.67 (1 H, dd, J 8.4 and 4.1); m/z 192.0 (M', 
- 139 - 
10%), 191.0 (100%), 171.1 (25%), 113.0 (37%), 69.0 (45%). 
Analytical HPLC using a BioRad Organic Acids column eluting with 50 mM formic acid 
(0.6 mL/min) gave the major peak eluting at 10.65 min [lit. (Duggan et al., 1995) 10.8 
mini. However, when a preparative run was attempted the compound was found to have 
decomposed. 
Literature characterisation data for (6S)-6-fluoroshikimic acid were not obtainable, 
however, data for the methyl ester has been published (Bowles et al., 1990). 
SH(400 MHz; CDCl3) 6.95 (1 H, dd, J 5.0 and 1.0,2-H), 5.23 (1 H, br dd, J 48.0 and 6.0,6- 
H), 4.49 (1 H, br dd, J 5.0 and 4.0,3-H), 4.23 (1 H, ddd, J 17.0,9.0 and 6.0,5-H), 3.82 (3H, 
s, OCHS), 3.69 (1 H, dd, J 9.0 and 4.0,4-H), 2.70 (3H, br s, 30H) 
This data, particularly the coupling constant for the hydrogen on C-6, suggested that 
desired enantiomer had indeed been synthesised. 
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5.6 Experimental for Chapter 3 
Synthesis of tri-O-acetyl shikimic acid 80 
CO2H 
AcO" OAc 
OAc 
Shikimic acid 9 (1.00 g, 5.72 mmol) was dissolved in dry pyridine (20 mL) and the stirred 
solution cooled to 0°C. Ac2O (2.4 mL, 25 mmol) was added drop-wise and the solution left 
stirring overnight at room temperature. The solution was then evaporated under reduced 
pressure and the product dissolved in DCM (30 mL). Saturated NaHCO3 aq. (200 ml-) was 
added, and the organic and aqueous phases separated after it was ascertained that the pH of 
the aqueous layer was above pH 8. The aqueous layer was acidified to pH 3 using aqueous 
HCI (2M) and extracted using CHCI3 (4 x 300 mL).. The combined organic extracts were 
dried (MgSO4) and evaporated under reduced pressure to give the tri-acetate 80 (1.68 g, 
5.61 mmol, 98%) as a white amorphous solid which was used without further purification. 
vý, a, (CaF2)/cm-' 3676,3518,3172,3023,2966,2927,2853,2677,2629,2520,1745,1701, 
1657,1508,1429,1372,1232,1149,1110,1079,1043; 8H(400 MHz; CDCl3) 9.55 (11-1, 
broad s, COZH), 6.81 (1 H, m, HCCCOZH), 5.69 (1 H, in, CHCHOCOCH3) 5.26-5.20 (2H, 
m, 2x CHOCOCH3), 2.83 (1 H, broad d, J 17) and 2.37 (1 H, broad d, J 18), HO2000H,, 
2.05 (3H, s, COCH3), 2.03 (3H, s, COCH3), 2.00 (3H, s, COCH3); 8C(100 MHz; CDCI3) 
170.8 (COZH), 170.4 (2 x COCH3), 170.3 (COCH3)1135.4 (CEICCO2H), 131.0 (CCOZH), 
67.8 (CHOCOCH3), 67.1 (CHOCOCH3), 66.4 (CHOCOCH3), 28.4 (CHZ), 21.3 (OCH3), 
21.1 (2 x OCH3); m/z 318.1 (IM+NH4I', 100%. 
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Synthesis of N-a-t-butoxycarbonyl-N-s-benzyloxycarbonyl-L-lysyl-L-phenylalanine 
methyl ester 81 
Ný 
OMe 
Y0 
HN 
0 `--O 
L-Phe methyl ester hydrochloride (260 mg, 1.21 mmol) was dissolved in dry DMF (20 mL) 
and the stirred solution cooled to 0°C after which Et3N (0.67 mL, 4.8 mmol. ) was added. 
Boc-Lys-(Z)-OH (460 mg, 1.21 mmol) was then dissolved in dry DMF (20 mL) and the 
solution added to the reaction mixture. EDC (280 mg, 1.51 mmol) and HOBt (192 mg, 
1.42 mmol) were added and the solution left stirring for 16 h during which time the 
temperature returned to rt. The solution was evaporated under reduced pressure to dryness 
to give the crude product. Silica-gel column chromatography (ethyl acetate: petrol, 1: 4 - 
ethyl acetate gradient elution) gave the pure dipeptide 81 (555 mg, 1.02 mmol, 85%) as a 
white solid. 
m. p. 98-100°C (lit. 105-106°C; Visser, 1968); v,,,,, (CaF2)/cm"' 3435 (broad, NH), 3163 
(weak, CH), 2979 (weak, CH), 2939 (weak, CH), 1709 (CO), 1679 (CO), 1500 (Ph), 1499 
(Ph); 8(400 MHz; CDCI3) 7.27-7.02 (1OH, in, 2x Ph), 6.54(11-1, broad d, J7.6, NI-I), 5.1, 
1 H, broad d, J 6.8, NH), 5.03 (21-1, s, OCH2Ph), 4.98 (1 H, m, NH), 4.76 (11-1, m, CH), 3.98 
(1 H, m, CH), 3.58 (3H, s, OCH3), 3.10 (4H, m, CH, Ph and CH2N), 1.7-1.23 (6H, m, 3x 
CHZ Lys), 1.35 (9H, s, C(CH3)3); Sc(100 MI-1z; CDCI; ) 172.2 (C02)9 157.0 (CO2), 156.0 
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(C02), 137.0 (C-Ar), 136.2 (C-Ar), 129.6 (CH), 129.0 (CH), 128.9 (CH), 128.5 (2 x CH), 
127.5 (CH), 80.4 (CMe3), 67.0 (CH2), 54.6 (OCH3), 53.5 (CH), 52.7 (CH), 40.7 (CH2), 38.2 
(CH2)032.3 (CH2), 29.7 (CH2), 28.7 (C(CH3)3), 22.7 (CH2); m/z 542.2 (IM+H]r, 32%), 442.2 
([M+H-Boc]+, 100%), 91.5 (Z+, 83%). 
Synthesis of N-a-t-butoxycarbonyl-N-s-(tri-O-acetyl-shikimoyl)-L-lysyl-L- 
phenylalanine methyl ester 82 
NjN 
OMe 
OH0 
OAc 
H 
... OAc 
O 
OAc 
Boc-Lys(Z)-Phe-OMe 81 (126 mg, 0.23 mmol) was dissolved in dry DCM (15 mL). 10% 
Pd/C (0.1 g) was added and the flask evacuated and flushed with H2 gas three times. The 
suspension was then stirred under H2 for 42 h, filtered through celite and concentrated 
under reduced pressure to give the crude deprotected dipeptide (107 mg). This was then 
dissolved in dry DCM (10 mL) and the stirred solution cooled to 0°C after which Et3N 
(0.20 mL, 1.43 mmol) was added. Tri-O-acetyl shikimic acid 80 (43 mg, 0.14 mmol) was 
dissolved in dry DCM (5 mL) and added to the reaction mixture. EDC (70 mg, 0.36 
mmol) and HOBt (50 mg, 0.36 mmol) were added and the solution left stirring under N2 for 
16 h during which time the temperature returned to rt. 
The solution was evaporated under reduced pressure to give the crude product as a brown 
mass. Silica-gel column chromatography (ethyl acetate: petrol, 1: 5 - ethyl acetate gradient 
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elution) gave the pure shikimate derivative 82 (85 mg, 0.12 mmol, 88%) as a white 
amorphous solid. 
m. p. 76-84°C; vmaz(CaF2)/cm"' 3435 (broad), 3330 (broad), 3089,3067,3032,3006,2984, 
2953,2936,2861,2261,2248,1745,1712,1644,1517,1499,1455,1437; 8H(400 MHz; 
CDCI3) 7.21-7.05 (5H, m, Ph), 6.87 (1 H, broad d, J 6.5, NH), 6.50 (1 H, m), 6.28 (1 H, m, 
NH), 5.61 (1 H, m), 5.33 (1 H, d, J 7.7, CHOCOCH3), 5.26-5.13 (2H, m, 2x CHOCOCH3), 
4.73 (1 H, m, CH), 4.05 (1 H, m, CH), 3.61 (3 H, s, OCH3), 3.19 (2H, m, CH2Ph), 3.08-2.90 
(3H, m, CH and CH2N), 2.33 (1 H, dd, J 6.3 and 18.2, CH), 1.99 (3H, s, OCOCH3), 1.97 
(3H, s, OCOCH3)11.96 (3H, s, OCOCH3), 1.68-1.15 (7H, m, CH and CH2), 1.34 (9H, s, 
C(CH3)3); Sc(100 MHz; CDCl3) 172.4 (C=O), 172.1 (C=O), 170.5 (C=O), 170.3 (C=O), 
166.7 (C=O), 156.0 (C), 136.2 (C-Ar), 136.2 (C), 129.5 (CH), 128.9 (CH), 127.4 (CH), 
126.0 (CH), 80.2 (OCHS), 77.8 (C), 68.8 (CH), 67.1 (CH), 66.4 (CH), 60.7 (CH2), 54.5 
(CH), 53.6 (CH), 52.6 (CH), 39.5 (CH2), 38.1 (CH2), 32.1 (CH2), 29.6 (CH2), 29.2 (CH2), 
28.6 (CH3), 22.9 (CH2), 21.3 (O2CCH3), 21.1 (OZCCH3), 21.0 (OZCCH3), 14.5 (CH); m/z 
(FAB`) 712.5 ([M+Na]+, 100%), 590.4 (16%), 176.1 (12%), 121.2 (15%). 
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Synthesis of N-E-shikimoyl-L-lysyl-L-phenylalanine 83 
H2Ni OH 
O 
H 
H 
... OH 
O 
OH 
The shikimate conjugate 82 (312 mg, 0.43 mmol) was dissolved in THF: H20 = 4: 1. NaOH 
(190 mg, 4.72 mmol) was added with stirring. The stirring was continued for 23 h until no 
trace of the starting material could be detected by TLC (petrol). The solution was 
evaporated to dryness and the solid residue dissolved in distilled H2O (50 mL). The 
aqueous solution was washed with Et2O (4 x 50 mL) and the resulting aqueous layer stirred 
with ion exchange resin (Amberlite IR 120, hydrogen form, 1 g) until it reached p1-I 2. The 
solution was then filtered through celite and concentrated to give the crude product (212 
mg) as a pale yellow viscous oil. This oil was dissolved in TFA (15 mL) and stirred at 0°C 
for 45 min. The solution was allowed to return to room temperature and stirred for a 
further 45 min after which it was evaporated to dryness to give the crude product 83 as a 
white solid. No further purification was carried out. 
SH(400 MHz; CDC13) 7.06-6.96 (5H, m, Ph), 6.61 (1 H, s, CHCCON), 4.48-4.44 (11-1, m, 
CH), 4.19 (1H, s, CH), 3.79 (2H, s,, CH, N11), 3.73-3.70 (1H, in, CH), 3.51-3.49(111,111, 
C1-i), 3.01-2.97 (2H, in, CHZPh), 2.89-2.79 (1 H, m, CH), 2.50 (11-1, dd, J 4.5 and 17.4, 
OCCCHA), 1.98 (1 H, dd J 6.5 and 17.4, OCCCH), 1.63-1.58 (2H, m, CH, -Lys), 1.36-1.28 
(2H, m, CH2-Lys), 1.10 (21-1, broad d, J 6.1, CH2-Lys); 6C(100 MHz; CDCI3) 174.4 (C), 
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171.9 (C), 170.3 (C), 169.8 (C), 163.4 (C), 138.5 (C), 136.7 (C), 133.4 (C), 131.1 (CH), 
129.4 (CH), 129.3 (CH), 129.0 (CH), 127.5 (CH), 71.7 (CH), 66.6 (CH), 66.1 (CH), 54.5 
(CH), 54.0 (CH), 53.1 (CH), 39.3 (CH), 36.4 (CH2), 31.3 (CH2), 30.8 (CH2), 28.2 (CH2)9 
27.0 (CH2), 21.5 (CH2); m/z (FAB) 593.2 (7%), 493.2 (12%), 456.3 ([M+7H 1 , 51%), 455.3 
(I M+6H ]+, 40%), 341.1 (18 %), 340.1 (15 %), 247.0 (23 %), 246.0 (16%), 169.1 (16%), 121.2 
(57%). 
Synthesis of L-alanyl-L-alanyl-N-B-shikimoyl-L-lysine 88a on solid phase 
H2NN 
JYH 
NJOH 
H0 
OH 
Using the method described in General Procedures (Section 5.4.3), tri-O-acetyl shikimic 
acid (65 mg, 0.22 mmol) 80 was coupled to Fmoc-Lys(Mtt)-Wang Resin (100 mg, 72 
F¬mol) using HOBt (30 mg, 0.22 mmol) and DIC (91 rng, 0.113 mL, 0.72 mmol). Fmoc- 
Ala-OH (67 mg, 0.22 mmol) was coupled to the amino-acid conjugate to give the resin- 
bound tripeptide after the second iteration. The desired tripeptide-shikimate conjugate 88a 
was obtained as a crude mixture after cleavage from the resin and deprotection (crude 
product 43 mg; max. theoretical yield 32 mb). m/z (ES) 445.20 (I M+H 1 , 100%) 
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Synthesis of L-leucyl-L-leucyl-N-c-shikimoyl-L-lysine 88b on solid phase 
H2NJN 
N"kH 
H 0 
OH 
Using the method described in General Procedures (Section 5.4.3), tri-O-acetyl shikimic 
acid (65 mg, 0.22 mmol) 80 was coupled to Fmoc-Lys(Mtt)-Wang Resin (100 mg, 72 
ymol) using HOBt (30 mg, 0.22 mmol) and DIC (91 mg, 0.113 mL, 0.72 mmol). Fmoc- 
Leu-OH (76 mg, 0.22 mmol) was coupled to the amino-acid conjugate to give the resin- 
bound tripeptide conjugate after the second iteration. The desired tripeptide-shikimate 
conjugate 88b was obtained as a crude mixture after cleavage from the resin and 
deprotection (crude product 62 mg; max. theoretical yield 38 mg). m/z (ES) 529.30 
([M+1-11+, 95%) 
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Synthesis of L-phenylalanyl-L-phenylalanyl-N-E-shikimoyl-L-lysine 88c on solid phase 
2H 
H2 
N 
NýOH 
H0 
6H 
Using the method described in General Procedures (Section 5.4.3), tri-O-acetyl shikimic 
acid (65 mg, 0.22 mmol) 80 was coupled to Fmoc-Lys(Mtt)-Wang Resin (100 mg, 72 
pmol) using HOBt (30 mg, 0.22 mmol) and DIC (91 mg, 0.113 rnL, 0.72 mmol). Fmoc- 
Phe-OH (84 mg, 0.22 mmol) was coupled to the amino-acid conjugate to give the resin- 
bound tripeptide conjugate after the second iteration. The desired tripeptide-shikimate 
conjugate 88c was obtained as a crude mixture after cleavage from the resin and 
deprotection (crude product 86 mg; max. theoretical yield 43 mg). ar/z (ES) 597.3 (IM+HI', 
100%) 
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Synthesis of L-seryl-L-seryl-N-$-shikimoyl-L-lysine 88d on solid phase 
OH 
H2N 
=NN 'OH 
HOB 
0 
OH 
Using the method described in General Procedures (Section 5.4.3), tri-O-acetyl shikimic 
acid (65 mg, 0.22 mmol) 80 was coupled to Fmoc-Lys(Mtt)-Wang Resin (100 mg, 72 
µmol) using HOBt (30 mg, 0.22 mmol) and DIC (91 mg, 0.113 mL, 0.72 mmol). Fmoc- 
Ser(tBu)-OH (83 mg, 0.22 mmol) was coupled to the amino-acid conjugate to give the 
resin-bound tripeptide conjugate after the second iteration. The desired tripeptide- 
shikimate conjugate 88d was obtained as a crude mixture after cleavage from the resin and 
deprotection (crude product 67 mg; max. theoretical yield 34 mg). nt/z (ES) 477.27 
([ M+H [+, 100%) 
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Synthesis of L-glutamoyl-L-glutamoyl-N-E-shikimoyl-L-lysine 88e on solid phase 
OH 
JH 
H2N 
NN OH 
H0 
HO O 
H 
HO', ', 2 OH 
OH 
Using the method described in General Procedures (Section 5.4.3), tri-O-acetyl shikimic 
acid (65 mg, 0.22 mmol) 80 was coupled to Fmoc-Lys(Mtt)-Wang Resin (100 mg, 72 
µmol) using HOBt (30 mg, 0.22 mmol) and DIC (91 mg, 0.113 mL, 0.72 mmol). Fmoc- 
Glu(OtBu)-OH (91 ing, 0.22 mmol) was coupled to the amino-acid conjugate to give the 
resin-bound tripeptide conjugate after the second iteration. The desired tripeptide- 
shikimate conjugate 88d was obtained as a crude mixture after cleavage from the resin and 
deprotection (crude product 81 mg; max. theoretical yield 40 mä). m/z (ES) 477.27 
(IM+HI', 100%) 
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Synthesis of L-alanyl-L-alanyl-N-E-(6S)-6-fluoroshikimoyl-L-lysine 4 on solid phase 
H 
H2N 
N OH 
HO 
HN 
,. F 
Ha" OH 
ÖH 
Using the method described in General Procedures (Section 5.4.3), Fmoc-Ala-OH (35 mg, 
0.11 mmol) was coupled to Fmoc-Lys(Mtt)-Wang Resin (50 mg, 36; imol) using HOBt (15 
mg, 0.11 mmol) and DIC (45 mg, 0.05 ml-, 0.36 mmol) to give the resin-bound tripeptide 
after the second iteration. The protected (6S)-6-fluoroshikimic acid derivative 90 (38 mg, 
0.11 mmol) was coupled to the tripeptide using BOP (120 mg, 0.28 rnmol) and Et3N (0.28 
mmol). A crude mixture containing the tripeptide-(6S)-6-fluoroshikirnic acid conjugate 4 
was obtained after cleavage from the resin and deprotection (crude yield 61 mg; max. 
theoretical yield ). The desired conjugate eluted at 5.09 min on an RP Max HPLC column 
cluting with 3- 50 % 50 mM formic acid in MeCN. m/z (ES) 463.30 ((M+H(`, 100%) 
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Synthesis of L-leucyl-L-leucyl-N-E-(6S)-6-fluoroshikimoyl-L-lysine 5 on solid phase 
H 
H2N 
JN 
N 
OH 
H 
yo 
H 
,. 
F 
HO''*' OH 
OH 
Using the method described in General Procedures (Section 5.4.3), Fmoc-Leu-OH (36 mg, 
0.11 mmol) was coupled to Fmoc-Lys(Mtt)-Wang Resin (50 mg, 361imol) using HOBt (15 
mg, 0.11 mmol) and DIC (45 mg, 0.05 mL, 0.36 mmol) to give the resin-bound tripeptide 
after the second iteration. The protected (6S)-6-fluoroshikimic acid derivative 90 (38 mg, 
0.11 mmol) was coupled to the tripeptide using BOP (120 mg, 0.28 mmol) and Et3N (0.28 
mmol). A crude mixture containing the crude tripeptide-(6S)-6-fluoroshikimic acid 
conjugate 5 was obtained after cleavage from the resin and deprotection (crude yield: 65 
mb). The desired conjugate eluted at 10.9 min on an RP Max HPLC column eluting with 3 
- 50 % 50 mM formic acid in MeCN. The fractions containing the desired compound 5 
were lyophilised and stored at -20°C. m/z (ES) 543.3 ([M+H)+, 100%) 
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Synthesis of L-phenylalanyl-L-phenylalanyl-N-E-(6S)-6-fuoroshikimoyl-L-lysine 6 on 
solid phase 
H2JN 
H 
OH 
HO= 
HN 
,. F 
Ha" OH 
OH 
Using the method described in General Procedures (Section 5.4.3), Fmoc-Phe-OH (42 mg, 
0.11 mmol) was coupled to Fmoc-Lys(Mtt)-Wang Resin (50 mg, 36 <<mol) using HOBt (15 
mg, 0.11 mmol) and DIC (45 mg, 0.05 mL, 0.36 mmol) to give the resin-bound tripeptide 
after the second iteration. The protected (6S)-6-fluoroshikimic acid derivative 90 (38 mb, 
0.11 mmol) was coupled to the tripeptide using BOP (120 mg, 0.28 mmol) and Et3N (0.28 
mmol). A crude mixture containing the crude tripeptide-(6S)-6-fluoroshikimic acid 
conjugate 6 was obtained after cleavage from the resin and deprotection (crude yield: 87 
mg). The desired conjugate eluted at 11.5 min on an RP Max HPLC column eluting with 3 
- 50 % 50 mM formic acid in MeCN. The fractions containing the desired compound 6 
were lyophilised and stored at -20°C. ink (ES) 543.3 ([M-3H]', 100%), 546.3 (M+, 5%) 
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Synthesis of L-seryl-L-seryl-N-E-(6S)-6-fluoroshikimoyl-L-lysine 7 on solid phase 
OH 
H2N 
JN 
N 
OH 
H O 
HO( 
OH 
Using the method described in General Procedures (Section 5.4.3), Frnoc-Ser(tBu)-OH (41 
mg, 0.11 mmol) was coupled to Fmoc-Lys(Mtt)-Wang Resin (50 mg, 36 jrmol) using HOBt 
(15 mg, 0.11 mmol) and DIC (45 mg, 0.05 mL, 0.36 mmol) to give the resin-bound 
tripeptide after the second iteration. The protected (6S)-6-fluoroshikimic acid derivative 90 
(38 mg, 0.11 mmol) was coupled to the tripeptide using BOP (120 mg, 0.28 mmol) and 
Et3N (0.28 mmol). A crude mixture containing the crude tripeptide-(6S)-6-fluoroshikimic 
acid conjugate 7 was obtained after cleavage from the resin and deprotection (crude yield: 
99 mg). in/z (ES) 495.3 (1M+HJ+, 15%) 
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Synthesis of L-glutamoyl-L-glutamoyl-N-s-(6S)-6-fluoroshikimoyl-L-lysine 8 on solid 
phase 
OH 
H 
H2 
NN OH 
HO 
HO O 
H 
HO" OH 
ÖH 
Using the method described in General Procedures (Section 5.4.3), Fmoc-Glu(OtBu)-OH 
(46 mg, 0.11 mmol) was coupled to Fmoc-Lys(Mtt)-Wang Resin (50 mg, 36 jimol) using 
HOBt (15 mg, 0.11 mmol) and DIC (45 in-, 0.05 inL, 0.36 mmol) to give the resin-bound 
tripeptide after the second iteration. The protected (6S)-6-fluoroshikimic acid derivative 90 
(38 mg, 0.11 mmol) was coupled to the tripeptide using BOP (120 mb, 0.28 minol) and 
Et3N (0.28 mmol). A crude mixture containing the crude tripeptide-(GS)-6-fltioroshikimic 
acid conjugate 8 was obtained after cleavage from the resin and deprotection (crude yield: 
109 mg). m/z (ES) 579.3 (1M+H1`, 100%) 
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5.7 Experimental for Chapter 4 
2,2,3,3-Tetramethoxybutane 108 (Montchamp et al, 1996) 
M 1Mý ÖMe 
According to the method of Montchamp et al., 2,3-butanedione 106 (22 mL, 0.25 mol), 
trimethyl orthoformate 107 (65 mL, 0.59 mol) and MeOH (32 mL) were treated with 
sulfuric acid (3 drops). The resulting solution was refluxed under N2 for 20 h. Powdered 
NaHCO3 (710 mg) was added to the cool reaction mixture which was then concentrated 
under reduced pressure to give a reddish-brown oil. This liquid was diluted with Et20 (150 
mL) and washed with sat. NaHCO3 (3 x 100 mL). The organic layer was dried (Na2SO4) 
and concentrated under reduced pressure to give an orange oil. The oil was distilled (T1, 
22°C, 0.2 mm Hg) to give a clear colourless liquid identical by 'H- and "C-NMR to the 
literature compound 108 (20.0 g, 0.11 mol, 45%). 
8H(400 MHz; CDCI3) 3.32 (12H, s, 4x OCH3), 1.33 (6H, s, 2x CH3); 8C(100 MHz; 
CDCI3) 103.3 (C), 49.6 (OCHS), 19.1 (CH3). 
Methyl quinate (Montchamp & Frost, 1994) 
O 
HQ 
OMe 
HO' OH 
OH 
A mixture of (-)-quinic acid 19 (5.0 g, 26.0 mmol) and Dowex 501 -l' (1 g) was refluxed for 
14 h in dry McOI-I (50 mL). After cooling, the mixture was filtered and concentrated under 
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reduced pressure to give a white solid (5.12 g, 24.5 mmol). This was recrystallised from 
EtOH to give the product as white crystals (4.87 g, 23.6 mmol, 90%) 
m. p. 121-124°C [lit. (Montchamp & Frost, 1994) 127°C]; SH(400 MHz; CD3OD) 4.07-4.06 
(1 H, m, CH), 4.01-3.95 (1 H, m, CH), 3.72 (3H, s, OMe), 3.41 (1 H, dd, J3 and 9, CH), 
2.12-1.82 (4H, m, 2-CH2 and 6-CH2); Sc(100 MHz; CD3OD) 176.3 (C=O), 77.2 
(CCOZCH3), 76.9 (CO2CH3), 71.8 (CH), 68.6 (CH), 53.3 (CH), 42.4 (CH2), 38.7 (CH2); mlz 
(FAB*) 435.1 ([2M+Na]', 7%), 413.1 ([M+Na]', 18%), 229 (]M+Na]`, 17%), 207.0 
(100%), 171.0 (23 %), 111.2 (14%). 
Methyl 3,4-0-(2,3-dimethoxybutan-2,3-diyl) quinate 97 
0 
e 
In a modification of the procedure detailed by Montchamp & Frost in 1994, quinic acid 19 
(2.7 g, 14.1 mmol), trimethyl orthoformate 107 (7.2 mL, 6.98 b, 65.8 rnrnol), TMB 108 
(2.54 g, 14.3 mmol) and pTsOH (135 mg, 0.71 mmol, 5 mol%) were dissolved in dry 
MeOH (40 mL). The mixture was refluxed under N. for 20 h, allowed to cool, and treated 
with powered NaHCO3 (500 mg). The solvent was removed tinder reduced pressure to give 
an orange oil. This oil was partitioned between EtOAc (100 ml-) and sat. NaHCO3 (100 
mL) and the aqueous layer extracted with EtOAc (2x 100 mL). The combined organic 
extracts were dried over MgSO4, filtered through silica, and concentrated under reduced 
pressure to give a cream solid (3.83 g). The product was dissolved in hot EtOAc, cooled, 
and crystallised by the dropwise addition of hexane to give white needles (3.15 g, 9.85 
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mmol, 70 %). 
m. p. 131-133°C [lit. (Montchamp & Frost, 1994) 139-140°C[; v,,,, x(NaCI)/cm` 
3577 
(broad), 3503 (broad), 2997 (sharp), 2955 (broad), 2905 (broad), 2835,1736 (C=O), 1451; 
SH(400 MHz; CDC13) 4.31 (1 H, ddd J 4.6,10.2,12.2, CH), 4.25 (1 H, s, CH), 4.19 (1 H, qJ 
3.1, CH), 3.79 (3H, s, OCHS), 3.60 (1H, dd J 2.9 and 10.1, CH), 3.26 (2 x 3H, s, OCHS), 
3.15 (1 H, dd J 0.7 and 3.8, CH), 2.19 (1 H, dt J 3.0 and 14.9, CH), 2.10 (1 H, ddd J 2.9,4.6, 
12.8, CH2), 2.04 (1 H, m, CH2), 1.95 (1 H, tJ 12.4, CH2), 1.83 (1 H, s, CH, ), 1.34 (3 H, s, 
CCH3), 1.30 (3H, s, CCH3); 6C(100 MHz; CDC13) 174.0 (C=O), 138.5 (OCCOZMe), 100.4 
(OCOMe), 99.8 (OCOMe), 75.8 (C), 72.7 (COZCH3), 69.2 (OCHS)9 62.4 (OCH3), 53.0 
(OCH), 47.9 (OCH), 38.6 (CH3), 37.4 (CH3), 17.8 (CH2), 17.7 (CH2); nt/z (CI') 338.2 
([M+NH4]+, 100%), 306.2 ([M+NH4-OMe]+, 80%), 289.2 (IM -OMeJ4,55%), 274.1 (20%). 
Methyl 3,4-0-(2,3-dimethoxybutan-2,3-diyl) 5-dehydroquinate 98 (Montchamp et al., 
1996b) 
O 
HO 
OMe 
O 
,,, 
OMe 
MeO 
The protected methyl quinate derivative 97 (3.12 g, 9.74 mºnol) was dissolved in CCI4 (20 
mL). To this was added MeCN (20 mL), H2O (30 mL), KIO4 (9.0 b), and RuCI3. H20 (150 
mg). The suspension was stirred vigorously at room temperature for 20 h. The reaction 
mixture was filtered through celite, the solid material washed with CCI, (20 mL) and the 
aqueous and organic layers were separated. The aqueous layer was saturated with NaCl 
and extracted with EtOAc (3 x 80 mL). The combined organic extracts were dried 
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(M, SO4) and concentrated. The crude material was redissolved in CHCI3 (70 mL) and 
filtered through celite to remove all remaining ruthenium species. The solution was dried 
(MgSO4), filtered and concentrated to give a white foaming solid 98 (2.45 g, 7.69 mmol, 79 
%). 
m. p. 209-213°C flit (Montchamp et al., 1996b). 212-214°CJ; 811(40OMHz; CDCI3) 4.42 
(IH, dd, J 0.8,10, CHO), 4.27 (IH, ddd J 4.4,10,12, CHO), 3.85 (3H, S, C02Me), 3.27 
(3H, s, COMe), 3.23 (3H, s, COMe), 2.90 (1 H, dd J 1.2 and 14.4, CH2), 2.51 (1 H, dd J 2.8 
and 14.4, CH2), 2.36 (1 H, tJ 12.6, CH2), 2.12 (1 H, ddd J 3.2,4.4,13.2, CH2), 1.40 (3H, S, 
CCH3), 1.30 (311, S, CCH3); 8C(100MHz; CDCI3) 199.5 (C=O), 174.0 (C=O), 100.4 
(OCOMe), 99.6 (OCOMe), 77.2 (COZCH3), 74.0 (I-I000O2Me), 67.0 (CH), 53.6 (CH), 
49.0 (CH2), 48.3 (CH3), 48.0 (CH3), 38.2 (CH2), 17.6(CH3), 17.3 (CH3); m/z (Cl') 336.2 
(JM+NH4J', 100%), 304.1 (JM+NH4-OMeJ', 60%), 287.1 (IM -OMeJ`, 35%), 272.1(15%). 
Methyl 3-dehydroquinate 109 
O 
HO 
OMe 
O- OH 
OH 
The protected dehydroquinate derivative 98 (100 mg, 0.3 mmol) was dissolved in CH2CI2 
(5 mL) and H2O (0.2 mL). The mixture was stirred at -5°C for 5 min. CF3CO, H (4,8 mL) 
was added and the mixture stirred for a further 15 min to give a yellow solution. This 
solution was concentrated under reduced pressure to give a colourless oil (91 mg). The oil 
was extracted into CD3OD and 'H NMR showed the presence of the desired compound. 
8H(40OMHz; CD3OD) 4.16 (1 H, d J9.2), 3.99-3.90 (11-1, ni), 3.82 (31-1, s, OCI-13), 3.07 (11-1, 
dd J 0.8 and 14), 2.56 (1 H, dd J 3.2 and 14.4), 2.33-2.20 (2H, m). 
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3,3', 4,4'-Tetrahydro-6,6'-bi-2H-pyran 113 (Ley et al., 1992) 
CiIÖ 
tBuLi (1.7M in pentanes, 14 mL, 24 mmol) was added dropwise to a solution of dry, 
distilled 3,4-dihydro-2H-pyran 115 (2 mL, 22 mmol) in THE (4 mL) at -78°C under N2. 
The cloudy mixture was stirred for 1h at 0°C to give a clear, pale-yellow solution. This 
solution was added via cannula to a cooled (0°C), rapidly stirred slurry of 
Pd(II)Cl2(MeCN)2 (140 mg, 0.54 tmol) and anhydrous CuCI2 (3.1g, 24 mmol) in THE (20 
mL). The resulting black slurry was stirred at 0°C for 1 h. The reaction was quenched by 
addition of sat. NH4CI/0.88 ammonia solution (4: 1, pH 10,50 ml-) and extracted into ether 
(3 x 100 mL). The combined ether extracts were dried (MgSO4), filtered and concentrated 
under reduced pressure to give a yellow solid (500 mg). The crude material was purified 
by silica gel chromatography (10% Et20-hexane) and crystallised from petroleum ether to 
give white crystals (342 mg, 2.1 mmol, 19%). 
m. p. 47-49°C [tit (Ley et al., 1992) 49-50°C]; S(400 MHz; CDC13) 5.18 (2H, t, J 4,5-H 
and 5'-H), 4.06-4.03 (4H, m, 2-CH2 and 2'-CH, ), 2.18-2.10 (4H, m, 4-CH2 and 4'-CH2), 
1.87-1.57 (4H, m, 3-CH2 and 3'-CH2); SC(100 MHz; CDCI3) 148.0 (C), 97.2 (CH), 66.6 
(CH2), 22.8 (CH2), 20.6 (CH2). 
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(1S, 3R, 4R, 5R)-4,5-benzylidenedioxy-l-hydroxycyclohexane-1,3-carbolactone 101 
HQ O 
Hý--O 
Ph 
In a modification of the procedure detailed by Manthey et al., 1997; benzene (125 mL) was 
heated to reflux in a Dean-Stark apparatus for 2h and allowed to cool to rt. To this dried 
solvent was added freshly distilled benzaldehyde (4 mL, 39.4 rnmol), quinic acid 19 (5.0 g, 
26 mmol) and pTsOH (250 mg, 1.31 mmol) and the mixture was heated to reflux. After 7h 
the solvent was removed under reduced pressure. The residue was diluted with Et2O (200 
mL) and decanted from the solid. The solvent was removed under reduced pressure to give 
the crude product as a clear oil (5.31 g). The mixture was purified by silica gel column 
chromatography on 1L silica (gradient Et20: Petrol, 1: 1 to neat Et2O to give the desired 
compound 101 as a mixture of epimers at the benzylic centre in the form of a white 
crystalline solid in a colourless oil (2.38 g, 9.1 mmol, 35 %). The major epimer was 
obtained by recrystallisation from Et20. 
m. p. 105-107°C (lit. (Manthey et al., 1997) 100-101°CI; 8(400 MHz; CDCI3) 7.52-7.42 
(5H, m, Ph), 5.78 (1 H, s, PhCHO2), 4.83 (1 H, dd, J 6.3 and 2.2), 4.56 (1 H, td, J 7.0 and 
2.5), 4.40 (1 H, ddd, J 6.9,2.1 and 1.5), 3.02 (1 H, s), 2.80 (1 H, d, J 12.0), 2.48 (11-1, ddd, J 
15.1,7.5 and 2.1), 2.38 (1 H, dd, J 15.1 and 2.6), 2.37 (1 H, ddt, J 11.9,6.3 and 1.9); Sc(100 
MHz; CDC13) 178.8 (C), 135.4 (C-Ar), 129.9 (CH-Ar), 128.6 (CH-Ar), 126.6 (CH-Ar), 
103.8 (OCHPh), 75.6 (3-CH), 73.0 (CHOI-1), 72.7 (CHO1-1), 71.4 (1-CO1-1), 37.7 (C1-I2)9 
34.4 (CH2); m/z (EI+) 262 (M', 70%), 261.1 (1M-HJ', 100%), 105.1 (1 PIICHO1', 50%). 
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(1S, 3R, 4R, 5R)-1,4,5-trihydroxycyclohexane-1,3-carbolactone 102 
HQ O 
O 
HO" 
OH 
Benzene (150 mL) was heated to reflux in a Dean-Stark apparatus for 2h and allowed to 
cool to rt. Quinic acid 19 (10.0 g, 52.0 mmol) and pTsOH (1.0 g, 5.8 mmol) were added 
and the suspension heated to reflux for 20 h. The benzene was removed under reduced 
pressure and the residue washed with EtOAc (200 mL). The EtOAc was removed by 
filtration and the residue dried under high vacuum to give a yellow solid (8.75 g). NMR 
analysis showed that 89 % of the material was the desired lactone, giving a yield of 7.79 g 
(44.8 mmol, 86 %). 
m. p. 181-183°C [lit. (Manthey et al., 1997) 184-185°C[; 81, (400 MHz; CDJOD) 4.90 (3H, s, 
3x OH), 4.74 (1 H, dd, J 5.12), 4.02 (1 H, t, J 4.59), 3.74 (1 H, ddd, J 11.44,6.57 and 4.48), 
2.55 (1 H, d, J 11.40), 2.26 (1 H, ddd, J 11.36,6.02 and 2.90), 2.07 (1 H, dddd, J 11.75,6.61, 
2.99 and 0.51), 1.91 (1 H, t, J 11.60); bc(I00 MHz; CD, OD) 179.87 (CO., ), 78.27 (CH), 
73.50 (C[OH1CO2), 67.73 (CHOH), 67.23 (CHOH), 40.50 (CH2), 38.23 (CI-12); m/z 
(Isobutane CI') 175.08 ([ M+H [, 100%), 157.07 (9%), 139.07 (8%), 111.07 (11%), 79.02 
(10%). 
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(1S, 3R, 4R, 5R)-4-tert-butyldimethylsiloxy-1,5-dihydroxycyclohexane-1,3-carbolactone 
104 (Manthey et al., 1997) 
HQ O 
0 
HO" 
OTBDMS 
The lactone 102 (1.68 g, 9.6 mmol) was dissolved in dry DMF (20 mL). To this solution 
was added DMAP (215 mg, 1.8 mmol), Bu4NI (220 mg, 0.6 mmol), Et3N (2.0 mL, 14.3 
mmol) and TBDMSCI (1.68 g, 11.1 mmol). The mixture was heated to 90°C for 22 h, and 
allowed to cool to rt. The solution was diluted with EtOAc (200 mL) and filtered through 
celite. The filtrate was washed with 2M HCI (200 mL) and brine (3 x 200 mL), dried 
(MgSO4), filtered and concentrated to give the crude product as a yellow oil (3.46 g). The 
material was purified by silica gel column chromatography (800 mL silica, gradient elution 
DCM-2% acetone to 10% acetone) to give the desired compound 104 as a white solid (1.23 
g, 4.3 mmol, 45%). 
m. p. 148-152°C [lit. (Manthey et al., 19971 154-155°C); 8(400 MHz; CDCI3) 4.68 (1H, 
dd, J 5.7 and 5.1), 4.11 (1 H, t, J 4.6), 3.87-3.78 (1 H, m), 2.8 (1 H, s), 2.53 (1 H, d, J 11.5), 
2.30 (1 H, ddd, J 11.4,6.1 and 3.0), 2.18 (l H, ddd, J 12.2,6.6 and 3.0), 1.85 (1 H, t, J 11.6), 
0.95 19H, s, SiC(CH3)3], 0.17 (3H, s, SiCH3,0.14 (3H, s, SiCH3); Sc(100 MHz; CDCI3) 
177.6 (CO2), 76.5 (CH), 71.9 (C(OH)CO21,66.7 (CH), 66.1 (CH), 40.6 (C11, ), 36.3 (CH2), 
25.6 (SiC(CH3)31,18.0 (SiCMe3), -4.6 (SiCH3), -4.9 (SiCH3) 
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(1S, 3R, 4R, 5R)-4-tert-butyldimethylsiloxy-l-hydroxy-5-oxocyclohexane-1,3- 
carbolactone 105 (Manthey et at., 1997) 
HQ O 
O 
OTBDMS 
3A molecular sieves (2.0 g) were heated under high vacuum for 10 min and allowed to cool 
to rt. Dry DCM (20 mL), PDC (2.5 g, 6.65 mmol) and the protected lactone 104 (0.90 g, 
3.12 mmol) were added and the suspension stirred tinder N2 at rt. After 5h no further 
change in TLC was visible and the mixture was diluted with Et20 (150 mL) and filtered 
(celite). The resulting solution was washed with 1M HCI (150 mL) and brine (2 x 150 
mL), dried NOW, filtered and evaporated to give the crude product. A flash column (2 
cm x6 cm silica, 400 mL Et2O) gave a white solid in a yellow oil (0.75 g). Crystallisation 
(petrol) yielded the desired protected 3-DHQ 105 as fine white needle-shaped crystals (0.41 
g, 1.45 mmol, 46%) 
m. p. 93-94°C, IIit. (Manthey et at., 1997) 92-93°CJ; SH(400 MHz; CDCI3) 4.71 (11-1, dd, J 
6.21 and 3.93), 3.99 (1 H, d, IJ 3.68), 3.23 (1 H, s), 3.03 (1 H, d, J 17.06), 2.79 (1 H, d, J 
12.16), 2.74 (1 H, dd, J 17.11 and 2.35), 2.61 (1 H, ddd, J 12.10,6.05 and 2.83), 0.89 19H, s, 
SiC(CH3)3], 0.16 (3H, s, SiCH3), 0.11 (3H, s, SiCH3); Sc(100 MHz; CDCI3) 203.17 (CO), 
177.51 (C02), 75.47 (CH), 71.81 IC(OH)CO2J, 71.26 (CH), 50.36 (CH, ), 36.20 (C1-1Z), 
25.91 ISiC(CH3)31,18.42 (SiCMe3), -4.49 (SiCH3)9 -4.85 (SiCI-! 3); in/z (Isobutane Cl') 
287.1 ([ M+H 1,100%), 269.1 (10%), 241.1 (8%), 229.1 (85%), 201.1 (10%), 157.1 (30%), 
129.1 (7%), 75.0 (10%). 
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(1S, 3R, 4R, 5R)-1,4-hydroxy-5-oxocyclohexane-carboxylic acid (3-dehydroquinic acid) 
10 
HQ C02H 
O OH 
OH 
The protected DHQ derivative 105 (1.73 g, 6.0 mmol) was dissolved in water (40 mL) and 
acetic acid (10 mL) and heated to 50°C. After 48 h the solution was cooled to rt and the 
solvent removed by freeze-drying overnight. The crude material Evas dissolved in l l20 
(200 mL) and washed with EtOAc (2 x 200 mL). The water was removed by freeze-drying 
overnight. The washing and freeze drying was repeated to finally give 3-dehydroquinic 
acid 10 as a white solid/glass (1.04 g, 5.47 mmol, 91%). The material was dissolved in 
water and aliquoted out to give 20 mg portions after freeze-drying. 
SH(400 MHz; D20) 4.12 (1 H, dd, J 9.53 and 0.59), 3.75 (1 H, dt, J 9.43 and 7.14), 2.99 (11.1, 
dd, J 14.37 and 0.70), 2.42 (1 H, dt, J 14.34 and 1.56), 2.17-2.14 (21-1, m); Sc(100 Nil-lz; 
D20) 208.44 (CO), 176.79 (C02), 80-95 (CH), 74.38 (CIOH ]CO_), 71.64 (CH), 47.84 
(CHZ), 39.86 (CH2). 
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Steady-state kinetic investigation of B. subtilis F28Y type II dehydroquinase 
The assays were carried out as described in `Enzyme Assays' (Section 5.4.1). 
The concentration of enzyme in the stock solution was determined by calculation based on 
an extinction coefficient of 0.465 at 280 nm for the enzyme. All reactions involved 40 jib 
of the enzyme. 
Kinetic data was obtained by varying the concentration of substrate between 100 pM and 2 
mM. The initial rate data obtained was fitted to the Michaelis-Menten equation by non- 
linear regression using Microcal Origin software. The value of k,.,, was calculated using M, 
18 000 for the B. subtilis F28Y enzyme subunit. 
At 20°C in 50 mM Tris. acetate buffer pH 7.0, Km 622 y M= and k, a, = 
0.22 s" 
Steady-state kinetic investigation of H. pylori type II dehydroquinase 
Assays were carried out at 20°C in 50 mM Tris. acetate buffer pl-I 7.0. 
The assays were carried out as described in `Enzyme Assays' (Section 5.4.1). 
The concentration of enzyme in the stock solution was determined by calculation based on 
an extinction coefficient of 0.25 at 280 nnm for the enzyme. All reactions involved 150 jig 
of the enzyme. 
Kinetic data was obtained by varying the concentration of substrate between 50 prtil and I 
mM. The initial rate data obtained was fitted to the Michaelis-Menten equation by non- 
linear regression using Microcal Origin software. The value of k,;,, was calculated using M, 
20 000 for the H. pylori enzyme subunit. 
At 20°C in 50 mM Tris. acetate buffer pl-I 7.0, K,,, 251 jiM= and kc,,, = 19.4 s-' 
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Stopped-flow kinetic investigation of B. sublilis F28Y and II. pylori type II 
dehydroquinases 
Assays were carried out at 13°C in 50 mM Tris. acetate buffer pH 7.0. 
The concentration of DHQ was determined according to the published method (Kleanthous 
et al., 1991) using S. coelicolor type II dehydroquinase to convert DFIQ to DHS. 
The type II dehydroquinase (either I mg or 2 mä in I mL buffer) was mixed rapidly with 
DHQ (approx. 0.1 mM, 10 mL) in the stopped flow apparatus. 
Observation of the graphical output of the apparatus showed no lag phase in the reaction 
involving either B. subtilis F28Y or H. pylori type II dehydroquinase. 
The apparatus and results were validated by calculating the K,,, and k, for the B. subtilis 
F28Y enzyme. 
At 13°C in 50 mM Tris. acetate buffer pH 7.0 Km = 300 fiM and k,.  =0.085 s''. This is 
within the expected range for the enzyme taking into account the low temperature at which 
the assay was carried out. 
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Appendix 2: Model compounds - Peptide shikimate conjugates (88a - e) 
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Sample Volume (pl): 0.00 
ISTD Mount: 0.00 
Dil Factor: 1.00 
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